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The study uses data linkage methodology to investigate the effects of exogenous exposure to endocrine agents in
women with malignant and benign breast disease. The study is in two parts:
ParUA:Tamoxifen is widely used as first-line endocrine therapy in the treatment of breast cancer and women
may be exposed to many years of treatment. The aim of this part of the study was to add to the body of evidence
available on the risk to benefit profile of long-term tamoxifen use. The method was linkage of the Scottish
adjuvant tamoxifen trial database with Scottish hospital inpatient statistics (SMR1), cancer registration (SMR6)
and death records from the General Registry Office (GRO). The Scottish adjuvant tamoxifen trial recruited 1323
patients between 1978 and 1984 and includes women who have received up to 18 years of tamoxifen therapy.
The data linkage enabled ascertainment of causes of admission to hospital, registration of new primary cancers
and causes of death in the trial population to the end of March 1996. Analysis by Cox Proportional Hazards
method considered tamoxifen status as 'never use', 'ever use' or 'current use'. The results confirm a reduced
incidence of ischaemic heart disease and increased thromboembolism. An increased risk of cataract in tamoxifen
users was also detected. The effect of long-term tamoxifen_therapy on the incidence of new primary
malignancies and fractures is also discussed.
Part B: The Edinburgh Breast Unit database has a record for every woman presenting to the department. The
details recorded include previous exposure to exogenous oestrogens in the form of hormone replacement therapy
(HRT) and oral contraception (OC). Many prospective epidemiological studies have looked at the effects of
long-term exposure to exogenous oestrogens, mostly using annual or biennial questionnaires to determine
events, with the inevitable problems of incomplete ascertainment. Data linkage in Scotland provides an
alternative means ofascertaining events and offers an opportunity to study the effects ofoestrogen exposure on a
range of pre-defined endpoints. The aim of this part of the study was to determine the risk of death from
cardiovascular disease and incidence of new primary cancers by exposure status to exogenous oestrogen, using
case-control studies nested within the population presenting to the EBU between 1989 and 1994. Analysis was
by conditional logistic regression. The problem ofmissing data reduced the power of the study. This is discussed
and suggestions for further study are proposed.
ABSTRACT OF THESIS











CHAPTER 1 Rationale and Objectives - Part A
1.1 Tamoxifen morbidity and non breast cancer mortality 1
1.2 The Scottish Adjuvant Tamoxifen Trial 3
1.3 Rationale 4
1.4 Objectives 6
Rationale and Objectives - Part B
1.5 Evidence ofother health effects of oestrogen exposure... 8




Morbidity of long-term tamoxifen therapy within the Scottish adjuvant
tamoxifen trial
CHAPTER 2 Tamoxifen: clinical development and mode of action
2.1 Background 11
2.2 Metabolism 13
2.3 Clinical studies in breast cancer 15
2.4 Duration of treatment 16
2.5 Tamoxifen in combination with other therapies 18
2.6 Primary systemic therapy 20
2.7 Breast cancer treatment in elderly patients 21
2.8 Chemoprevention 22
2.9 Mechanisms of tamoxifen action 24
2.10 Tamoxifen resistance 29
Contents
CHAPTER 3 Other Health Effects ofTamoxifen
3.1 Cardiac effects 31
3.2 Thromboembolic effects 36
3.3 Carcinogenic effects 39
3.4 Other Effects on the Endometrium 48
3.5 Skeletal Effects 49
3.6 Ocular Effects 58
CHAPTER 4 Record Linkage and Data Acquisition
4.1 Record Linkage System 61
4.2 Confidentiality and Data Protection 64
4.3 Linkage with the Scottish tamoxifen trial data 64
4.4 Linkage Validation 72
4.5 Linkage updates 78
4.6 Ascertainment of'Events' 79
4.7 Analysis Database 82
4.8 Trial Follow-up 84
4.9 Glossary 88
CHAPTER 5 Statistical Methods - Part A
5.1 Overview of statistical methods 89
5.2 Statistical methods in the current study 103
5.3 Preparation ofdata for analysis 108
5.4 Implementation of the Cox model 109
5.5 Statistical analyses Ill
5.6 Expression of results 112
5.7 Supplementary analyses 112
CHAPTER 6 Results - Part A
6.1 Validation ofmatched records in linked dataset 114
6.2 Tamoxifen trial follow-up 116
6.3 Ascertainment of 'Events' 116
6.4 Statistical Analyses 124
6.5 Other failure events 137
6.6 Supplementary analyses 138
CHAPTER 7 Discussion - Part A
7.1 Statistical Aspects 141
7.2 Risk/Benefit assessment of tamoxifen 151
7.3 Myocardial infarction and ischaemic heart disease 152
7.4 Thromboembolic disease 154
7.5 Cerebrovascular disease 155
7.6 New primary malignancies 156
7.7 Effects on the skeleton 160
7.8 Ocular effects 162
7.9 Benign endometrial disease 165
7.10 Dementias 166
7.11 The tamoxifen life-cycle 167
Contents
PART B
Effect of exposure to exogenous oestrogens on mortality and incidence of new
primary cancers
CHAPTER 8 8.1 Introduction 170
8.2 Epidemiological studies ofexogenous oestrogen use 171
8.3 Hormone Replacement Therapy (HRT) 172
8.4 Oral Contraception (OC) 178
CHAPTER 9 Case-control Study: Methods and Analysis
9.1 Types ofepidemiological studies 183
9.2 Methodology of case-control studies 187
9.3 Analysis of observational studies 193
9.4 Design ofcurrent study 197
9.5 Data linkage 204
9.6 Statistical methods 211
9.7 Changes to the study design 214
CHAPTER 10 Results - Part B
10.1 Results of linkage ofEBU data with SMR6
and GRO records 215
10.2 Number ofevents 215
10.3 Scope of the current study 217
10.4 Data validation 218
10.5 Overview of results ofdata collection 219
10.6 Power of the study 222
10.7 Results for ischaemic heart disease 224
10.8 Results for thromboembolism 225
10.9 Results for endometrial cancer 226
CHAPTER 11 Discussion - Part B
11.1 Study power: comparison with published studies 228
11.2 Recent published data ofoestrogen exposure
and cardiovascular disease 230
11.3 Suggestions for future work 231
CHAPTER 12 Final Discussion
12.1 Study Conclusions 234
12.2 New agents for hormone replacement therapy 235
12.3 Selective Estrogen Receptor Modulators
(SERMs) 236
12.4 SERMs as oestrogen replacement therapies 236
12.5 Triphenylethylene derivatives 240




Appendix 1 McDonald CC et al. (1991) BMJ303;435-437
Appendix 2 McDonald CC et al. (1995) 5M/311;977-980
Appendix 3 Microsoft Access SQL queries
Appendix 4 Structure ofTambase database
Appendix 5 Microsoft Access update queries
Appendix 6 Sample of case-control data for ischaemic heart disease prepared for
conditional logistic regression analysis
Appendix 7 Sample ofcase-control data for thromboembolism prepared for

































American Standard Code for Information Interchange
'Adjuvant Tamoxifen Alone or in Combination'
'Adjuvant Tamoxifen Treatment-Offer More?'












Early Breast Cancer Trialists' Collaborative Group
Edinburgh Breast Unit












HRT hormone replacement therapy
hx hysterectomy
IBIS International Breast Cancer Intervention Study
IGF Insulin-like growth factor
ICRF Imperial Cancer Research Fund
IHD Ischaemic heart disease
ISD Information and Statistics Division
ITT Intent to treat
LDL low density lipoprotein
LH-RH luteinizing hormone-releasing hormone
LMP last menstrual period





MORE Multiple Outcomes ofRaloxifene
MS Microsoft
NATO Nolvadex Adjuvant Trial Organisation
N-dMT N-desmethyltamoxifen
NSABP National Adjuvant Surgical Breast & Bowel Project





PAC Privacy Advisory Committee
PE pulmonary embolism




RCT Randomised controlled trial
RR relative risk
RUTH Raloxifene Use for the Heart
SCTO Scottish Cancer Trials Office
SCTN Scottish Cancer Therapy Network
SD Standard deviation
SEER Surveillance, Epidemiology and End Results
SMR ScottishMorbidity Record
SMR1 Scottish hospital discharge records
SMR6 Scottish cancer registration records
SQL Structured Query Language
STAR Study ofTamoxifen and Raloxifene
TGF Transforming growth factor
TOES Tamoxifen Evaluation Study
UICC International Union against Cancer





Table 3.1 Relative risk ofendometrial cancer in some large
adjuvant tamoxifen trials 44
Table 4.1 Database field names and description for importing
the linked dataset 67
Table 4.2 Endpoints and their ICD9 classification, for the study of
morbidity within the Scottish adjuvant tamoxifen trial 80
Table 4.3 Key variables on analysis database (Tambase) imported
from original trial database 83
Table 5.1 Survival times (months) for women in breast cancer study 91
Table 5.2 Calculation ofKaplan-Meier estimate of survivor function
for two groups of sample data in Table 5.1 93
Table 5.3 Calculation of log rank statistic for data in Table 5.1 97
Table 5.4 Additional variables created in the analysis database 107
Table 5.5 Description of tamoxifen status and illustration of switching
between time dependent variables tO and tl 109
Table 6.1 Number and percentage ofmanually validated records with
matching scores of 17-23 inclusive 115
Table 6.2 Total number ofevents identified from the validated, linked
dataset, by ICD9 classification and randomised option 118
Table 6.3 Fractures identified in the validated, linked dataset,
by ICD9 classification of site and randomised option 120
Table 6.4 New primary malignancies identified in the validated,
linked dataset, by ICD9 classification of site and randomised
option 121
Table 6.5 Ocular events identified in the validated, linked dataset,
By ICD9 classification and randomised option 123
Table 6.6 Log-rank analysis comparing the survival experience of
the tamoxifen group with the observation group, as randomised 125
List of Tables
Table 6.7 Hazard Ratios and 95% Confidence Intervals for specified
outcomes by randomised option, ever/never, and current/not
current use of tamoxifen, using the proportional hazards method. ..135
Table 6.8 Hazard Ratios and 95% Confidence Intervals for specified
outcomes by adding randomised option, ever/never and current/not
current use of tamoxifen to a model containing age as a
continuous variable, using the proportional hazards method 137
Tale 6.9 Tamoxifen status, duration ofexposure and time since stopped
in 11 cases of endometrial cancer 138
Table 6.10 Results of comparison of incidence ofocular endpoints, with
no censoring at metastatic relapse, between the randomised groups,
ever/never and current/not current use of tamoxifen 139
Table 6.11 Results of comparison of incidence of fracture between the
randomised groups, ever/never and current/not current use of
tamoxifen, adjusted for the presence or absence ofmetastatic
disease 140
Table 7.1 Summary of risk to benefit profile of tamoxifen in healthy
women and those with breast cancer 168
Table 9.1 Causes ofdeath endpoints for study 198
Table 9.2 Sites ofnew primary malignancy as endpoints 199
Table 9.3 Variables extracted from EBU database for linking with
SMR6 and FRO records 205
Table 9.4 Structure of linked dataset showing records from
3 different sources - EBU, SMR6, GRO 207
Table 9.5 Structure ofdatabase for entering exposure data obtained
From EBU database 209
Table 9.6 Description of calculated fields for the case-control analyses 212
Table 10.1 Number ofevents identified from linkage ofEBU data
with GRO records 216
Table 10.2 Number ofnew primary malignancies at all sites (excluding
breast) identified from linkage ofEBU data with SMR6 records....216
Table 10.3 Number ofnew primary malignancies at sites of interest
for the current study 217
Table 10.4 Data inconsistencies identified in EBU database 218
List of Tables
Table 10.5 Number of cases available for analysis on the EBU database 220
Table 10.6 Overview ofdata collected from EBU database 221
Table 10.7 Minimum sample size required in terms ofdetectable odds ratio
for exposed compared with non exposed individuals for different
correlation coefficients ofexposure between cases and controls 223
Table 10.8 Numbers ofexposed, non exposed and exposure unknown cases
and controls for the endpoint of ischaemic heart disease 224
Table 10.9 Numbers ofexposed, non exposed and exposure unknown cases and
controls for the endpoint of thromboembolism 226
List of Figures
LIST OF FIGURES
Figure 2.1 Chemical structure if cis and trans forms of tamoxifen 12
Figure 2.2 Potential ligands produced by tamoxifen metabolism 14
Figure 4.1 Sample output from linked data imported into MS Access
database 68
Figure 4.2 Sample output from linked dataset after structural
modification of the MS Access database 73
Figure 4.3 Flow diagram for validation of linked records in tamoxifen
trial and combined databases 76
Figure 5.1 Schematic representation of censoring 90
Figure 5.2 Survival curve for data in Table 5.1 95
Figure 6.1 Survival curves showing rate ofMI in the two randomised
groups 126
Figure 6.2 Survival curves showing rate of IHD (other than MI)
in the two randomised groups 127
Figure 6.3 Survival curves showing rate ofPE/DVT in the two
randomised groups 128
Figure 6.4 Survival curves showing rate ofCVA in the two
randomised groups 129
Figure 6.5 Survival curves showing rate ofnew primary cancers
in the two randomised groups 130
Figure 6.6 Survival curves showing rate of fracture in the two
randomised groups 131
Figure 6.7 Survival curves showing rate ofocular outcomes
In the two randomised groups 132
Figure 7.1 Cumulative log hazard for randomised groups with respect
to MI 143
Figure 7.2 Cumulative log hazard for randomised groups with respect to
other IHD (other than MI) 144
List of Figures
Figure 7.3 Cumulative log hazard for randomised groups with respect to
PE/DVT 145
Figure 7.4 Cumulative log hazard for randomised groups with respect
to CVA 146
Figure 7.5 Cumulative log hazard for randomised groups with respect to
new primary malignancies 147
Figure 7.6 Cumulative log hazard for randomised groups with respect to
fractures 148
Figure 7.7 Cumulative log hazard for randomised groups with respect to
ocular toxicity 149
Figure 7.8 Structure of toremifene 159
Figure 7.9 Structure of ICI 182780 159
Figure 9.1 Design of a cohort study 183
Figure 9.2 Design of a case-control study 184
Figure 9.3 Design of a nested case-control study 186
Figure 9.4 Schematic representation of confounding 190
Figure 9.5 Calculation of the Relative Risk and Odds Ratio 194
Figure 9.6 Comparison ofOR and RR in a cohort study where disease
is frequent 195
Figure 9.7 Comparison ofOR and RR in a cohort study where disease
is rare 196
Figure 9.8 Schematic representation ofpopulations from which
Cases and controls were selected 202
Figure 12.1 The structure of some triphenylethylene derivatives 238
Figure 12.2 The structure ofa benzothiophene derivative 242
Chapter 1 Rationale and Objectives
Part A
Morbidity of long-term tamoxifen therapy within the Scottish adjuvant
tamoxifen trial
1.1 Tamoxifen morbidity and non breast cancer mortality
Tamoxifen is now included in the treatment of choice for the majority of women
diagnosed with breast cancer and is widely prescribed as adjuvant therapy after local
treatment (surgery, radiotherapy). Only those women whose primary tumours exhibit
no, or very low levels of, oestrogen receptor protein appear to gain little benefit from
treatment. A number of trials have been initiated to determine whether tamoxifen has
a role to play in the chemoprevention of breast cancer in women at high risk of the
disease and these are described in Chapter 2, Section 2.8. The US Breast Cancer
Prevention Trial demonstrated a 49% reduction in risk of invasive breast cancer in
the tamoxifen group compared with the placebo group (Fisher, 1998) but this result
has not so far been confirmed in other studies which are still ongoing
The acute side effects of tamoxifen treatment are well known. They are generally
mild and include flushing and weight gain. Less is known about the late morbidity
associated with long-term exposure to tamoxifen. A study of hospital admissions in
patients randomised within the Stockholm trial of adjuvant tamoxifen found little
difference in intercurrent mortality between tamoxifen and control patients. The total
number of hospital admissions was similar for both groups, with significantly fewer
admissions for immunologic diseases, such as thyroid disease, in the tamoxifen
group (RR = 0.4, 95% CI: 0.2-0.9). There were non-significant increases in
thromboembolic events and benign gynaecological disease in the tamoxifen group.
However, the median follow-up in the study was only 4.5 years with a maximum
exposure to tamoxifen (40 mg daily) of two years (Fornander et al., 1991). A later
analysis, with a median follow-up of 6 years, showed a significantly reduced
incidence of hospital admission due to cardiac disease (RR= 0.68,95% CI:0.48 -
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0.97). The results favoured a longer duration of tamoxifen treatment (5 years as
opposed to 2 years) (Rutqvist & Mattson, 1993).
A study of 153 breast cancer patients who had participated in two Cancer Research
Campaign trials of adjuvant tamoxifen were recruited into a study of the long-term
effects of tamoxifen exposure. Cholesterol levels were significantly lower, some
hormone levels significantly higher and bone density was non significantly higher in
current users. However, results in ex-users suggested that these effects are reversible
on the cessation of treatment (Cuzick, 1993).
Published data on non breast cancer causes of death in women receiving tamoxifen
therapy are scarce. The 1995 overview of randomised trials of tamoxifen therapy in
early breast cancer, carried out on behalf of the Early Breast Cancer Trialists'
Collaborative Group, included an analysis of non breast cancer mortality (Early
Breast Cancer Trialists' Collaborative Group, 1998). The underlying causes of death
that were not due to breast cancer were subdivided into 10 categories; endometrial
cancer, other neoplastic, cardiac, cerebrovascular, pulmonary embolus, other
vascular, respiratory, infective, other medical and non-medical causes. A significant
difference in mortality between tamoxifen and control groups was evident only for
endometrial cancer.
Two published studies, in which this author was closely involved, have investigated
non breast cancer morbidity and mortality within the Scottish adjuvant tamoxifen
trial. The first showed a reduction in fatal myocardial infarction in women
randomised to receive adjuvant tamoxifen compared with the control group
(McDonald & Stewart, 1991) (Appendix 7). The second study involved linkage of
trial data with Scottish inpatient hospital statistics and provided evidence of a
significantly decreased risk of hospital admission due to myocardial infarction and a
significantly increased risk of admission due to thromboembolism associated with
tamoxifen use (McDonald et al., 1995) (Appendix 2). The Scottish adjuvant
tamoxifen trial is described in detail in Section 1.2
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Although the available evidence indicates that tamoxifen has a beneficial oestrogenic
effect on ischaemic heart disease and the skeletal system, data continue to point to
the carcinogenic potential of tamoxifen. As the issue of optimal duration of treatment
has not yet been settled, the clinical decision to prescribe tamoxifen over a prolonged
period continues to be based on an analysis of risk versus benefit. Furthermore,
tamoxifen was licensed in the US in November 1998 for reducing the incidence of
breast cancer in healthy women and is now being prescribed to women who are
considered at high risk ofdeveloping the disease.
It is therefore important to be able to define the risks and benefits of tamoxifen
therapy as precisely as possible and the objective of this study is to make a
contribution to the available body of evidence and help to clarify the risk-benefit
profile of tamoxifen therapy.
1.2 The Scottish Adjuvant Tamoxifen Trial
Between 1978 and 1984, the Scottish adjuvant tamoxifen trial recruited 1323 patients
who were undergoing mastectomy for operable breast cancer. Randomisation was for
adjuvant tamoxifen, 20 mg daily for at least 5 years, or no adjuvant systemic therapy
but tamoxifen to be given for at least six weeks on local or systemic relapse of
disease. A key feature of the trial was the secondary randomisation, whereby those
patients who were alive, free from disease and still receiving tamoxifen therapy 5
years from randomisation, were re-randomised at this time to stop treatment or to
continue indefinitely. Consequently, to the end of March 1996, there are patients
within the study who have had continuous exposure to tamoxifen of up to eighteen
years. Prolonged durations of tamoxifen exposure are also seen in long-surviving
recurrent patients in the observation arm, who started treatment at the time of relapse.
Patients eligible for inclusion in the study were those under 80 years of age with
early breast cancer (Tl-3, N0-1, MO by the UICC TNM Classification of Malignant
Tumours, Third Edition, 1978) suitable for mastectomy. Premenopausal women with
involved axillary nodes were excluded and were, instead, considered for entry into
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another Scottish study comparing chemotherapy and oophorectomy (Scottish Cancer
Trials Breast Group and ICRF Breast Unit, 1993). Patients were stratified at the time
of randomisation by node status (involved, not involved, unknown), menstrual status
(premenopausal, postmenopausal), geographical source (Aberdeen, Dundee,
Edinburgh, Glasgow) and initial local therapy. Local therapy was either mastectomy
with axillary node clearance and no postoperative radiotherapy or mastectomy with
axillary node sample. Patients having a node sample received postoperative
radiotherapy if there was histological involvement of the axillary nodes and patients
in whom there was no histological assessment of the nodes were randomised to
receive, or not receive, postoperative radiotherapy.
Eleven patients who were recognised, within one month of entry, to be major
violators of the eligibility criteria, were excluded from the analyses. The first
analysis of trial data involving 1312 evaluable patients was published in 1987 and
showed a highly significant delay in first relapse and in overall survival in the
adjuvant arm of the trial (Breast Cancer Trials Committee, 1987).
1.3 Rationale
There are a number ofunique factors, related to the Scottish adjuvant tamoxifen trial
and to the hospital record system in Scotland, that combine to make the current study
feasible and offer a valuable opportunity to add significantly to the available data on
long-term tamoxifen morbidity.
Firstly, there are a number of key features in the design of the Scottish adjuvant
tamoxifen trial:
i) This was the first randomised tamoxifen study in which patients were
randomised to receive 5 years of adjuvant therapy and those in the
control arm received delayed tamoxifen on disease recurrence. Other
studies were looking at one or two years of treatment.
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ii) The secondary randomisation procedure, after 5 years of treatment, to
stop tamoxifen or continue indefinitely, has resulted in patients having
exposures to tamoxifen of up to eighteen years. An analysis in 1998
showed that 354 women had received adjuvant tamoxifen for 5 years
or more and 171 of these had received treatment for 10 years or more
(Stewart, 1998 Personal Communication).
iii) Patients were carefully followed-up annually, at the anniversary of
their mastectomy, and strenuous efforts were made by the staff of the
Scottish Cancer Trials Office (SCTO), under the direction ofDr Helen
Stewart, to obtain follow-up information on all patients with the result
that very few individuals have been lost to follow-up. Seven patients
were lost before routine annual follow-up stopped in 1993 and a
further sixteen have their last follow-up information prior to 1996.
iv) The design of the study is such that patients' tamoxifen status can
change during the course of the study for a number of different
reasons including starting tamoxifen on disease recurrence. Data
collection for the trial included obtaining details of tamoxifen starting
and stopping dates. It is therefore possible to classify individuals
according to their tamoxifen status - never received therapy, received
therapy and stopped, currently receiving therapy - throughout the
entire follow-up period.
The second unique facility which provides the basis for the current study is the
availability in Scotland of a well-developed record linkage system, whereby a
permanently linked data set of Scottish health related data - containing all hospital
discharge data, cancer registrations and General Registry Office death records from
1981 to 1995 - can be linked with each other and with external data sets of various
types. This procedure is carried out at the Information and Statistics Division of the
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Scottish Health Service in Edinburgh (ISD) and provides a very powerful tool for
studying morbidity and mortality.
1.4 Objectives
Two studies related to the incidence of cardiovascular mortality and morbidity in the
Scottish adjuvant trial have already been published (.Appendices 1 and 2). The second
of these studies utilised the linkage of trial data with hospital discharge data to the
end of 1992. The objectives of the current study were to:
i) Develop robust methods of handling the large quantity of electronic
data received from ISD
ii) Update the analysis of cardiovascular morbidity, using trial follow-up
and hospital discharge data to the end ofMarch 1996
iii) Include information from cancer registration (SMR6) and General
Registry Office (GRO) death records in the linkage with trial data.
The previous study had linked only with hospital inpatient statistics
(SMR1).
iv) Extend the scope of the earlier studies to look at a range of other
relevant, pre-defined morbidities within the trial population.
Outcomes of interest for the current study included the incidence of
hospital admissions for fractures, benign endometrial lesions, ocular
problems and the incidence of new primary malignancies.
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v) Analyse the data to obtain point estimates of the relative risk of the
specified endpoints, associated with tamoxifen use, together with 95%
confidence intervals. An important feature of the analyses is the
inclusion of tamoxifen status as a time-varying covariate, to reflect
the changes occurring in a patient's tamoxifen status, between 'ever',
'never' and 'current' use, throughout the follow-up period.
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Part B
Effect of exposure to exogenous oestrogens on mortality and incidence of new
primary cancers
1.5 Evidence of other health effects of oestrogen exposure
Women are widely exposed to exogenous oestrogens, in the form of oral
contraception for premenopausal women and hormone replacement therapy for
postmenopausal women. For many years, investigators have been looking at the
evidence pertaining to the risks and benefits of such treatments. Studies investigating
these issues in the past have generally been large, prospective epidemiological
studies involving thousands of women being followed-up for many years.
Ascertainment of outcomes is usually by questionnaire and the problem of obtaining
complete follow-up information increase as the study duration increases. Flagging
patients is an alternative means ofdetermining cause ofdeath and cancer incidence.
Current evidence suggests that postmenopausal hormone therapy reduces the risk of
osteoporosis and cardiovascular disease and premenopausal hormone use increases
the risk of thromboembolic disease. Reports on the effect of oestrogen use on the
development of malignant tumours are inconsistent, with a reduction in the risk
colorectal cancer, a reduction in ovarian cancer in premenopausal women and an
increase in breast cancer incidence in postmenopausal women having been described.
The literature describing the effects of exogenous oestrogen exposure is reviewed in
Chapter 8.
1.6 Edinburgh Breast Unit database
A clinical database for the collection of details of patient demography, clinical
history, diagnosis, treatment and follow-up has been in existence at the Edinburgh
Breast Unit for 10 years. All women presenting to the Unit since 1989 have then-
details entered onto this database, which therefore contains records pertaining to
women with breast cancer and benign breast disease.
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Information relating to previous and current oestrogen use, as oral contraception or
hormone replacement therapy, are recorded on the database at the time of the
patient's presentation to the Unit and these details are also available in the hospital
case-notes. Patients' notes are held within the Unit for malignant cases or within the
main hospital medical records section for discharged patients with a diagnosis of
benign disease.
1.7 Rationale
The facility available in Scotland to link an external database to inpatient hospital
records, cancer registration and death records has already been mentioned in Section
1.3. This, combined with the extensive database of all patients presenting to EBU,
offers a unique opportunity to investigate the effect of exposure to exogenous
oestrogens on mortality and cancer incidence within a large population of pre and
postmenopausal women. The advantage of data linkage methodology over
conventional methods ofquestionnaire and interview for such a study is the ability to
get complete ascertainment of the outcomes being studied. The current study has
been designed as a nested case-control study within the historical cohort of EBU
patients.
1.8 Objectives
The objectives of this observational study were to determine whether previous and
current exposure to exogenous oestrogens, as oral contraception or hormone
replacement therapy, is associated with:
i) An altered death rate from specific causes, other than breast cancer.
The causes ofdeath to be studied were those for which published data
were available and were defined as all ischaemic heart disease,
including myocardial infarction, cerebrovascular disease and
thromboembolic disease as determined by pulmonary embolism and
deep vein thrombosis.
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ii) An altered incidence of second primary cancers. In the first instance,
all second primary cancers, other than breast cancer, were to be
ascertained. Breast cancer was excluded because of the problems
associated with differentiating new primary cancers from previously
diagnosed breast cancer in this population and because of the inherent
bias in ascertaining breast cancer incidence in a population ofwomen
presenting to a breast disease clinic. The sites of new primary
malignancy selected for further analysis would depend on the number
of cases available and whether a possible association of incidence
with oestrogen exposure had been hypothesised in the literature.
For both of these objectives, data linkage between the EBU database and cancer
registration records (SMR6) and General Registry Office (GRO) death records would
be used to identify cases with the outcomes of interest. Controls, who had not
experienced these outcomes would be selected from the EBU database. Oestrogen
exposure of both cases and controls, together with other relevant baseline
information, would then be obtained by examination of available hospital data
sources.
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2.1 Background
Tamoxifen, originally referred to as ICI 46474, is the trans isomer of l(p-beta-
dimethylamino ethoxy-phenyl)-l,2-diphenylbut-l-ene, a derivative of triphenylethylene
(Figure 2.1). It was first synthesised in 1963 and found to be a potent antioestrogen in
several, but not all, mammalian species. The alkylaminoethane side chain is essential for
its antiestrogenic activity. Harper and Walpole were the first to compare the properties
of the trans isomer with those of the oestrogenic cis isomer (Jordan et al., 1977).
Tamoxifen was initially developed as a possible anti-fertility agent in the 1960's but was
found, instead, to promote fertility and it is in the field of hormone-dependent cancer that
this class of compounds has developed a key role.
Preclinical studies in rats demonstrated that the principal mode of action as an anti-
oestrogen was specific antagonism of the effect of oestrogen at the level of the steroid
receptors within the target tissue, by competition for the same receptor sites (Murphy et
al., 1991). However, it became apparent that tamoxifen exhibited a species-specific
pharmacology showing only agonist activity in the mouse, partial agonist/antagonist
activity in the rat and antagonist activity only in the chick oviduct (Jordan et al., 1980).
This selective stimulatory/inhibitory action was also shown in human tissue.
Transplantation of human endometrial and breast cancer cells on either side of an athymic
mouse and administration of tamoxifen, resulted in a stimulation of the growth of the
endometrial cancer while the growth of the breast cancer was inhibited (Gottardis et al.,
1988). In this model, tamoxifen was acting as an oestrogen to stimulate growth of the
endometrial cancer and an antioestrogen to inhibit growth of the breast cancer. The
agonist effects of tamoxifen may, in part, be explained by a significant increase in
circulating oestrogen levels seen clinically in women with breast cancer after long-term
administration of tamoxifen. This may also represent a mechanism for the development of
drug resistance (Lum et al., 1997).
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Figure 2.1
ICI 47699 cis isomer
ICI 46474 trans isomer
Chemical structure of cis and trans forms of l(p-beta-dimethylamino ethoxy-
phenyl)-l,2-diphenylbut-l-ene
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Further work by Jordan on the pharmacology of tamoxifen in laboratory rats,
demonstrated that treatment resulted in a dose-related decrease in the appearance and
numbers of rat mammary tumours, 30 days after induction with dimethylbenzanthracene
(DMBA). Oestrogen and progesterone receptor rich tumours responded more favourably
to treatment but only continuous therapy maintained animals in a tumour free state,
indicating that the action of tamoxifen is cytostatic rather than cytotoxic (Jordan et al.,
1980).
2.2 Metabolism
The major metabolite of tamoxifen is N-desmethyltamoxifen (N-dMT), which is a weak
antioestrogen. Other metabolic pathways produce metabolite E and bisphenoL, which are
oestrogenic {Figure 2.2). Para hydroxylation of the phenyl ring on carbon 1 of but-l-ene
is a minor metabolic pathway, but the product, 4-hydroxytamoxifen (4-OHT), has a very
high binding affinity for the oestrogen receptor and is intrinsically 100 times more active
as an oestrogen receptor antagonist than is the parent drug (Jordan et al., 1977). This is
due to the location of the hydroxyl group in an equivalent position to the 3-phenolic
hydroxyl of 17 beta-oestradiol. A subsequent extensive study of structure-activity
relationship has shown that this structure is optimal for the production of a potent
antioestrogen (Murphy et al., 1991). 4-OHT metabolite has a less potent antitumour
action in rats than the parent compound and this is probably due to its rapid clearance in
this species (Jordan et al., 1980). The hydroxylation reaction is catalysed by human
cytochrome P450 in liver microsomes and work is ongoing trying to identify the specific
isoforms responsible for the catalytic action (Crewe et al., 1997). It has been
demonstrated that 4-hydroxytamoxifen forms free radicals more rapidly than tamoxifen
and causes much greater DNA damage. These radical mechanisms may play a role in the
carcinogenic effects of tamoxifen on the endometrium and other target organs (Davies et
al., 1997).
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Figure 2.2
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2.3 Clinical studies in breast cancer
Trials of tamoxifen in the palliation of advanced breast cancer started in 1969 and the first
clinical paper showing evidence of its effectiveness was published in 1971 (Cole et al.,
1971). In this study, 10/46 patients (22%) showed regression of their tumours. A review
of subsequent studies in advanced disease during the 1970's and 1980's, involving 5,353
patients in 86 major clinical studies, demonstrated a 34% response rate with mean or
median durations of response varying between 2 months and more than 24 months.
Tamoxifen dose was between 20 mg and 40 mg daily (Litherland & Jackson, 1988). This
overview, deriving data from 33 publications, noted the high tolerability of tamoxifen.
The side effects of treatment appeared to be unrelated to dosage and resulted in
discontinuation of therapy in less than 3% ofpatients. Longer duration of therapy did not
result in increased adverse event reporting. The most frequent toxicity was
gastrointestinal disturbance, including nausea and vomiting (10%) and hot flushes (10%-
20%). More recently, data accrued from 200 subjects participating in the pilot feasibility
study of tamoxifen for the prevention of breast cancer, coordinated by the Royal Marsden
Hospital in London, showed that compliance to medication was high and the same for
both tamoxifen and placebo groups. There was relatively low acute toxicity in both
groups, with only hot flushes occurring in significantly more women receiving tamoxifen
(27%) than in the placebo group (11%) (Powles et al., 1989). However, a prospective
study of 161 patients with advanced breast cancer carried out at the Edinburgh Breast
Unit found significant differences in hot flushes, weight gain and vaginal discharge in
patients compared with controls. These symptoms were frequently described by the
patients as 'worrying', and serve to emphasise that any side effects of treatment should be
of concern (Ray & Leonard, 1996).
In 1973, tamoxifen was licensed in the UK as Novaldex® and, in 1977, clinical trials
ofadjuvant tamoxifen therapy in non-metastatic, operable breast cancer started. Many
such studies, using a variety of tamoxifen regimens were initiated in Europe and the
first overview analysis by the Early Breast Cancer Trialists' Collaborative Group was
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reported in 1988 (Early Breast Cancer Trialists' Collaborative Group, 1988). A total
of 16,500 women, in 28 randomised, controlled trials of adjuvant tamoxifen with up
to 5 years of follow-up, were included and a reduction in the annual odds of death, in
women over 50 years, of 20% was seen. A further analysis was carried out in 1990,
by which time data were available on 30,000 women entered into clinical trials of
tamoxifen. This analysis confirmed highly significant reductions in the annual rates of
recurrence (25% SD 2) and death (17% SD 2) with the protective effect extending
out to 10 years in spite of treatment being of much shorter duration (most commonly
2 years) (Early Breast Cancer Trialists' Collaborative Group, 1992).
Although the first overview analysis demonstrated a significant benefit in survival only
in those women aged at least 50 years, the later evidence suggests that both pre and
postmenopausal women benefit from treatment, with the 1990 data showing that
tamoxifen produces a highly significant delay in recurrence in women under 50 (p <
0.001). These data counter early expectations that tamoxifen treatment may stimulate
breast tumour growth in premenopausal women by inhibiting feedback control
mechanisms resulting in high levels of circulating oestrogen. The proportional risk
reductions are similar for both node positive and node negative disease with an
absolute risk reduction greater in the node positive group. The most recent overview
data (Early Breast Cancer Trialists' Collaborative Group, 1998) suggest that for
women with ER negative tumours, the use of adjuvant tamoxifen requires further
research, but for 30,000 women with ER positive or ER untested tumours, adjuvant
tamoxifen treatment substantially improves the 10-year survival. Proportional
reductions in breast cancer recurrence and in mortality appeared to be largely
unaffected by other patient characteristics or treatments.
2.4 Duration of treatment
The optimal duration of treatment is still an unresolved question. Results, published in
1987, from the NSABP B-09 trial in which women received tamoxifen, in addition to
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a chemotherapy regimen ofmelphalan plus fluorouracil, suggested that the addition of
a third year of tamoxifen was beneficial (Fisher et al, 1987). Few data were available
in the 1990 overview on tamoxifen durations exceeding two years, but indirect
comparisons, of one year or less compared with two or more years, suggest that the
longer durations of treatment are more effective in delaying death, with an indication,
in a very small number of patients, that 5 years of treatment may be better still (Early
Breast Cancer Trialists' Collaborative Group, 1992). Preliminary results from the
Cancer Research Campaign trial, evaluating tamoxifen in women aged 50 years and
over, suggest that 5 years of treatment may be better than two, with a significant
delay in the time to relapse for patients receiving treatment for the longer time
(Current Trials Working Party of the CRC Breast Cancer Trials Group, 1996). The
Swedish Breast Cancer Cooperative Group also published results in 1996
demonstrating a significant advantage of five years of treatment compared with two,
in postmenopausal women with oestrogen-positive tumours (defined in this study as
greater than or equal to O.lfmol/pg DNA) (Swedish Breast Cancer Co-operative
Group, 1996). In the overview data published in 1998, there was considerably more
evidence available from trials of 5 years or more of tamoxifen and a highly significant
trend towards greater effect with longer treatment was seen (2p<0.00001) (Early
Breast Cancer Trialists' Collaborative Group, 1998). The proportional reductions in
recurrence in 30,000 women during 10 years of follow-up were 21% (SD 3), 29%
(SD 2) and 47% (SD 3) respectively for trials of 1 year, 2 years and 5 years of
adjuvant tamoxifen respectively.
Although these results all concur with the view that longer is better, studies
investigating more than 5 years of tamoxifen treatment do not demonstrate such
definitive results. Data published from the NSABP B-14 trial for women with primary
operable breast cancer, no axillary involvement and tumours with an oestrogen
receptor content of 10 or more fmol/mg protein, showed significant benefit in disease-
free and overall survival in women randomised to receive tamoxifen. This benefit
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persisted through 10 years of follow-up but no additional benefit was seen in
continuing therapy for more than 5 years (96% survival for those who discontinued
tamoxifen after 5 years and 94% for those who continued active treatment) (Fisher et
al., 1996). The report suggests that more than 5 years' adjuvant treatment is not
warranted in routine clinical practice. The results of the comparison of 5 years
adjuvant tamoxifen treatment with continuous therapy within the Scottish adjuvant
tamoxifen trial suggest no additional benefit in extending therapy beyond 5 years and
show a trend towards an increased incidence of endometrial carcinoma in those
receiving prolonged treatment (Stewart et al., 1996).
With no clear direct evidence of a benefit of long term therapy, and the possibility of
an increase in morbidity resulting from large cumulative doses of tamoxifen, a number
of clinical trials are currently underway to directly compare the effect of different
durations of tamoxifen therapy. The aTTom, trial, organised by the UKCCCR and
coordinated at the CRC Trials Unit in Birmingham, randomises patients who have
completed at least 2 years adjuvant tamoxifen therapy and who are disease-free, to
continue treatment for at least a further 3 years or to stop therapy (Rea et al., 1998).
The trial started in 1991 and aims to recruit 8,000 women to determine whether there
is an overall survival benefit from extending the duration of therapy with adjuvant
tamoxifen. The principal criterion for entry into the study is that the treating clinician
is unsure whether or not to continue tamoxifen treatment. As of September 1998 just
over 2,900 women had been randomised (UKCCR Register of Cancer Trials,
www.ctu.mrc.ac.uk/ukcccr).
2.5 Tamoxifen in combination with other therapies
The issue of whether additional benefit can be derived by the addition of tamoxifen
treatment to polychemotherapy was first addressed by the 1990 EBCTCG overview
(Early Breast Cancer Trialists' Collaborative Group, 1992). The assessment of this
combined modality treatment is complex, but the data suggested that tamoxifen and
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chemotherapy act independently and that their effects are approximately additive.
Further data which were accrued in the 1995 EBCTCG overview, show that
chemotherapy plus about 5 years of tamoxifen was substantially better than the same
chemotherapy alone, with mortality reductions of 39% (SD 22) and 49% (SD 10) for
age less than 50 and more than 50 respectively (Early Breast Cancer Trialists'
Collaborative Group, 1998). However, the report emphasises that this is not
statistically reliable evidence, even with such a large dataset and that, as yet, there are
no results available from large, directly randomised comparisons of concurrent versus
consecutive chemoendocrine therapy.
A study was set up in the UK in 1993 to address the question of combined
chemotherapy and endocrine therapy. The ABC (Adjuvant Breast Cancer) Trial aims
to test whether adjuvant chemotherapy and/or ovarian suppression add to the benefits
of tamoxifen. All patients receive tamoxifen and randomisation for postmenopausal
women is for, or not for, chemotherapy. Pre and perimenopausal women are
randomised into one of two groups, with an elective decision being made for the other
treatment:
• Chemotherapy or no chemotherapy (elective ovarian suppression
or not)
• Ovarian suppression versus no suppression (elective chemotherapy
or not)
The trial opened in 1993 and has an accrual target of 8,000. As of June 1998 2,638
patients had been entered into the study (UKCCCR Register of Cancer Trials). A
further trial is ongoing in Scotland for premenopausal women for whom clinicians feel
that tamoxifen treatment on its own is inadequate. The Scottish Chemo-Endocrine
Trial D is being undertaken in collaboration with the EORTC and all patients receive
chemotherapy and are randomised to receive tamoxifen or not.
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An adjuvant trial in post-menopausal breast cancer investigating treatment with a
combination of tamoxifen and anastrozole (Arimidex®) is being co-ordinated by the
CRC Breast Cancer Trials Group in collaboration with Zeneca. Anastrozole is an
aromatase inhibitor and acts by decreasing the level of circulating oestrogen by
inhibiting the production of oestradiol from oestriol and oestrone in the adrenal gland.
Aromatase within the breast is also a significant source of oestrogen and therefore of
ostrogen mediated tumour proliferation (Brodie et al., 1999). The primary objectives
of the ATAC trial are to compare the equivalence of tamoxifen and anastrozole and to
compare the difference between tamoxifen alone and the combination of tamoxifen
and anastrozole as adjuvant therapy, in terms of time to recurrence and tolerability.
The trial opened in July 1996 and recruitment stopped on 31st October 1999 with
>9000 patients entered. Two studies are also ongoing in Europe in which young,
premenopausal women are being treated with combination endocrine therapy
comprising tamoxifen and the LH-RH antagonist, goserelin. Adjuvant chemotherapy
is an elective therapy in one study and the comparative therapy in the other. Over
3,500 women have been randomised.
2.6 Primary systemic therapy
Neoadjuvant chemotherapy is well established in the treatment of large primary breast
tumours (Smith et al., 1995). The rationale of this treatment is to reduce tumour bulk
and down-stage the tumour so that it can be successfully treated with less radical
surgical treatment. This methodology can also be applied to endocrine therapy in
endocrine-responsive tumours. Thus, primary endocrine therapy can be used to
assess the response of the tumour to systemic therapy which can then be administered
in the adjuvant setting after local treatment. In Edinburgh, the policy since the mid-
1980's has been to delay the local surgical treatment in women with large, but
technically operable tumours (greater than 4 cm in maximum diameter) until the
response to systemic therapy has been assessed. In a pilot study of 88 women,
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tamoxifen was the primary therapy of choice in postmenopausal women with ER
positive tumours (20 fmol/mg cytosol protein or above) (Anderson et al., 1991).
2.7 Breast cancer treatment in elderly patients
Tamoxifen has been used as primary treatment in elderly women not considered
suitable for surgery. When oestrogen receptor content was used to select patients
suitable for conservative tamoxifen treatment, early progressive disease was markedly
reduced at 6 months, from 30% in the unselected control group to 2% in the study
group (p<0.001) (Low et al., 1992). However, although some women maintain a
long-lasting complete remission, the use of tamoxifen alone as first-line therapy is
associated with a high risk of treatment failure (Bergman et al., 1995).
More recently, controlled trials in elderly patients with operable breast cancer have
demonstrated the importance of local cancer control and highlighted the increased
relapse rate and mortality in patients receiving sub-optimal surgical treatment. Modern
anaesthesia has reduced the risks ofmajor therapy and the low rate of post-operative
mortality and high rate of tumour control makes local surgery the preferred primary
therapy for many elderly patients (Fentiman, 1997). Further, patients progressing on
endocrine therapy or whose metastatic disease is life-threatening should be considered
for chemotherapy. Older women in generally good health tolerate standard doses of
chemotherapy as well as their younger counterparts (Muss, 1994).
Current thinking is therefore that patients should be treated according to their
biological, rather than chronological age and tamoxifen therapy alone should only be
used for elderly breast cancer patients who are too frail or unwilling to undergo
surgery or radiotherapy.
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2.8 Chemoprevention
The first evidence of a significant reduction in contralateral breast cancer in patients
receiving tamoxifen therapy was published in the Lancet in 1985 (Cuzick & Baum,
1985). Further evidence accrued from the Stockholm adjuvant tamoxifen trial of a
significant reduction in the incidence of contralateral breast cancers in the tamoxifen
treated patients (RR 0.55, 95% CI:0.31 - 0.98) (Fornander et al., 1989). The 1990
EBCTCG overview of randomised clinical trials of adjuvant therapy for early stage
breast cancer demonstrated a 39% odds reduction of developing cancer of the
contralateral breast in those women receiving adjuvant tamoxifen (Early Breast
Cancer Trialists' Collaborative Group, 1992). One large case-control study identified
234 cases of contralateral breast cancer through a population-based cancer registry.
Controls were matched for age, stage of disease and year of initial breast cancer
diagnosis. Tamoxifen therapy, ofmean duration less than 2 years, was associated with
a decreased risk of a second primary breast cancer (matched odds ratio=0.5, 95%CI:
0.8-0.9) (Cook, 1995).
These data, together with laboratory evidence that tamoxifen interferes with the
initiation and promotion of mammary cancer (Jordan & Morrow, 1993), that its
action is tumouristatic rather than tumouricidal (Jordan, 1988) and the lack of adverse
side effects, suggested that tamoxifen may have a role in the chemoprevention of
breast cancer. A number of studies have been initiated to investigate the use of
tamoxifen in the chemoprevention of breast cancer. The Royal Marsden pilot
chemoprevention study has reported a planned interim analysis which did not show
ant effect of tamoxifen on breast cancer incidence in healthy women with a family
history of breast cancer. The analysis included 2471 women (1238 tamoxifen, 1233
placebo) with a median follow-up of 70 months and there were 34 cases of breast
cancer in the tamoxifen arm and 36 cases in the placebo arm (Powles et al., 1998). A
study started in 1992 in Italy accrued 5408 women. The median follow-up is 46
months and there have been 19 and 22 cases of breast cancer in the tamoxifen and
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placebo arms respectively (Veronesi et al., 1998). The US BCP Trial, under the
auspices of the NSABP, began recruiting patients in 1992 and news that it was to be
stopped more than a year early was announced on April 6th 1998 (NCI, Press
Release). Analysis showed a 49% reduction in breast cancer incidence among the
high-risk patients who took tamoxifen. A total of 13,388 women, aged 35 and older,
were recruited (6,681 in the tamoxifen arm and 6,707 in the placebo arm) with a mean
follow-up of about 4 years. Of women who received tamoxifen, 84 (17.9 per 1,000
women) developed invasive breast cancer, compared with 154 (32 per 1,000 women)
who received placebo (Fisher et al., 1998). The IBIS study is being co-ordinated in
the UK and has been underway since November 1993. The trial aims to randomise
7,000 women, with a strong family history of breast cancer, to receive 20 mg
tamoxifen daily for 5 years, or placebo. As of September 1998 a total of 4,750
patients have been recruited from the UK, Spain, Finland, Switzerland, Belgium,
Australia and New Zealand.
A major issue arising from these trials is that, although most women will not develop
breast cancer, half will potentially be at risk of encountering the symptoms and side
effects of tamoxifen. The unblinding and early termination of the BCP Trial has stirred
some controversy, with accusations that the data cannot contribute to the question of
duration of tamoxifen treatment. Another fundamental, and as yet unanswered,
question is whether the reduction in incidence seen in the study will translate into a
comparable reduction in mortality. Meanwhile, the UK and Italian studies are
continuing.
In addition to its potential use in breast cancer prevention, there is evidence to suggest
that tamoxifen may have chemopreventative effects in other cancers. For example, a
reduced (although not statistically significant) incidence of 1,2-dimethylhydrazine-
induced colon cancers was observed in rats fed tamoxifen daily, compared with
controls (Ziv et al., 1997).
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2.9 Mechanisms of tamoxifen action
2.9.1 Inhibition of oestrogen receptor
Oestrogen causes replication of breast cancer cells by binding to high affinity protein
binding sites located within the nucleus of the cell. This binding of oestrogen to
oestrogen receptors activates a cascade of subcellular events. These include the
induction of progesterone receptor, an increase in the stimulatory growth factors
TGFa and IGFII and a decrease in the inhibitory factor TGFp. Cell growth requires
the synergistic actions of growth factors in the correct sequence and combination and
inhibition of one or more has a profound inhibitory effect on cell growth. An example
of the effect of tamoxifen on these processes has been shown in the expression of
insulin-like growth factors (IGFI and IGFII) and TGFa. For example, serum IGFI
levels, determined by radioimmunoassay, were significantly lower in 19 tamoxifen
patients after two years treatment, than in 19 controls (p<0.05). The effect was
greater in postmenopausal than in premenopausal women (Friedl et al., 1993). It has
also been observed that tamoxifen lowers the production of TGFa in ER positive
tumours (Noguchi et al., 1993). It has been difficult to demonstrate an effect of
tamoxifen on TGFP production by ER positive breast cancer cell lines in vitro and in
fact there are data suggesting that TGFp signaling does not play a role in the
tamoxifen mediated growth inhibition of hormone dependent cell lines (Koli et al.,
1997).
Early in vitro work supported the view that tamoxifen is a competitive inhibitor of
oestrogen and acts by binding to the oestrogen receptor, thereby blocking the action
of oestrogen (Jordan, 1976). Two experimental systems, the dimethylbenzanthracene
(DMBA)-induced rat mammary carcinoma model and the immune deficient (athymic)
mouse implanted with MCF7 breast cancer cell lines, provided much of the early
information supporting the use of long-term adjuvant tamoxifen therapy as a
chemosuppressive strategy in breast cancer (Jordan, 1988). In both models tumour
growth is suppressed by tamoxifen but re-growth occurs when treatment is stopped,
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indicating a cytostatic rather than cytotoxic action. However, care is required when
extrapolating these in vitro results to the human situation because of the differential
effect that tamoxifen exerts depending on the species and tissue being studied.
More recent research has further elucidated the molecular mechanisms involved in
the binding to oestrogen receptor. Oestradiol binds to the oestrogen receptor which
then activates, dimerises and binds to an oestrogen response element (ERE). This in
turn activates gene regulation. There are therefore numerous opportunities for an anti-
oestrogen to confound oestrogen action and it is thought that specific antiestrogenic
action may differ depending on the compound being studied (Jordan, 1994).
Tamoxifen and related triphenylethylene-type antioestrogens bind to the oestrogen
receptor and cause a change in folding of the steroid binding domain which blocks
oestrogenic action and prevents gene activation. The pure antioestrogens have a
different mode of action and appear to cause a rapid loss of receptor allowing little
opportunity to activate the ERE thus halting oestrogen-regulated gene function.
2.9.2 Hormone independent mechanisms
Growth factors
In the order of 10% of oestrogen negative tumours respond to tamoxifen treatment.
This observation has led to a proliferation of research on the hormone-independent
mechanisms by which tamoxifen may exert its effects. Such non ER mediated action
requires higher concentrations of tamoxifen and is observed at concentrations above
10"6 M. The hormone independent anticancer effect may in part be mediated by direct
interaction of the antioestrogen with the transcriptional activation of responsive genes
and a consequent modulation of growth factors. For example, tamoxifen has been
shown to increase TGFp production in cultured fibroblasts (Colletta et al., 1990) and
increased levels of stromal TGFp have been demonstrated in biopsies of both ER
negative and ER positive breast tumours, after 3 months of tamoxifen treatment
(Butta et al., 1992).
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Apoptosis and Cytotoxicity
The binding of tamoxifen to specific antioestrogen receptors and also to other non¬
specific sites raises the intracellular concentration of tamoxifen and its principal
metabolite, N-desmethyltamoxifen. At these higher concentrations a non-specific
cytotoxic effect of tamoxifen has been observed and a variety of mechanisms have
been postulated as contributing to this effect. This hormone-independent cytotoxicity
may, in part, be explained by the effect of antioestrogens on programmed cell death
or apoptosis. This process is controlled by genes, such as c-myc, erb-B2, bcl-2, p53,
which respond to intra and extracellular signals. Antioestrogens contribute to complex
genomic effects which result in the removal of inhibitors to apoptosis and a cytotoxic
effect, independent ofhormone responsiveness of the tumour (Kellen, 1996).
A tamoxifen-induced increase in intracellular ionised calcium concentration and cell
death has been demonstrated at tamoxifen concentrations above 10"6 M, which is the
range at which non-ER mediated cytotoxicity is reported (Jain & Trump, 1997).
Interaction of tamoxifen with calcium ions (Ca2+) has been implicated by a significant
correlation between the growth inhibitory potency of triphenylethylene derivatives in
vivo and their ability to inhibit Ca2+-calmodulin-dependent cAMP phosphodiesterase
in vitro, which is involved in cell signalling. (Fanidi et al., 1991). Another potential
interaction of tamoxifen with Ca2' is suggested by the observation that tamoxifen
suppresses the invasive phenotype of breast cancer cell lines and restores the function
of the E-cadherin/catenin complex. Alterations of function or expression of this
tumour suppressor complex are frequent features of invasive cells. This effect of
tamoxifen is influenced by Ca2+ channel modulators and may depend on a Ca2+
pathway (Charlier et al., 1996).
Human breast tumours contain elevated levels of protein kinase C (PKC) which is
inhibited by higher concentrations of tamoxifen in vitro. PKC in turn regulates the
phospholipase D system which is thought to be an important component of cell signal
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transduction. It has been shown that longer-term (24-hour) treatment with tamoxifen
can inhibit phospholipase D activity in an ER negative subline ofMCF-7 human breast
cancer cells, and this action may contribute to the hormone-independent cytotoxic
effects of tamoxifen (Kiss & Anderson, 1997).
A study has been reported in which mice received cytotoxic T lymphocytes isolated
from other tumour bearing animals and then were treated with oral tamoxifen. An
enhanced tumour suppresser response was seen in these animals. Tamoxifen seems to
increase host resistance by sensitising the tumour target to killer cell mediated lysis
(Nagy et al., 1997).
Angiogenisis
Tamoxifen has been shown to exert angiostatic activity which is not related to the
inhibition of oestrogen action. It is suggested that this activity may contribute to the
therapeutic effect of tamoxifen in ER negative tumours (Gagliardi & Collins, 1993).
The inhibition of angiogenesis and subsequent endothelial growth causes reduced
vascularization and impaired tumour perfusion with resultant enhanced necrosis and
tumour regression. Magnetic resonance imaging in MCF7 human breast cancer cells,
implanted in nude mice, has demonstrated a highly significant decrease in endothelial
density and a significant increase in the extent of necrosis of tumours (Haran et al.,
1994).
Reversal ofMultidrug Resistance
Multidrug resistance (mdr) is a major obstacle to successful cancer chemotherapy.
The most widely implicated mechanism is the P-glycoprotein efflux pump which is a
product of the mdrl gene and results in a reduced concentration of the cytotoxic
agent within the cell and a reduction in cell kill. Tamoxifen has been shown to bind to
P-glycoprotein, thus inhibiting the transport of cytotoxic drugs out of the cell. The
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cellular accumulation of tamoxifen is not affected and therefore it does not appear to
be transported by the protein (Callaghan & Higgins, 1995).
2.9.3 Antioxidant actions of tamoxifen
Current evidence clearly indicates that free radicals play a prominent role in the
incidence and progression of breast cancer (Malins et al., 1996, Murrell, 1991).
Tamoxifen is an effective antioxidant and protects membranes and low density
lipoprotein (LDL) particles against oxidative damage. The protection by tamoxifen of
cellular membranes, including the nuclear membrane, against the formation of
genotoxic reactive intermediates and products of lipid peroxidation, could be
important in the prevention of nuclear DNA damage. Such an anticarcinogenic
mechanism may be important in the use of tamoxifen in the prevention of breast
cancer (Wiseman & Halliwell, 1994). The tamoxifen metabolite, 4-hydroxytamoxifen,
is a more potent anticancer agent than the parent molecule and is also a more
powerful inhibitor of lipid peroxidation. This enhanced activity is thought to be due to
the ability of the hydroxyl group to donate a hydrogen atom to quench free radicals
capable of initiating the membrane oxidative degradation (Custodio et al., 1994).
The primary mediator of tamoxifen's antioxidant action is thought to be the ability to
decrease membrane fluidity and enhance membrane stability. Membrane stability is
very important for the normal functioning of membrane proteins. A positive
correlation has been demonstrated in ox-brain phospholipid liposomes between the
decrease in membrane fluidity conferred by tamoxifen and related compounds, and
their antioxidant ability as inhibitors of liposomal and microsomal lipid peroxidation
(Wiseman et al., 1993).
The antioxidant effect of tamoxifen has been shown clinically with a significantly
decreased rate of lipid peroxidation demonstrated in 64 postmenopausal women after
3 and 6 months tamoxifen treatment, compared with controls. Increased levels of
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selenium and the antioxidant vitamins A, C and E were also detected in the tamoxifen
treated women (Thangaraju et al., 1994).
As well as playing an important role in the anticancer action of tamoxifen and
contributing to its observed cardioprotective effect (Chapter 3), membrane-mediated
mechanisms, through a putative modulation of membrane fluidity, are also likely to
play a role in the ability of tamoxifen to reverse multidrug resistance and could also
lead to clinical uses as an anti Candida and antiviral agent (Wiseman, 1994).
2.10 Tamoxifen resistance
Resistance to tamoxifen therapy can be classified as 'de novo' or 'acquired'. De novo,
or intrinsic, resistance is shown in 65% ofpatients with assessable disease and 40% of
these will be ER positive tumours. Only 15% of these non responders will respond to
a second-line endocrine agent. Tumours which respond initially to first-line tamoxifen
therapy will, invariably, acquire resistance to treatment and relapse. This is often seen
as a tamoxifen withdrawal response with further clinical response occurring when
treatment is stopped. This phemomenon suggests that tamoxifen stimulates tumour
growth prior to cessation of treatment. Unlike de novo resistance, 50% of these who
develop resistance will respond to second line treatment.
Mechanisms of acquired tamoxifen resistance have been studied in the laboratory
using cell lines and tumours which have been developed to be capable of growth in
the presence of clinically relevant concentrations of tamoxifen. Tissue culture has
shown that mutations in the oestrogen receptor can cause a receptor occupied by an
antioestrogen to behave as though it were occupied by oestrogen and display
tamoxifen stimulated growth (Wolf& Jordan, 1993).
Resistance to tamoxifen therapy may develop due to changes at the level of the ER
itself or at pre and post receptor points in the ER response pathway. Several
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mechanisms have been proposed but a single, distinct mechanism has not been
identified. There are a number of steps within the ER mediated signal transduction
pathway which may be altered and lead to tamoxifen resistance. These include:
• defects in the ER - such as a defect in phosphorylation
• loss or mutation of the ER
• defects in ER post-translational modification
• alteration of the oestrogen response element (ERE)
These proposed mechanisms are discussed in detail elsewhere (Tonetti & Jordan,
1995, Lykkesfeldt, 1996).
Resistance may also be mediated by changes in the antioestrogen itself, including
altered uptake, retention and metabolism. There are clinical data showing reduced
levels of tamoxifen in the tumours of patients with acquired resistance. This suggests
that reduced uptake or increased efflux from cells may be implicated (Johnston et al.,
1993)
Antioestrogens working by a different mechanism of interaction with the ER should
prove useful in the treatment of some tamoxifen resistant breast cancer
(Katzenellenbogen et al., 1997). The new pure antioestrogens appear not to be
affected by mutations in the ER and can control tamoxifen stimulated growth. Such
compounds may prevent the development of receptor mutants if used as first-line
therapy (Jiang & Jordan, 1992).
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3.1 Cardiac effects
3.1.1 Clinical studies
Data showing that tamoxifen therapy reduces the incidence of cardiac events are
accumulating. Two studies looking at cardiac morbidity and mortality in patients
entered into the Scottish adjuvant tamoxifen trial have previously been published
(Appendices 1 and 2). The first of these demonstrated a significant reduction in the
incidence of fatal myocardial infarction (MI) in patients randomised to tamoxifen (10)
compared with the control group in (25) (p=0.0087). Only patients who were free of
distant disease at the time ofdeath were included in the analysis, thereby removing the
confounding effects ofmetastatic disease and its treatment on the results. Information
for analysis was obtained from the review ofpatients' hospital case-notes. The second
study considered non fatal as well as fatal outcomes by looking at hospital
admissions, within the trial population, which were identified on the hospital discharge
summary as being due to cardiovascular disease. This study made use of the ability to
link external databases to the computerised record of the hospital discharge. Use or
intended use of tamoxifen was associated with lower rates of hospital admission for
MI. The hazard ratio for women in the control group was 1.92 (95% CI: 0.99 to
3.73) compared with women allocated to adjuvant treatment. The association was
stronger for current use with a hazard ratio for non users of 3.49 (95% CI: 1.52-8.03,
p=0.001) compared with current users (McDonald et al., 1995).
A facility similar to that in Scotland which allows external databases to be linked to
hospital records, exists in Sweden and one report (Rutqvist & Mattson, 1993) shows
a significant reduction in hospital admissions for any cardiac disease in 2,365
postmenopausal patients randomised to tamoxifen use within the Stockholm adjuvant
tamoxifen trial (relative hazard 0.68, 95% CI:0.48-0.97). Median follow-up was 6
years. The study involved randomisation for adjuvant tamoxifen (40 mg per day for 2
years) or no adjuvant treatment. A further randomisation for those free from disease
recurrence and still receiving tamoxifen at 2 years was to stop tamoxifen or continue
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treatment for a further 3 years. A significant reduction in cardiac morbidity was also
seen in those receiving tamoxifen for 5 years compared with those receiving treatment
for 2 years (relative hazard 0.37, 95% CI: 0.15-0.92). In this study there was no
significant reduction in women randomised to tamoxifen use in the hospital
admissions for the subgroup suffering myocardial infarction.
These analyses were based on data collected in a computerised, population-based
register of hospital admissions and corresponding discharge diagnoses, covering about
95% of all hospital admissions in the Stockholm area. The study differs from the
Scottish study in that only an analysis of treatment allocated by randomisation was
performed - the trial database did not contain sufficient information on tamoxifen use
to allow analyses by actual tamoxifen status.
Data on mortality from coronary heart disease in patients with early stage breast
cancer enrolled in the NSABP B-14 trial of tamoxifen therapy have been published
(Constantino et al., 1997). The findings are consistent with the Scottish and Swedish
results, with a reduction in death from MI, or other definite coronary heart disease, in
patients randomised to 5 years of adjuvant tamoxifen compared with those
randomised to placebo. The data fail to reach statistical significance (relative hazard
0.66, 95% CI: 0.27-1.61), but the consistency of these results with those from the
Scottish and Swedish trials confirm the need to continue follow-up of these studies to
accumulate enough data so that reliable conclusions can be reached.
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3.1.2 Mechanisms of action
Lipid profile
The protective effect of tamoxifen on the cardiovascular system is likely to be
mediated, in part, by a reduction in low density lipoprotein (LDL), an increase in
subclass 2 high density lipoprotein (HDL) and a resultant beneficial change in lipid
profile. Studies in the 1950's demonstrated that the decrease of endogenous
oestrogen secretion after the menopause is followed by an increase in serum lipid
levels and a corresponding increase in coronary artery disease (Oliver, 1959).
Premature cessation ofovarian function was shown to be associated with an increased
risk of non fatal myocardial infarction (Rosenberg et al., 1981) . However, most
published studies of lipids, lipoproteins and cardiovascular disease have been in men
and in an overview of blood cholesterol levels in adults, concentrations of plasma
cholesterol and its LDL fraction were cited as being related to coronary artery disease
in men (The Expert Panel, 1988). A review suggests that cholesterol levels may not
be as closely linked with coronary heart disease in women (Isles, 1993).
Nevertheless, if we accept that atherosclerotic cardiovascular disease is associated
with high levels ofplasma low density lipoproteins and low levels of circulating HDL
cholesterol concentrations, then the reversal of these abnormalities should reduce
cardiovascular disease. A review of 23 studies supports the hypothesis that the
favourable effect ofpostmenopausal oestrogen therapy on the lipid profile results in a
reduction of cardiovascular disease in women treated with oestrogen replacement
therapy (Knopp, 1988). A reduced hospitilisation rate for active myocardial infarction
has been observed in oestrogen users compared with non users (Henderson, 1988).
Recent data has confirmed that current use of oestrogen replacement therapy is
associated with decreased cardiovascular morbidity and a reduction in sudden cardiac
death (Sourander et al., 1998).
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Tamoxifen has been shown to exert a similar effect on lipid profile as oestrogen, both
in animal studies and in humans. Studies in female Wistar rats with experimental
atherosclerosis showed an increase in total plasma lipids in animals suffering from
atherosclerosis. HDL cholesterol was increased and LDL cholesterol decreased in
tamoxifen-treated groups (Vinitha et al., 1997). Concomitant rises in marker enzyme
levels, such as serum transaminases, lactate dehydrogenase and creatine
phosphokinase, were seen in the atherosclerotic animals and these effects were
reversed in tamoxifen-treated groups (Vinitha & Sachdanandam, 1997). Similar
changes in lipid profile have been demonstrated in other animal models, for example
monkeys (Williams et al., 1997) and particularly in rats, with the ovariectomised rat
model being characterised for studies in this area (Lundeen et al., 1997).
Work in transgenic mice has studied the effect of tamoxifen on increasing
apolipoprotein (a) concentration, TGFp activity and lipid lesion development, which
represents a major risk factor for vascular diseases including atherosclerosis,
restenosis and stroke. Tamoxifen appears to break the feedback loop whereby
increased apo (a) concentration causes inhibition of TGFp and further apo (a)
increases (Bruning et al., 1988). Oral tamoxifen can prevent apo (a) accumulation and
a sevenfold decrease in total cholesterol levels in mice has been demonstrated,
irrespective ofdiet (Reckless et al., 1997).
A number of clinical studies have looked at the effect of tamoxifen on various blood
parameters which are of relevance in cardiovascular disease. As part of a controlled
trial of the use of tamoxifen in the treatment of mastalgia, a panel of haemastatic
variables were measured. There was a reduction in LDL cholesterol and an increase
in subclass 2 of HDL cholesterol. No alteration was seen in clotting function but
hepatic function was altered, with an increase in concentration of sex hormone
binding globulin (Caleffi, 1988). A randomised, double blind clinical study of two
years of tamoxifen versus placebo, in women with axillary node negative breast
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cancer, showed generally favourable effects on lipid and lipoprotein profile, with a
decrease in total cholesterol and low density lipoprotein levels, in the tamoxifen
treated women (Love et al., 1991). An analysis of lipid levels in 68 women
randomised within the Italian trial of tamoxifen in the prevention of breast cancer has
shown a significant reduction in total and LDL cholesterol levels in women treated
with tamoxifen, over a 6 month treatment period (Mannucci et al., 1996).
A subset of patients in the Scottish trial showed a decrease in total cholesterol while
on tamoxifen treatment but this effect was no longer apparent when treatment was
stopped (Dewar et al., 1992). A decrease in total serum cholesterol, a decrease in
LDL cholesterol and an increase in HDL2 cholesterol has been observed in breast
cancer patients on tamoxifen therapy (Morales et al., 1996). Some changes are
observed after as little as 3 months of tamoxifen therapy (Ingram, 1990) and are
maintained after 6 months and 12 months of treatment (Love et al., 1990). The Royal
Marsden pilot tamoxifen chemoprevention study has shown a significant reduction in
serum cholesterol in tamoxifen-treated women which has been maintained out to 5
years (Powles et al. 1994). A rise in plasma levels of sex hormone binding globulin is
indictative of the intrinsic oestrogenic action of tamoxifen in the liver (Bruning et al.,
1988).
Arterial status
Another hypothesis proposed to explain the relationship between oestrogens and
cardiovascular disease considers the effect of oestrogen on arterial flow. Oestrogen
increases arterial flow with a 50% reduction in the impedence to flow within the
artery. This effect is possibly mediated by a receptor mechanism in the muscularis of
major vessels (Bourne et al.,1990). However, the same effect has not been seen with
tamoxifen. In a randomised study looking at the pulsatility index of cerebral arteries in
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postmenopausal women, oestrogen caused a significant reduction in the pulsatility
index but tamoxifen had no effect. (Penotti, 1998).
Antioxidant properties
Much work has been done on the action of tamoxifen as an antioxidant and its ability
to protect membranes against the damaging effects of lipid peroxidation (Chapter 2,
Section 2.9.3). Oxidative damage to LDL plays an important role in the development
of atherosclerosis (Wiseman, 1994, Steinberg et al., 1989). Tamoxifen has been
shown to protect rat cardiac membranes against the damage caused by lipid
peroxidation (Wiseman et al., 1993) and it can also protect human LDL against Cu2+-
dependent lipid peroxidation (Wiseman, et al., 1993). This antioxidant action is
mediated by modulation of membrane fluidity and is in addition to the favourable
effect of tamoxifen on lipid profile which has already been discussed.
3.2 Thromboembolic effects
3.2.1 Introduction
Early concerns about possible complications of tamoxifen treatment resulting from its
oestrogenic actions focused on its effect on blood coagulation, and in particularly on
the activity of antithrombin III, the most important physiological inhibitor of blood
coagulation. A number of case reports appeared in the literature, describing
thromboembolic complications in patients receiving tamoxifen therapy, including a
report on 7 patients who developed venous thrombosis or pulmonary embolism within
6 months of starting treatment (Lipton et al., 1984 (Dahan, 1985). Another case
describes occlusion of the finger arteries and thrombotic retinal angiopathy during
adjuvant tamoxifen treatment (Schlich et al., 1997).
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However, thromboembolic disease is a recognised and relatively common cause of
morbidity and mortality in cancer patients undergoing chemotherapy (Shlebak &
Smith, 1997) and it can be difficult to disentangle these effects from the incidence of
events precipated by tamoxifen use in such anecdotal reports. The aetiology of
thromboembolism in cancer patients is multifactorial and includes the release of
procoagulants by tumour cells and effects of anticancer drugs on protein C,
fibrinopeptide production and endothelial cell reactivity. There is reliable information
available on the incidence of thromboembolism for patients with breast cancer
(Levine, 1997). In patients with stage II disease receiving chemotherapy, the
incidence of thrombotic complications is of the order of 5%. The risk in metastatic
disease is likely to be greater, because of the increased tumour burden.
3.2.2 Antithrombin III activity
In 1984, a study in women with metastatic breast cancer demonstrated a reduction in
functional activity of antithrombin III in 42% of patients receiving tamoxifen,
compared with 9% in women not receiving tamoxifen (Enck & Rios, 1984). Other
studies have demonstrated a depression of antithrombin III levels associated with
tamoxifen use, but these levels were still within the normal range and not considered
to be of clinical significance (Jordan et al, 1987) (Love et al., 1992) (Auger &
Mackie, 1988) (Bertelli et al., 1988). These results may reflect an action of disease
activity, rather than tamoxifen, on antithrombin III levels. The Royal Marsden pilot
chemoprevention study has noted a decrease in both antithrombin III and fibrinogen
levels, with no resultant detrimental effect on the ratio of these clotting factors, this
being the important clinical parameter (Powles et al., 1994).
3.2.3 Clinical studies
Early results from the Royal Marsden pilot study of the use of tamoxifen in the
chemoprevention of breast cancer showed no evidence of an increase in
thromboembolic events after a maximum follow-up of 36 months (Jones, 1992).
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However, the study of cardiovascular morbidity within the Scottish tamoxifen trial
reported significantly more hospital admissions for the thromboembolic events of
pulmonary embolism and deep vein thrombosis in current users of tamoxifen
compared with those who were not current users (HR 0.4, 95% CI: 0.18-0.90,
p=0.025) (McDonald et al., 1995) (Appendix 2). The comparison of the randomised
groups for incidence of thromboembolic disease in the Scottish study was not
significant and the Swedish study of tamoxifen morbidity, described in Section 3.1.1,
also failed to demonstrate a statistically significant difference between the randomised
groups in terms of first admission to hospital for thromboembolic disease (Rutqvist &
Mattson, 1993).
The incidence of thromboembolism has been investigated in large randomised trials of
combined chemotherapy and tamoxifen, given as adjuvant therapy. The results show a
greater risk for patients receiving a combination of chemotherapy and tamoxifen than
for those receiving either chemotherapy or tamoxifen alone. In a randomised study of
tamoxifen versus tamoxifen plus 6 months of concurrent CMF chemotherapy, there
were five (5) thromboembolic events in 352 women (2.6%) in the tamoxifen alone
group and 48 in 353 women allocated to receive tamoxifen plus CMF (13.6%)
(Pritchard et al., 1996). In a retrospective review of seven studies of adjuvant therapy
(chemotherapy and/or tamoxifen) for breast cancer, the records of 2,673 women were
reviewed for the occurrence of vascular complications. For premenopausal patients,
the frequency of thromboembolic events was 0.8% in patients receiving chemotherapy
and 2.8% in patients receiving combined chemotherapy and tamoxifen (p=0.03). A
similar picture emerged in postmenopausal patients with an incidence of 2.3% and
8.0% in the tamoxifen and tamoxifen plus chemotherapy groups respectively (Saphner
et al., 1991).
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3.3 Carcinogenic effects
3.3.1 Introduction
Although a striking feature of the use of tamoxifen in the treatment of breast cancer is
its low toxicity profile, one aspect of major concern is its carcinogenic potential. The
clinical data, relating to the incidence of second primary tumours associated with
breast cancer use, are ambiguous, due to inadequate surveillance and the difficulties in
obtaining the histological diagnoses necessary to distinguish new primary tumours
from metastatic relapse.
3.3.2 Mechanisms
It is postulated that free radical mechanisms may have a role to play in the
carcinogenicity of tamoxifen. Although the molecule acts as an antioxidant towards
lipids, it may exert pro-oxidant effects on other molecules, such as DNA (Wiseman &
Halliwell, 1993). The major metabolite of tamoxifen, 4-hydroxytamoxifen, has been
shown to be more rapidly susceptible to free radical breakdown, with a consequent
potential to inflict greater DNA damage than tamoxifen itself (Davies et al., 1997). It
has also been suggested that the carcinogenic effects seen with high doses of
tamoxifen may be related to changes in drug metabolising and antioxidant enzyme
activities induced by tamoxifen treatment (Ahotupa et al., 1994). In vitro studies,
demonstrating the agonist activity of tamoxifen in the presence ofmutated oestrogen
receptors, suggest that mutations in the oestrogen receptor may account for the
tamoxifen stimulated tumours seen clinically. However, this has not been confirmed in
reproducible laboratory models of human breast and endometrial carcinomas
(Bilimoria et al., 1996).
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3.3.3 Hepatocellular carcinogenicity
Animal Studies
Animal studies have confirmed the ability of tamoxifen to induce liver cancer in rats,
this effect being dose, duration and species dependent (Greaves et al., 1993). The
doses given in the study were high (5, 20 and 35 mg/kg per day) and an increase in
the incidence of hepatocellular carcinomas was observed after 31 weeks of treatment
in the highest dose group. At doses of < 3 mg/kg per day, no hepatoproliferative
changes were found in rats exposed for up to one year (Williams et al., 1993). The
dose-response curve is very steep; no carcinogenic effect was seen at doses below 3
mg/kg whereas concentrations of 15 mg/kg produced liver tumours in 50% of
animals, after treatment for one half of a lifetime (Jordan & Morrow, 1994). Studies
using a more realistic model, administering the therapeutic dose (-0.25 mg/kg) and
equivalent times and durations to those used clinically, have not been undertaken, but
these dose regimens are below the level that causes adduct formation, suggesting that
it is unlikely that the animals would develop liver tumours, as is the clinical
experience. However, in some strains of rat, tamoxifen can cause cancers in the liver
at blood levels similar to those in women being treated for breast cancer with this
agent (Robinson et al., 1991). In contrast to the effect in rats, tamoxifen is non
carcinogenic in mice because it does not cause sufficient cumulative DNA damage, or
act as a promoter by causing cell proliferation (Martin et al., 1997). Hepatocellular
carcogenicity has not been reported in any other animal species.
Clinical Data
Fears of the results seen in rats being reproduced in humans have been allayed to
some extent. Early data from Sweden reported two cases of hepatocellular carcinoma
in the adjuvant group compared with none in the control group (Fornander et al.,
1989). However, no subsequent study has reported an excess of liver cancers
associated with tamoxifen use. There are two possible explanations for the difference
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between the preclinical data and clinical experience. Firstly, the dose and duration of
treatment in the human is a fraction of that used to initiate carcinogenesis in the rat.
Secondly, a study looking at the number of adducts in rats and humans found the
number of adducts in rats were two orders ofmagnitude greater than the number in
humans. In humans the number of adducts in the tamoxifen treated group was not
significantly different from the control group (Martin et al., 1995).
A combined analysis of the results from the Stockholm Breast Cancer Study Group,
the Danish Breast Cancer Group Trial and the South-Swedish Trial found no evidence
that tamoxifen increases the incidence of liver cancer in humans (Rutqvist et al.,
1995). This is in spite of the high daily dose given (40 mg daily), which is twice that
used in the UK and the US.
DNA Adducts
The hepatocarcinogenic effects of tamoxifen are attributed to the formation of DNA
adducts in the liver, in a time and dose-dependent manner. Activation of tamoxifen by
cytochrome P450 drug-metabolising enzymes results in reactive intermediates that
bind covalently to DNA to form adducts. It has been postulated that conjugation of
alpha-hydroxytamoxifen takes place in the liver to give an ester which alkylates DNA
(Osborne et al., 1997). Other mechanisms have also been proposed by which a
reactive tamoxifen intermediate, capable of forming DNA adducts, is produced by
epoxidation reactions of tamoxifen (Tonetti & Jordan, 1996).
In vitro experimental systems have shown that tamoxifen derived DNA adducts,
alpha-(N-2-deoxyguanosinyl) tamoxifens, have high miscoding potentials (Shibutani
& Dasaradhi, 1997). Local detoxifying mechanisms and DNA repair will limit the
likely expression of clinical cancer. At present, there are few intermediate markers of
carcinogenic risk and quantitative prediction of any human risk is not possible.There
are few data relating to levels of DNA adducts in the liver in tamoxifen treated
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patients. One small clinical trial found no difference in the level of adducts in women
being treated with tamoxifen compared with controls (Martin et al., 1995). More
recently, increased levels of adducts have been detected in leukocyte DNA from
eleven breast cancer patients. The level of adducts in 6 tamoxifen-treated patients was
5.5 adducts/109 nucleotides as compared with a level of 1.9 adducts/109 nucleotides
in 5 untreated controls (Hemminki et al., 1997).
3.3.4 Uterine carcinogenicity
The true incidence of endometrial cancer, related to the oestrogenic effect of
tamoxifen, is difficult to estimate from case reports because breast and endometrial
cancer share hyperoestrogenism as a risk factor. Body fat distribution is an important
variable in relation to endogenous oestrogen production and women with excess
upper body fat may have an inherent risk of developing endometrial lesions, even
when not taking tamoxifen.
Since the demonstration in 1988 of the ability of tamoxifen to stimulate the growth of
a hormone responsive endometrial cancer and block the oestrogen dependent growth
of a breast cancer co-transplanted in the same athymic mouse (Gottardis et al., 1988),
there has been concern about the ability of tamoxifen to cause endometrial cancer in
women. Hardell suggested a causal relation between tamoxifen and the risk of uterine
cancer in 1988 (Hardell, 1988).
Tamoxifen's oestrogen-like action on the uterus may combine synergistically with its
known genotoxic effect to make the uterus a potential prime site for carcinogenic risk
in humans. In a study of 19 postmenopausal, tamoxifen treated breast cancer patients
who underwent endometrial sampling, tamoxifen associated changes in endometrial
steroid receptors were identified, supporting an oestrogenic effect which may
contribute to the pathogenesis of polyps and carcinomas associated with tamoxifen
use (Schwartz, 1997). In vitro studies using endometrial cell lines, have demonstrated
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oestrogen agonist effects of tamoxifen on proliferation and plasminogen activation
(Hochner-Celnikier et al., 1997). The effect of tamoxifen on the endometrium is
related to cumulative dose and duration of exposure. This dose dependency is
supported by a prospective study of 19 tamoxifen treated breast cancer patients which
identified a spectrum ofpathological findings, with endometrial malignancies confined
to those who had taken more than 35 g of tamoxifen (Ismail, 1995).
The evidence of an association between tamoxifen and endometrial carcinoma is based
primarily upon clinical observation rather than laboratory data. Early clinical evidence
of an increased incidence of endometrial cancer associated with tamoxifen use was
seen in a case report in 1985 (Killackey et al., 1985). By 1995, there were reports of
more than 250 cases of endometrial cancer in women taking, or having completed,
tamoxifen therapy (Assikis & Jordan, 1995).
Observations in randomised clinical trials of adjuvant tamoxifen therapy are consistent
with a small, but real increased risk of endometrial cancer in women who take
tamoxifen. These data are tabulated in Table 3.1. A review of the literature on the
carcinogenic potential of tamoxifen was published in 1998 and concludes that the data
suggest that tamoxifen may be a tumour promoter in the human endometrium
(Stearns & Gelmann, 1998). There are problems in obtaining data on the risk of
endometrial cancer in studies which were not designed to assess this outcome. For
example, information on risk factors, such as exogenous oestrogen exposure, is not
collected. Although patients in randomised studies undergo more extensive medical
evaluation with a possibility of detection bias, this should not differ in tamoxifen and
control groups.
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Stockholm 1 40 2-5 yrs 2729 5.6 1.9-16.2
Danish Breast
Cancer Group 2
30 48 weeks 1710 3.3 0.6-32.4
South Sweden 3 30 1 year 719 NS NS
Combined
Scandinavan* 1
As above As above 4914 4.1 1.9-8.9
NSABP4 20 5 years 2843 7.5 1.7-32.7
Relative risk of endometrial cancer in some large adjuvant tamoxifen trials
*Combined analysis of the Stockholm. Danish Breast Cancer Group and South Sweden trials
1
(Rutqvist et al., 1995)
2
(Andersson et al., 1992)
3(Ryden et al., 1992)
4
(Fisher et al., 1994)
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One of the earliest randomised trials of adjuvant tamoxifen was conducted by the
Novaldex Adjuvant Trial Organisation (NATO). Between 1977 and 1981 1,285
patients were randomised to receive adjuvant tamoxifen, 20 mg per day for two years,
or no further therapy. After 6 years of follow-up no cases of endometrial cancer had
been reported (Novaldex Adjuvant Trial Organisation, 1988). Several other
randomised studies, some involving only one year of tamoxifen therapy, have also
looked at the incidence of endometrial cancer and have shown no evidence of an
increased risk (Stewart & Knight, 1989, (Ribeiro & Swindell, 1992, Hubay et al.,
1985, Castiglione et al., 1990, Boccardo et al., 1992, Cummings et al., 1993). The
Royal Marsden pilot tamoxifen chemoprevention trial reported two cases of
endometrial cancer, both in the tamoxifen arm in which women received 20 mg
tamoxifen per day for up to 8 years (Powles et al., 1994).
There have also been case-control and cohort studies reported in the literature. One
case-control study identified 98 patients who had endometrial cancer diagnosed at
least 3 months after a primary breast cancer, through the population based
Netherlands Cancer Registry and two hospital based registeries. Controls (285) were
matched for age, year of breast cancer diagnosis and survival time with an intact
uterus. Tamoxifen had been used by 24% of patients with subsequent endometrial
cancer and 20% of controls (RR 1.3, 95%CI: 0.7-2.4). The relative risk rose to 2.3
(95% CI: 0.9-5.9) in women who had used tamoxifen for more than two years. There
was a significant trend of increasing risk with duration (p=0.049) and cumulative dose
(p=0.046). In this study, the duration-response trends were similar with daily doses of
40 mg or 30 mg and less (van Leeuwen et al., 1994).
A nested case-control study identified 42 cases of endometrial cancer following a
primary breast cancer. Controls (two controls for every case) were matched to cases
on age, year of initial breast cancer diagnosis and disease stage. The mean duration of
tamoxifen use was less than 2 years and the results were consistent with no
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association (matched odds ratio 0.6, 95%CI: 0.2-1.9) This study also identified 39
cases of second primary ovarian cancers and showed no association of development
of this tumour with tamoxifen use (matched odds ratio 0.6, 95% CI: 0.2-1.8) (Cook,
1995).
A case-control study involving 1,017 patients treated at one centre for primary breast
cancer between 1978 and 1989 was undertaken. Four hundred and thirty one (431)
cases were excluded because of inaccurate records (56) or a previous hysterectomy
(375). Information on confounding variables was collected and exposure to tamoxifen
was found to be an independent risk factor for the development of endometrial cancer
(odds ratio 15.2, 95% CI: 2.8-84.4) (Robinson et al., 1995).
The only published cohort study, in which the incidence in a group of subjects is
compared to incidence in the general population as a factor of exposure to the
suspected causal agent, is the incidence of second primary cancers among 87,323
women with breast cancer reported to the SEER (Surveillance, Epidemiology and
End Results) Program. A significant excess of uterine corpus cancers was seen in the
tamoxifen treated group (Ratio of observed to expected 2.03, 95% CI: 1.59-2.55)
(Curtis et al., 1996).
Grade ofendometrial cancer
In 1993, a retrospective study looking at the histological features of uterine cancer in
53 patients with a history of breast cancer was published. Fifteen of the subjects had
received tamoxifen as adjuvant therapy. The results suggested that tamoxifen is
associated with high-grade endometrial cancers having a poor prognosis (Magriples et
al., 1993). This led to speculation that tamoxifen may be causing progression of pre¬
existing disease.
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A retrospective review of clinical history and uterine pathology of 72 patients who
developed malignant neoplasm of the uterine corpus after being treated for breast
cancer with either tamoxifen or other therapeutic regimens revealed several features
of the uterine malignancies. There was a previously unreported high incidence of clear
cell carcinomas and leiomyosarcomas and a higher incidence of serous carcinoma in
patients treated for 12 months or more (Silva et al., 1994).
Carcinosarcoma of the female genital tract is a relatively rare but well described
neoplasm which usually arises in elderly women. It most commonly originates within
the uterus and accounts for 1.5% of tumours of this organ. It is a biphasic tumour
composed of an admixture of carcinomatous and sarcomatous elememts. It is also
referred to as malignant mixed mesodermal tumour or malignant mixed Mullerian
tumour. Uterine carcinosarcoma is a highly aggressive neoplasm which usually deeply
invades the myometrium and commonly results in metastatic disease.
There have been suggestions that prolonged, unopposed oestrogenic stimulation with
tamoxifen may be a possible etiologic factor in the development of uterine
carcinosarcoma. This is based on data, mainly from case reports, of an excess of this
type ofuterine tumour in patients receiving long-term tamoxifen therapy (McLuggage
et al. 1997) (Altaras et al., 1993). If such an association did exist, this would be
highly important given the aggressiveness of this lesion. However, the main body of
evidence to date does not support the association of tamoxifen therapy with high-
grade tumours, with the majority of uterine tumours reported in tamoxifen treated
patients being ofgrade 1 and 2 endometrial carcinomas (Assikis & Jordan, 1995).
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3.3.5 Other primary cancers
Although most interest on the carcinogenic effects of tamoxifen has focussed on liver
and uterine cancers, some published data suggest an increased incidence of other
primary tumours, associated with tamoxifen use. In the South Sweden adjuvant trial, a
higher rate of new primary cancers, other than breast, in the tamoxifen-treated
patients was reported (Ryden et al., 1992). In the Danish trial, involving 3,538
postmenopausal patients, data suggested tamoxifen related increases in
gastrointestinal cancers, particularly colorectal, in patients at high risk of recurrence
who had received radiotherapy (Andersson et al., 1991). A combined analysis of
data from these studies, plus the Stockholm trial, was published in 1995, involving a
total of 4,914 patients with a median follow-up of 8-9 years. The study reported an
excess of gastrointestinal cancers in tamoxifen treated patients, due to an increase in
colorectal cancers (RR 1.9, 95% CI: 1.1-3.3) and stomach cancers (RR 3.2, 95%
CI:0.9-11.7). These data suggest that gastrointestinal organs may be target sites for
tamoxifen induced carcinogenesis in humans (Rutqvist et al., 1995). However, these
results have not so far been supported by other studies (Curtis et al., 1996) ( Fisher et
al., 1996) and some doubt has been placed on the reliability of the data and the
analytical methods used (Jordan, 1995) (Simon, 1995). A recent analysis of 793
colorectal cancers identified within the SEER programme indicated that overall there
was no association between hormone therapy and colorectal cancer (RR 1.09, 95%
CI: 0.88-1.35). However there was a suggestion of an increased risk after 5 years of
treatment (RR 1.47, 95% CI: 1.00-2.15) (Newcomb et al., 1999).
A report was published in 1997 of two cases of acute myeloid leukaemia which
developed during tamoxifen therapy for breast cancer (Yalcin et al., 1997). A
significant increase in the incidence of non lymphatic leukaemia was observed in the
Danish adjuvant tamoxifen trial. However, this was confined to those patients who
had received postoperative radiotherapy, with or without adjuvant tamoxifen.
(Andersson et al., 1991).
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3.4 Other effects on the endometrium
A report in 1989 highlighted an increase in endometrial and endocervical polyps
detected at hysteroscopy in patients treated with tamoxifen, together with evidence of
a hyperplastic endometrial mucosa (Neven et ah, 1989). Further evidence was
obtained from the Royal Marsden pilot tamoxifen chemoprevention trial in which a
randomised cohort of 111 postmenopausal women were studied by transvaginal
ultrasonography, with colour doppler imaging and microscopic examination of
endometrial biopsies. The study found evidence of a larger uterus in the tamoxifen
group and a greater incidence ofendometrial hyperplasia and polyps (Kedar, 1994).
A study in 175 postmenopausal breast cancer patients has demonstrated different
coexisting histological features in the endometria of patients on tamoxifen treatment -
atrophic endometrium frequently coexisted with simple or complex hyperplasia . The
authors hypothesise that different endometrial sites may respond differently to
tamoxifen (Cohen et al., 1997). A study has correlated endometrial thickness with
duration of tamoxifen use greater than 5 years, in 91postmenopausal breast cancer
patients (Hann et al., 1997). Endometrial biopsy in women with endometrial thickness
of 8 mm or more revealed a variety of pathologies including endometrial polyps,
endocervical polyps and hyperplasia, more frequently than in biopsies of endometria
less than 8 mm. There are also case reports of endometrial polyps induced by
tamoxifen treatment (Eagle, 1996).
Page 49
Chapter 3 Other Health Effects of Tamoxifen
3.5 Skeletal effects
3.5.1 Introduction
Bone structure and metabolism
The skeleton carries out a range ofmechanical functions ranging from transmission of
sound waves in the middle ear to withstanding loads of many times body weight. In
addition, bone plays a role in the metabolism of calcium and magnesium and is the
major reserve of these elements. The mechanical and biochemical functions of bone
are dependent on each other.
Overall, the adult skeleton comprises about 80% cortical bone and 20% trabecular
(cancellous bone). The cylindrical shafts of the long bones, such as the radius, ulna
and femur, are composed predominately of cortical bone. The expanded ends of long
bones are composed of trabecular bone, as are the vertebrae. The amount of bone in
the skeleton depends upon the balance of bone formation by osteoblasts and bone
resorption by osteoclasts. The relationship between the two is dependent on age, with
peak bone mass remaining relatively stable from the age of about 25 years until about
50 years. Uncoupling of the action of osteoblasts and osteoclasts leads to an increase
of resorption over formation, with a resultant reduction in bone mass and atrophy of
the skeleton. At all ages, women have a lower bone mass than men.
Ionic exchange on the surface of bone crystal provides a physical basis for the
continuous process of remodeling and replacement of bone. About 700 mg of calcium
is exchanged between blood and bone each day, and this process is assisted by the
activity of bone cells and influenced by a number of factors. 1,25-dihydroxyvitamin D
(calcitriol) and parathyroid hormone (PTH) both stimulate bone resorption, while
calcitonin acts directly on osteoclasts to inhibit their activity. The secretion of PTH
and calcitonin are controlled by calcium ion concentration in the extracellular fluid. A
low concentration of calcium ion stimulates release of PTH, which mobilises bone
calcium and increases bone resorption while a high calcium ion concentration
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stimulates calcitonin release. At the molecular level, PTH is thought to act by
inducing changes in cellular metabolism which alter the rate of nucleic acid and
protein synthesis and thus the activity and number ofbone osteoclasts.
3.5.2 Effects of oestrogen on the skeleton
Bone mass
After the menopause, when circulating oestradiol concentrations decrease, there is an
acceleration of bone loss, which is particularly marked in trabecular bone. Typically,
in early menopause, the magnitude of oestrogen related bone loss represents a two to
threefold increase in turnover rate and results in a decrease in bone mineral density
(BMD) of about 15% after 5 years (Marcus, 1997). Conjugated oestrogens were
approved in the US for the treatment ofmenopausal symptoms in 1942, but it was not
until 1986 that the FDA announced a group of oestrogen products which were
effective in the treatment of postmenopausal osteoporosis. The clinical effects of
oestrogen, with or without added progestin, were assessed on BMD of the spine and
hip in a multicentre study conducted over 3 years. Unopposed oestrogen increased
BMD by 5% at the lumbar spine and 2% at the proximal femur. Similar changes were
seen with oestrogen plus medroxyprogesterone (PEPI Trial Investigators Writing
Group, 1996).
Fractures
Postmenopausal bone loss is a major problem and an estimated 30% of all
postmenopausal women have osteoporosis, according to a definition of bone mineral
density being more than 2.5 standard deviations below the mean for young healthy
adult women at any site (WHO Study Group on Assessment ofFracture Risk and its
Application to Screening for Post Menopausal Osteoporosis, 1994). This reduction in
bone mass brings with it an increased risk of fracture, particularly of the hip,
vertebrae and distal radius. A meta analysis of prospective cohort studies published
between 1985 and 1994, looked at the ability of a decrease in bone mineral density of
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one SD below the age adjusted mean to predict fracture risk. Such a decrease
measured at the spine equated with an increased risk of vertebral fracture (RR 2.3,
95% CI: 1.9-2.8) and an increased risk of hip fracture (RR 2.6, 95% CI: 2.0-3.5)
(Marshall et al., 1996).
In spite of the recognised association between reduced bone mass and fracture risk
and improved biochemical and densitometric methods of measurement, the use of
measurements of bone mineral density to screen for fracture risk, at the time of the
menopause, remain difficult in practice because there is no international consensus
concerning the definition or threshold value for a high fracture risk (Ringa et al.,
1994). Whether a low bone mass expresses itself as a fracture in the future depends
on a number of factors; the occurrence of a fall and a lack of muscle and fat which
may protect bone in the event of a fall. Most non-spine fractures result from a fall and
recent case-control studies have shown that the mechanics of a fall are the most
important determinant of whether it will result in a hip fracture (Cummings & Nevitt,
1994). It is suggested that it is important to determine not only the current status of
bone mass but to develop methods to predict future bone loss. A combination of
methods may be required to develop accurate predictive methods (McGowan, 1993).
There is now evidence that genetic factors may play a role in the regulation of bone
mass and that fracture risk may be due in part to changes in bone quality with a
decrease in crosslinking resulting in increased fragility (Ralston, 1997).
Data on the efficacy of preventative interventions, such as hormone replacement
therapy, on fracture incidence are relatively sparse compared with those showing
effects on bone mass. A retrospective cohort study of 490 women (245 oestrogen
users for at least 5 years, 245 age-matched postmenopausal non users) found a
statistically significant reduction in the incidence of wrist and vertebral fractures in
users compared with non users. The age-adjusted incidence ratio for wrist fractures
was 0.55 (95% CI:0.32-0.92) and for vertebral fractures was 0.57 (95% CI:0.41-
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0.80) (Maxim et al, 1995). In 1997 a review was published on the skeletal effects of
hormone replacement therapy and considered aspects such as dose, duration and the
age at which treatment should be initiated (Marcus, 1997).
Mechanisms
In vitro studies suggest that the action of oestrogen on bone involves a number of
mechanisms. Studies of bone turnover in ovariectomized rats, using dynamic bone
histomorphometry, showed that oestrogen prevents osteopenia, in part, by inhibiting
bone turnover (Turner et al., 1993). In vitro studies of the effect of oestradiol (1
mmol/L) on osteoclast cultures from rat long bones, demonstrated a 25% inhibition of
bone resorption (Tobias & Chambers, 1991). Oestrogen may also act, through
functional oestrogen receptors present in bone derived cells, to increase bone
formation and as well as inhibiting resorption by reducing responsiveness to PTH
(Ernst et al., 1989). Avian osteoclasts contain high levels of oestrogen receptors and
the inhibition of osteoclast resorption activity by oestradiol is thought to be
mediated, at least in part, by the regulation of osteoclast lysosomal gene expression
(Oursler et al., 1993). Oestrogen can also act directly on the thyroid C cell to
stimulate calcitonin secretion and thus inhibit bone resorption (Greenberg et al.,
1986), and there is evidence of the induction of apoptosis of the bone resorbing
osteoclasts by an oestrogen receptor mediated mechanism (Kameda et al., 1997)
3,5.3 Effects of tamoxifen on the skeleton
The first suggestion that tamoxifen had an oestrogen like effect on bone, was the
observation that breast cancer patients with bone metastases developed transient
hypercalcaemia on tamoxifen therapy (Legha et al., 1981). Subsequently, studies in
rats have demonstrated the oestrogenic action of tamoxifen in preventing bone loss. In
male rats, tamoxifen was able to reduce the trabecular bone loss resulting from
unilateral sciatic neurotomy, but had no effect on cortical bone disuse ostopenia or on
trabecular bone formation (Wakley et al., 1988). Studies in ovariectomised female rats
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have shown that ovariectomy results in large increases in the number and activity of
osteoclasts. This results in increased bone resorption with a net loss of trabecular
bone. Treatment with tamoxifen prevented these skeletal changes (Turner et al„
1988).
The effect of tamoxifen in preventing bone loss induced by ovariectomy has been
shown to depend on the circulating oestradiol concentration. While tamoxifen has
oestrogen agonist activity in oestrogen deficiency, it has antiestrogenic actions in the
presence ofoestrogen (Kalu et al., 1991). This effect was confirmed in later studies in
which tamoxifen was shown to exert an oestrogen agonist effect in ovariectomised
rats but produced a 31% bone loss in intact animals, demonstrating an oestrogen
antagonistic effect (Sibonga et al., 1996), (Li et al., 1996). The interaction between
tamoxifen and ovarian status observed in animal studies has implications for the use of
tamoxifen in the treatment of pre and postmenopausal women, particularly in its use
as a chemopreventative agent in younger women.
Mechanisms
The use of ovariectomised rats is a useful animal model of postmenopausal bone loss
in which the characteristics of the bone loss and its sequelae resemble those found in
postmenopausal women (Kalu, 1991). Ovariectomy causes an oestrogen deficiency,
which results in an accelerated bone loss similar to that found in early menopause.
This bone loss mimics postmenopausal bone loss in several ways;
• Increased rate ofbone turnover, with resorption exceeding
formation
• An initial rapid phase of bone loss is followed by much slower
phase
• Greater loss of trabecular bone than cortical bone
• Obesity provides some protection to bone loss.
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Similar skeletal responses to therapy with oestrogen, tamoxifen, bisphosphonates,
parathyroid hormone, calcitonin and exercise have been observed in this model.
Most of the evidence relating to the effect of tamoxifen on the skeleton indicates an
inhibition of bone resorption, rather than increased bone formation. A study in the
ovariectomised rat model showed that oestrogen was able to restore spinal bone
mineral density in rats with established osteopenia, whereas tamoxifen inhibited
further bone loss but was unable to restore spine BMD (Li et al., 1998). A number of
studies have tried to elucidate the mechanism of tamoxifen's action on the skeleton. In
vitro studies have shown that tamoxifen can completely block PTH induced bone
resorption at concentrations of 100 pM. A lower concentration (10 pM) of tamoxifen
is ineffective at blocking resorption and concentrations of40-50 pM partially inhibited
the response (Stewart & Stern, 1986).
Tamoxifen has been shown to have a strong, dose-dependent, inhibitory action on
1,25-dihydroxyvitamin D3 stimulated bone resorption in vitro (Vink van Wijngaarden
et al., 1995). This result was in contrast to that of an earlier study in which rats were
fed on low calcium diets to stimulate PTH secretion. Tamoxifen did not inhibit PTH
or calcitrol mediated bone resorption (Goulding et al., 1990).
Clinical studies
In vitro and animal data showing an inhibitory effect on bone loss are supported, to a
greater or lesser extent, by a number of clinical studies in which measurements of
bone mineral density and bone turnover have been made. Early clinical studies with
small numbers of women, having tamoxifen exposures up to two years, provided
reassurance that tamoxifen was not exerting antiestrogenic effects on the skeleton
and causing reductions in BMD (Love et al., 1988) (Turken et al., 1989). Lack of a
detrimental effect on bone mineral density at any site was confirmed in a retrospective
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study involving 19 tamoxifen treated patients and 19 age-matched controls. BMD
was measured at the femoral neck, lumbar spine and total body by dual energy X-ray
absorptiometry (Neal et al., 1993). Bone mineral density in women with breast cancer
has been shown to be lower in postmenopausal women with breast cancer compared
with controls, matched for age and number ofyears since menopause. Tamoxifen did
not increase the age-related bone loss in these women (Kostoglou-Athanassiou et al.,
1994).
In a two year randomised, double blind, placebo controlled trial of 140 women with
early breast cancer, tamoxifen increased the mean bone mineral density of the lumbar
spine compared with a decrease in those in the placebo arm. Tamoxifen had no effect
on radial bone mineral density (Love et al., 1992). This differential effect of
tamoxifen on cortical and trabecular bone was also seen in a double blind, placebo
controlled trial involving 57 healthy postmenopausal women. In those randomised to
tamoxifen, mean bone mineral density of the lumbar spine increased while a decrease
was observed in the placebo group (p<0.05). There was no significant effect of
tamoxifen on bone mineral density in the proximal femur (Grey et al., 1995). Other
studies have shown a stabilisation of bone mineral content in the forearms of
tamoxifen treated patients compared with a decrease in controls (Kristensen et al.,
1994). All of these studies demonstrated significant falls in biochemical markers of
bone turnover, such as serum alkaline phosphatase and ionised calcium. There are
published data suggesting that an exposure duration of as little as 10 weeks in women
over 70 years of age, is effective in inhibiting bone turnover (Kenny et al., 1995).
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Histological data on bone turnover, in 41 postmenopausal women, also provided
early evidence that tamoxifen did not have an antiestrogenic effect on bone and
indicated a possible oestrogenic effect. There was no evidence of an adverse or
protective effect of long-term tamoxifen treatment of the elemental composition of
bone minerals (Kalef et al., 1996).
Few data are available on the skeletal effects of tamoxifen therapy in premenopausal
women. Evidence from the ovariectomised rat model suggests that, whereas
tamoxifen mimics the action ofoestrogen in the postmenopausal skeleton, it may have
an antiestrogenic action on bone in the presence of circulating oestrogens (Sibonga
et al., 1996). Short-term administration (3 or 6 months) of tamoxifen to
premenopausal women with benign breast disease (mastalgia) did not measurably
influence spial or femoral bone density (Fentiman et al., 1989). However the
iteraction seen in the preclinical data is supported by data coming out of the
chemoprevention studies, with a transient bone loss reported durig the first two
years of treatment in premenopausal women in the Royal Marsden pilot prevention
trial (Powles, 1998). The effect of tamoxifen on the skeleton is therefore far from
clear and may differ depending on menstrual status.
Fractures
Although there are a lot of published data relating to measurement of BMD in
tamoxifen treated patients, there are little data relating these observed effects of
tamoxifen on bone mineral density to the incidence of fractures in women who are
receiving, or have received, tamoxifen treatment. To date, only one such study has
been published by the Danish Breast Cancer Cooperative Group, in which the
incidence of fracture in 1,716 postmenopausal women randomised into a trial of
adjuvant tamoxifen was determined by data linkage with the Danish National Registry
of Patients. The results show a similar incidence of fracture of the femur between the
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tamoxifen and control groups (64 and 51 cases respectively). Eleven patients in the
control group had one trochanteric fracture compared to 27 patients in the tamoxifen
group (HR=2.12, 95% CI:1.12-4.01) suggesting that tamoxifen use may increase the
risk of fractures at certain sites. (Kristensen et al., 1996).
3.6 Ocular effects
3.6.1 Mechanisms
The National Registry of Drug-Induced Ocular Side Effects records tamoxifen as
being implicated in the development of superficial corneal opacities, decreased visual
acuity and retinopathy (Fraunfelder & Meyer, 1983). These effects seem to occur at
higher doses of tamoxifen and are rarely seen until treatment has been ongoing for
about 12 to 18 months. It has been proposed that excitotoxic effects in the retina are
caused by an extracellular accumulation of glutamate. Glutamate uptake by pig retinal
pigment epithelial cell cultures is reduced in the presence of tamoxifen in a dose-
dependent fashion (Maenpaa et al., 1997). Cell culture studies have demonstrated that
tamoxifen exposure causes a decrease in activity of lysosomal enzymes within the
retinal pigment epithelium resulting in possible eye toxicity (Toimela et al., 1995).
The potential role of tamoxifen in the development of cataracts has been studied in
isolated bovine lens fibre cells in culture. Opacification of the lens appears to be
related to the effect of tamoxifen in blocking the chloride channels in the lens of the
eye. These channels are essential for maintaining normal lens hydration and
transmittance and for the process of volume regulation. Inhibition of the chloride
channels results in inhibition of volume regulation, lens swelling and opacification
(Zhang & Jacob, 1996). Tamoxifen caused lens opacity, associated with cataracts, at
clinically relevant concentrations (Zhang et al., 1994) (Zhang et al., 1995).
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3.6.2 Clinical evidence
Much of the clinical evidence on the ocular toxicity of tamoxifen is anecdotal and
presented as case reports. An early report, published in 1978, described four patients
who had received high dose tamoxifen for over a year, three of whom had a
significant decrease in visual acuity as the result of a retinopathy accompanied by
macular oedema. Unusual corneal changes were also evident (Kaiser-Kupfer &
Lippman, 1978). Nineteen patients treated at normal dose levels for periods of 3
months to 4 years were also studied and no ocular changes were observed (Beck &
Mills, 1979).
Other case reports document a variety of ocular effects including tamoxifen
retinopathy (Gerner, 1989), bilateral optic neuritis (Pugesgaard & Von-Eyben, 1986),
bilateral optic disc swelling and retinal haemorrhage after 3 weeks of treatment which
were completely reversible on cessation of tamoxifen therapy (Ashford et al., 1988),
bilateral intraretinal opacities, lesions at the level of the retinal pigment epithelium and
cystoid macular oedema (McKeown et al., 1981). Prolonged low-dose therapy for 9
years has also been reported to cause bilateral retinopathy which was partially
reversible after tamoxifen was stopped (Chang et al., 1992). A larger study of 135
visually asymptomatic tamoxifen treated patients identified only two patients with
intraretinal refractile crystals, consistent with tamoxifen retinopathy. Corneal crystals,
macular oedema and optic nerve changes were absent (Heier et al., 1994).
A cohort study involving 79 patients who had received tamoxifen in conventional
dosage for varying treatment durations and 115 patients who had no tamoxifen
exposure found no evidence of ocular toxicity (Longstaff et al., 1989). In 1992, a
prospective study in 63 patients receiving treatment at a daily dose of 20 mg for a
median duration of 25 months reported a variety of optical findings including
decreased visual acuity, bilateral macular oedema, yellow-white dots in the
paramacular and fovea areas and corneal opacities in 6.3% of patients. These effects,
Page 59
Chapter 3 Other Health Effects of Tamoxifen
apart from the corneal opacities, were reversible on cessation of treatment and
suggest that there is ocular toxicity associated with long-term, low dose tamoxifen
therapy (Pavlidis et al., 1992).
The only large study ofocular toxicity in patients receiving tamoxifen therapy within a
RCT has been carried out within the NSABP B-14 study of adjuvant tamoxifen in the
treatment of early breast cancer, in which patients were randomised to receive 10 mg
tamoxifen twice a day, or placebo, The Tamoxifen Ophthalmic Evaluation Study
(TOES) was performed in 303 women in this trial and within the TOES study there
were women who had never received tamoxifen (n=85), women who had received
tamoxifen for an average of 4.8 years and then been off treatment for an average of
2.7 years (n=140), and women who had been on tamoxifen continuously for an
average of 7.8 years (n=78). Compared with untreated women, those who had
received tamoxifen showed no difference in visual acuity or other tests of visual
function, except colour screening. Intraretinal crystals (OR=3.58, p=0.178) and
posterior subcapsular opacities (OR=4.03, p=0.034) were more frequent in the
tamoxifen-treated group (Gorin et al., 1998).
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4.1 Record Linkage System
In addition to the main Glossary, a description of the terms used in this chapter is
provided in Section 4.9.
4.1.1 Background
The Scottish record linkage system provides a means of linking together computerised
hospital discharge records (SMR1), cancer registration records (SMR6) and death
records from the General Registry Office (GRO) belonging to the same patient
(Kendrick & Clark, 1993). The idea was first conceived in 1967 when the decision
was taken that all hospital discharge records, cancer registrations and death records
would be held centrally in machine readable form and would contain patient
identifying information such as names, dates of birth and areas of residence.
Implementation of this system began in 1968.
A number of linkages were performed between the late 1960's and the mid 1980's, in
which pairs of records were linked. In the late 1980's increased computing power and
data storage facilities made possible the linking together of the set of records
pertaining to a given individual and the linkage system was reconstituted. All SMR1,
SMR6 and the GRO death record pertaining to a particular patient are grouped
together and the resulting combined database, which currently consists of over 14
million records relating to over 4 million individuals, can be linked to external
databases. The combined database is thus a source of person-based as well as
episode-based data.
4.1.2 Quality checking of the combined database
Quality checking of the combined database by ISD has indicated that, on a pair-wise
basis, both the false positive and the false negative rates are around 1 %. However,
the combined database is composed of groups of records, each group consisting of a
primary record and all other records associated with that primary record. The larger
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the group of records, the greater the possibility that it contains one or more records
that do not belong to that individual. In particular, patient record sets containing a
death record have been found to have a relatively high error rate. An ongoing clerical
checking procedure aims to keep the overall proportion of patient record sets
containing a mismatched record to around 1%.
4.1.3 Probability matching
The basis of the procedure, whereby the combined database is linked to an external
database, is probability matching. A computer algorithm calculates a score or
probability weight, for each pair of records (one from the combined database and one
from the external database), which is proportional to an estimated probability that
they belong to the same person. The overall score is the sum of the scores derived
from the comparison of each item of identifying information. In principle, any item
whose level of agreement or disagreement influences the probability that the two
records do, or do not, belong to the same person can be used by the computer
algorithm. However, items should, as far as possible, be statistically independent. For
example, postcode of residence and hospital of referral are likely to be related and
could not be used as independently contributing data items.
The data linking process can be conveniently divided into three steps:
i) bringing the records together
ii) calculating the probability weights
iii) making the linkage decision.
The process has been described in considerable detail elsewhere (Kendrick & Clark,
1993, Kendrick, 1997).
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The key to the calculation of probability weights is the odds ratio, this being the ratio
of the frequency of a given outcome in pairs of records which relate to the same
person and the frequency of a given outcome in pairs of records which do not belong
to the same person. An odds ratio is calculated for every outcome of the comparison
between the two records and combined, by multiplication, to give an overall odds
ratio. Frequencies of outcomes are determined in the first place by a combination of
previous experience and common sense. For example, the odds ratio for agreement of
month ofbirth is around 12.
The probability weights derived do not represent absolute odds that the records
concerned belong to the same person but rather are relative odds, which order the
pairs in a particular linkage according to the likelihood that they belong to the same
person. The relationship between relative odds and absolute odds depends upon
several factors, including the way that the linkage is structured and this is one of the
most important aspects ofdesigning a linkage.
The absolute odds of a correct match can only be determined by clerical checking and
the decision on the threshold probability weight to use in a linkage is usually
determined by clerical inspection of a sample of pair comparisons across the weight
range. Based on this, the decision of the appropriate threshold to use can either be
completely automatic, or can use supplementary clerical checking within a 'grey
zone'.
The discrepant spelling of surname is one of the most common reasons for
mismatching identifiers in two records belonging to the same person. The procedure
at ISD involves combining two different solutions to this problem. Soundex codes are
generated by bringing together similar sounding constonants and ignoring vowels. The
Soundex code is combined with the NYSIIS name compression algorithm, whereby
other commonly miscoded elements of surnames are brought together. The resulting
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Soundex/NYSIIS code is treated as for any other identifier. Account is taken of how
frequently each code arises and the degree of letter-by-letter agreement between
abbreviated surnames.
4.2 Confidentiality and Data Protection
Before the project was undertaken, a proposal was submitted to and approved by the
Privacy Advisory Committee of the Information and Statistics Division. Submission to
local ethics committees was not deemed necessary for this study. The use of named-
patient data was required for the study and the data protection requirements were
covered by the Data Protection Registration of the University of Edinburgh. It was
necessary to use named-patient data in order to access relevant trial documentation
and case-notes and due regard was paid to confidentiality at all times. The final
database for statistical analysis did not include patient names. The named-patient data
was archived, with password protection, and will be deleted in line with the request of
the PAC when final review of the thesis is complete.
4.3 Linkage with the Scottish tamoxifen trial data
4.3.1 Procedure
The Scottish tamoxifen trial database was created and maintained on a relational
database system (Knowledge Man vl.07, Micro Data Base Systems Inc.) at the
Scottish Cancer Trials Office at the University of Edinburgh until November 1993.
The trial notes and computerised database were then transferred to the Scottish
Cancer Therapy Network in Edinburgh, for archiving.
Key variables on this database, which were to be matched against variables on the
combined database during the linkage procedure, were exported into ASCII format
onto a 3.5" diskette and sent to ISD where the linking process was undertaken.
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Region ofhospital referral at breast cancer diagnosis
(Aberdeen, Dundee, Edinburgh or Glasgow)
Date of randomisation
Date ofdeath, if applicable.
The sex of all patients was known to be female and this was used in the matching
algorithm. The information on region of referral was a stratification variable in the
trial randomisation and was coded into the 7 digit trial number for each subject.
The linkage procedure carried out by ISD involved the comparison of trial records
with records on the combined database and assigning a probability weight which, as
already discussed, reflects the possibility that the records belong to the same
individual. On the advice of the experts at ISD, a probability weight of 15 was chosen
as that below which the chance of detecting a true match was minimal. If two linked
records had a matching score of 15 or greater then they were retained on the linked
dataset. In addition, the complete group of records associated with the primary linked
record on the combined database was also added to the linked dataset. Linked records
with a matching score of less than 15 were not added to the linked dataset.
4.3.2 Scope of the linkage output
The first output, containing the results of the linkage of Scottish tamoxifen trial
records with the combined database, was received from ISD in November 1996. At
that time, the combined database contained SMR1 records from 1981 to 30th June
1985, SMR6 records from 1980 to 31st December 1992, 90% of registrations for
1993 and approximately 60% of those from 1994. Death registration was complete
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from 1980 to 31st December 1994. Recruitment to the trial started in 1978; therefore
events occurring in 1978 and 1979 were not captured by the linkage process. Details
of an update to the linkage are described in Section 4.5.
4.3.3 Processing of linked dataset
The linked dataset was received on 3.5" diskette as a compressed ASCII text file
which was decompressed onto the hard drive of a pentium desktop computer. ASCII
files are, by definition, unstructured and unformatted and, in order to facilitate
utilisation of these data, it was necessary to import the file into a database or
spreadsheet software package. A relational database was created in Microsoft Access
and the data imported into this structure. A description of the fields created for the
database is given in Table 4.1 and sample output of the data after importing into the
database is shown in Figure 4.1.
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Table 4.1
FIELD NAME DESCRIPTION
Miscl Numeric identifier defining source of the
data:
1 = SMR1 Record
6 = SMR6 record
9 = death record
Surname Surname
Initial First Initial
DOB Date ofbirth in format yyyymmdd
Misc2 Sex (2=Female) and Marital Status
l=single, 2=Married, 3=Widowed,
8=Other, 9=NK
Postcode Postcode of address at trial entry
Dates SMR1: dates ofadmission, discharge,
outcome code
SMR6: date of registration and ICD9
code ofmalignancy




Cause SMR1: ICD9 codes for reason for
admission
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Figure 4.1 shows clearly that the data are presented as groups of records, with the
matching score, or overall probability weight, derived from the linking process,
appearing in the column Miscl and in the row immediately preceding the first member
of the group. This score is given as a numeric value to two decimal places and, as
previously described, is a measure of the relative odds that the trial record and the
record from the combined database with which it has been matched relate to the same
individual. A single record in each group is marked with an asterisk (*). This is the
primary record in the group which has been matched with the trial record. All other
records in the group are linked to this primary record in the combined database and so
they too are added to the linked dataset. However, it is important to remember that
the matching score relates only to the relationship between the primary record and the
trial record, and that no matching score is allocated to the other members of the
group. It is known from the quality checking procedures at ISD that in up to 1% of
groups in the combined database, one or more of the records belongs to a different
individual. It is therefore essential that all records in a group be reviewed as part of
the validation procedure, which is described in detail in Section 4.4.
The first row ofeach group, immediately below the matching score, contains the data
relating to the patients in the tamoxifen trial and comprises, from left to right,
surname, initial, date of birth, region of hospital referral (Aberdeen (A) Edinburgh
(EH) Dundee (DD) Glasgow (G)), date of death (000000 if not applicable) and date
of randomisation. Dates are all recorded in the format yymmdd, except for date of
birth which records a 4 digit year. The remaining records in each group contain the
data from the combined database which has been linked with that trial record.
Although not illustrated in Figure 4.1, a. single trial record may appear several times in
the linked dataset, having been linked with different primary records with different
matching scores. Only one of these linkages can be correct and this is assessed during
the validation process (Section 4.4).
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For SMR1 records the field Miscl includes a hospital case reference number. This is
specific for each episode of hospital admission and one individual may have several
different numbers. Therefore, this is not a particularly useful variable in the linkage
validation process except that if it is identical for two records, then this is
confirmation that the records belong to the same individual.
The information in the field Dates, varies depending on whether the source of the
information is SMR1, SMR6 or GRO death records. For SMR1 records the field
contains, from right to left, date of admission, date of discharge and a single digit
code indicating outcome of admission (discharge home or to another hospital, death
with or without postmortem, transfer to another speciality). For SMR6 records,
Dates contains the date of registration, the ICD9 classification of tumour site and a
procedure code. For GRO records, Dates contains date of death and ICD9 codes for
cause ofdeath.
For SMR1 records, the field Proc_date contains the date of any procedure (000000 if
no procedure was carried out) and Proc contains the procedure code. These fields are
both blank for SMR6 and death records.
The field Cause contains up to six reasons for admission to hospital for SMR1
records. The field is blank for SMR6 and death records.
4.3.4 Re-formatting of output structure
It is quite clear from Figure 4.1 and the above description that the Access database
created from the linked dataset has a variable record structure and is therefore not
immediately suitable for manipulation and interrogation in the normal way. In order to
produce a database that conformed to the conventional structure of columns (fields)
and rows (records), it was necessary to reformat the structure. A conventional
database structure was required so that records could be selected according to
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particular specified criteria; e.g. those with a probability score of 20 or those with an
ICD9 code of 4109 (myocardial infarction). None of the reformatting changes
described below involved editing the data in any way; only structural changes to the
database and the way in which the data are distributed within the database fields were
involved. Visual checks against the original data file were made on an ongoing
database to validate the changes. Master copies of the original data file and the
original database, before the described structural edits were carried out, were retained
for reference and archived under password protection (Section 4.2).
The main structural change made to the Access database was to create a field, Score,
which was populated with the matching score for every record in a linked group. As
has already been illustrated, the matching score in the original ISD output refers to the
match of the primary record from the combined database with the trial record. If all
records in the group refer to the same patient then that score is valid for every
member of the group. However, as has already been described, 1% ofgroups or more
contain a mismatched record. This field was therefore populated manually and due
care was taken during the process to identify all possible instances of a mismatched
record within a group. The occurrence of mismatches within a group is discussed
more fully in Section 4.4.1. Validation of apparently discrepant members of a group
was carried out using those checking procedures described in Section 4.4.2.
Table 4.1 also illustrates that SMR6 and GRO records differ from SMR1 records in
the location of the ICD9 code which identifies the events. For this reason, the single
digit identifying the source of the record (SMR1, SMR6, GRO) was split off into a
separate field, Type. This enabled separate criteria searches to be instigated for SMR6
and GRO records.
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The final structural change to the database was to create six discrete fields from the
field Cause, in order to separately record each ICD9 code of reason for admission
and thereby facilitate the search for relevant endpoints.
The final structure of the database was defined, in part by the original output received
from ISD. It was not possible to attain a totally regular row structure as the first
member of each group was necessarily the record from the Scottish trial data, which
had a different field structure to that of the linked group from the combined database.
An example of the final database for a single group of records is illustrated in Figure
4.2.
4.4 Linkage Validation
4.4.1 Mismatches within a group
Figure 4.2 also provides an illustration of the presence of a mismatched record within
a group. It can be seen that all members of the group have the same surname, initial
and date of birth but there are different hospital case reference numbers and
postcodes. Hospital case reference numbers refer to particular episodes of
hospitilisation and differences in this number are therefore not a valid criterion for
discarding a match although, if they are the same, that is sufficient information to
confirm a match. Postcode is dependent on address and may therefore change during
the course of follow-up. In Figure 4.2, the date of hospital admission ofRecord 14 is
after the date of death in Record 13. These records clearly belong to different
individuals. Records 2-13 refer to the tamoxifen trial patient identified in Record 1,
with agreement in the dates of breast cancer diagnosis/date of randomisation {Record
3) and date of death {Record 13). Records 14-19 refer to a different individual, who is
not a trial patient. The examples in Figures 1 and 2 are based on real data but the
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It is important to identify these cases ofmismatches within a group in order to avoid
false ascertainment ofevents. In the example shown, the individual, who we know is
not a trial patient, is recorded as having suffered a myocardial infarction, which is one
of the endpoints of the study. Failure to detect such mismatches could be a source of
error in the study.
During all validation procedures, every effort was made to identify groups which
contained one or more records incorrectly linked to the primary record matching the
trial record. Changes in surname and postcode occur relatively frequently in the
patient population in the study and where such changes were observed in a group of
records, careful manual checking was carried out. Nevertheless, the only method of
detection of mismatches within a group was by observation and incidental finding.
Complete ascertainment cannot therefore be guaranteed. In Figure 4.2 it can be seen
that the records in the group that are mismatched with the primary record have not
been assigned a matching score. This ensures that they will not be selected during the
ascertainment ofevents which is described in Section 4.6.
4.4.2 Clerical checking
All linked records with a matching score of 15 or more were included in the output
received from ISD. Scores were given to 2 decimal places but were truncated at the
whole number for the purposes of verification. It was not feasible, nor considered
necessary, to check clerically all of these records and a decision had to be made which
matches could be accepted or rejected without further checking.
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From the previous experience of the author, working with output from similar data
linkage procedures, it was known that matches with scores of 24 or more were robust
and those of scores 16 or less were, for the most part, mismatches. An arbitrary
decision was taken to check all matches with a score of20 and to subsequently work
progressively up from this score until the point was reached when the absolute odds
of a true match were 95 15 - i.e. 95% of the matches were verified as true matches.
All scores above this would be accepted as true matches without further checking. In
the same way, scores of less than 20 would be progressively checked until the score
which yielded 5% or less of true matches was reached. All matches with scores less
than this value would be rejected as mismatches without further checking. In this way,
the risk of including false positive matches or of excluding true matches was
minimised while, at the same time, maintaining a manageable level of clerical
checking.
All groups having a score of 20 were therefore printed out for manual checking as the
first step in this process. Verification of the matches was done by following the
procedure illustrated in the flow diagram (Figure 4.3). The process was complicated
by the fact that it was not always possible to compare like with like. For example, the
combined dataset contains a postcode, whereas the trial database only records the
region of referral. Also, the trial database has the date of randomisation whereas the
combined dataset has the date of diagnosis, which may or may not be the same as the
date of randomisation.
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Flow diagram for validation of linked records in tamoxifen trial and combined
databases
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If it was not immediately clear whether records were matched or mismatched, then
further validation steps were required. This involved firstly checking the dates of
breast cancer diagnosis and death which were recorded on the trial database against
the SMR6 and GRO records, and secondly reviewing the trial notes, located in SCTN
Central Office, to check date of birth, postal address and any surname changes. Date
of birth is a variable that is commonly recorded inaccurately. The algorithm used to
calculate the probability score is weighted heavily on date of birth as a matching
variable and it therefore has considerable influence on the final matching score. An
error in recording date of birth can therefore result in a true match having a falsely
low probability score. These errors could often be detected by review of the
documentation filed with the trial notes.
A further validation check was to compare the postcode provided on the linkage
output against the address recorded on the trial notes at time of entry into the study.
The postcode was not recorded on the trial database and so was not used in the
linkage procedure, but it was requested on the linkage output for the purpose of
providing additional verification. Its use was limited, however, in that the only
address routinely recorded in the trial notes was that at the time of trial entry.
Sometimes additional trial documentation highlighted a change of address that could
be reconciled with the postcode included on the linkage output.
One of the most reliable criteria for discarding a match, and one that was used quite
frequently, was if a trial record had an alternative matched record which could be
positively verified. No cases were detected where two matches were provided and
there was ambiguity about which of the matches was 'true' and which was 'false'. In
every case, the 'true' match could be positively identified. Further, no cases were
detected where two matches involving the same individual had a matching score
which would automatically classify both as 'true' (>23).
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One particular reason in this study for 'true' matches having a low probability score is
related to the trial numbers allocated to those patients randomised into the Pilot B
trial, which was one of the four constituent trials of the Scottish adjuvant tamoxifen
trial. Pilot B was the earliest of the four trials and patients came from Dundee and
Edinburgh. The trial numbers allocated to patients in this trial were not consistent
with the algorithm used to determine the area of referral for patients in the other three
trials; Trials B, C and D.
Although as standardised a procedure as possible was employed during the
verification process, the efforts described above illustrate that, in addition to the
formal procedures, keen observation was required and informed judgments had to be
made. During the verification process, the author remained blinded to tamoxifen
status.
4.5 Linkage updates
4.5.1 Scope of update
In April 1998, an update of the linkage between the tamoxifen trial database and the
ISD combined dataset was obtained, both on disk and as hardcopy. This update
included SMR1 data to 31st March 1996 and SMR6 and GRO death records to 31st
December 1995 and this reflected the status of the combined database at this time.
4.5.2 Processing of linkage update
There were two possible strategies for processing the updated linkage. Firstly, a
database could have been created and the linkage data imported into this and
subsequently processed as already described. Comparison of the two databases would
have identified the new data from the updated linkage. The second possibility was to
process the updated linkage data from hardcopy listings. The decision was taken to
proceed with the latter option, primarily because the procedures in Microsoft Access
for comparing two databases and fisting the discrepancies are cumbersome. Further,
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the author already had considerable experience of working with hardcopy listings of
linkage output and felt that a manual procedure could be implemented more quickly
and effectively.
The hardcopy output was scrutinised and all events occurring in 1995 or later were
highlighted. The matching score of each highlighted record was checked and matches
were accepted or rejected as before on the basis of this score. Scores of >23 were
accepted, scores of <18 were rejected and scores of 18 - 23 were checked manually
according to the criteria already described. Each accepted match was then reviewed
individually and where any of the predefined endpoints under study were present, this
record was added to the analysis database which is described in Section 4.7.
4.6 Ascertainment of 'Events'
After validation of the record matching was completed, the validated dataset was
searched for records containing the ICD9 classifications shown in Table 4.2. These
endpoints were predefined on the evidence of tamoxifen morbidity from the earlier
studies and from the medical literature.
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Table 4.2
Description ICD9
Ischaemic Heart Disease (IHD):
acute myocardial infarction (MI) 410
Other HID (excluding acute MI)
excluding 412 (old myocardial infarction) 411,413,414
Cerebrovascular Disease




pulmonary embolism, phlebitis, thrombophlebitis 451,415.1
Skeletal Effects:
Fractures 800 - 829
Malignancy:
primary neoplasms





Disorders of the eye and adnexa 360-379
Dementias:
Senile and presenile organic psychotic conditions 290
Benign Endometrial Disorders:
endometriosis - uterus




Endpoints and their ICD9 classification, for the study ofmorbidity within the
Scottish adjuvant tamoxifen trial
Note: where an ICD9 code is given to 3 digits, all further subclassifications are included e.g. 451
includes 4510-4519 inclusive
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The study does not attempt to look at the incidence of contralateral breast cancers
occurring within the Scottish adjuvant tamoxifen trial as the ICD9 coding does not
allow differentiation of the original breast tumour from new disease in the
contralateral breast.
Dementia was considered to be a valid and interesting outcome for study because,
although there are little data relating tamoxifen use to dementia, there are data which
indicate that postmenopausal oestrogen use can ameliorate the effects of Alzheimer's
disease (Whitehead, 1996) or exert a protective effect on the risk of developing
Alzheimer's disease (Kawas et al., 1997). Studies in the ovariectomised rat model
have shown that oestrogen replacement is active in tests of learning and memory and
activates basal forebrain cholinergic neurons and neurotrophin expression. In tissue
culture, oestrogen is neuroprotective for human neuronal cultures (Simpkins et al.,
1997). The level of interest in this topic is illustrated by the fact that cognitive
function is one of the outcomes being studied in the Multiple Outcomes of Raloxifene
(MORE) study of the drug raloxifene. This molecule has some oestrogenic and
antiestrogenic actions and is currently marketed for the treatment of postmenopausal
osteoporosis. Raloxifene and the MORE study are discussed further in Chapter 12.
For ischaemic heart disease, classification 412 (old myocardial infarction) was
omitted, as was classification 438 (late effects of cerebrovascular disease) in the
cerebrovascular disease category. These classifications do not allow determination of
the date of the definitive causal event. In the identification of new primary tumours,
only invasive malignant tumours are included - in situ cancers are excluded. The
ICD9 classification of phlebitis and thrombophlebitis (451) is referred to throughout
the text as deep vein thrombosis.
The database was searched by defining queries in MS Access for each of the
endpoints of interest. Separate queries were required to search SMR1, SMR6 and
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GRO death records, as already described, because of the structure of the database.
The queries were generated in SQL (Structured Query Language) and some examples
are included as Appendix 3. The use of cause of death and SMR6 data to determine
events distinguishes this study from that previously published in which linkage was
only with SMR1 and therefore, relevant events which were only notified as a cause of
death could not be ascertained.
4.7 Analysis Database
A database (Tambase) was created in Microsoft Access containing a record for each
of the 1312 tamoxifen trial patients. Key variables were imported directly into the
analysis database from the original tamoxifen trial database, to avoid transcription
errors, and updated as necessary. The fields and field descriptions of these key
variables of the analysis database are shown in Table 4.3.
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Table 4.3
Variable Name Description
trlno 7-digit tamoxifen trial number
dob date ofbirth
drand date of randomisation
option randomised option
drnr date of systemic relapse
dd date of death
tstart date tamoxifen started
tstop date tamoxifen stopped
dfup date of last information
Key variables on analysis database (Tambase) imported from original trial
database
In addition to the variables in Table 4.3 a field for each of the endpoints being studied
was created in which to record the date of the event. If the event had occurred this
field was populated otherwise it was left blank. The analysis database was updated
manually with the relevant information, which was obtained by interrogation of the
linked dataset to determine the incidence of the endpoints of interest.
Manual updating was necessary because of the different ways in which a patient was
identified on the linked dataset and the analysis database. Patients were identified on
the linked dataset by name and date of birth, while they were identified on the analysis
database, which did not contain patient names, by their unique 7 digit trial number.
Determination of a patient's trial number from their name and date of birth was
achieved by reference to a printed list which contained all three variables. If a
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particular event had occurred, the date field for that event was populated with the
date of first occurrence of the event, as noted by the date of admission to hospital,
date of new primary cancer or date of death for SMR1, SMR6 and GRO death
records respectively. Otherwise this field was left blank.
Two further checks were made as the analysis database was being updated. Firstly,
the date of birth on this database was checked against the date of birth on the linked
dataset, thus providing a further validation check of the linked dataset. Secondly, the
date of the event was checked against the date of randomisation. If the event occurred
prior to randomisation then it was not included on the database and the first
occurrence of that event occurring after randomisation, if available, was entered onto
the analysis database. If there was no subsequent recording of the event, then the date
field in the analysis database was left unpopulated.
A number of calculated variables were also added to Tambase. This procedure is
described in Chapter 5, Section 5.2.3. The complete structure of the resulting
database is attached as Appendix 4.
4.8 Trial Follow-up
4.8.1 Procedures
Tamoxifen trial follow-up was performed routinely by staff at SCTO, on an annual
basis, until transfer of the trial database to SCTN in 1993, at which time routine
follow-up stopped. At the time of the previous publication (McDonald et al. 1995),
for which linkage data to 31st December 1992 were used, there were 661 patients
alive and free of systemic relapse for whom further information on tamoxifen start and
stop dates, date of systemic relapse and date last seen or date of death were required.
However, it was decided to update the follow-up information on all alive patients,
including those for whom a date of metastases was recorded, in order to allow
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analyses to be performed which did not use the onset of metastatic disease as a
criterion for censoring.
New information on dates of patient follow-up, together with details of disease
recurrence and tamoxifen status (duration, stopped, continuing) were kindly supplied
by Dr. Helen Stewart on a Microsoft Excel spreadsheet. Data were available to 1996
or 1997 for most patients. The date of follow-up (d_fup), date of systemic relapse
(drar), date of death (dd) were extracted from the spreadsheet and added to the
analysis database. New information on tamoxifen start and stop dates (tstart, tstop)
dates were also added, using the assumptions described in Section 4.8.3 to determine
actual dates from the tamoxifen durations supplied by Dr Stewart.
During this updating process, a number of discrepancies were identified between the
analysis database (Tambase) and the spreadsheet. These arose because of routine
edits made to the original trial database since the data were downloaded to Tambase.
The discrepancies were reviewed and resolved individually by the author and Dr
Stewart, to ensure consistency was maintained between Tambase and the trial data
on the spreadsheet. As far as possible, follow-up information was obtained at the
anniversary of the patients' mastectomy. However, as time from mastectomy
increased, so did the likelihood that the patient had been discharged from routine
hospital follow-up into the care of her GP. In an attempt to elicit the most up to date
information, follow-up details were obtained by Dr Stewart for times other than the
anniversary dates. All available follow-up information was utilised, as it was
considered that the ascertainment of these data was random and not related to the
occurrence of a particular event.
The manual procedures, as described, for updating the analysis database were
laborious but unavoidable, due to the availability of the data from a number of
different sources. However, there is an advantage in that these procedures involve
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checking and re-checking the data and are therefore likely to result in data of greater
integrity and quality.
4.8.2 Definition of systemic relapse
For most of the analyses in the current study, patients were censored at systemic
relapse. Censoring is discussed in Chapter 5, Section 5.1.6. The definition of systemic
relapse used was in accordance with that defined in the protocol for the Scottish
adjuvant tamoxifen trial and the current staging definitions in use when the trial was
started (TNM Classification of Malignant Tumours, UICC, Third Edition, 1978)
Metastasis to the ipsilateral supraclavicular fossa constituted local rather than distant
spread. Whether disease in the contralateral breast was recorded as a new primary
breast cancer or as metastatic relapse was according to arbitrary rules defined and
implemented at the Scottish Cancer Trials Office. These rules stated that a cancer in
the contralateral breast was a new primary cancer, rather than metastatic spread of the
original tumour, ifall of the following applied:
i) this was the first recurrence of disease
ii) the disease occurred more than one year after the initial cancer
iii) there was no subsequent relapse of disease for at least one year
Disease occurring in the contralateral axillary or supraclavicular nodes, with no breast
involvement, was always considered to be distant metastatic spread.
Forty-seven (47) new breast primaries in the contralateral breast are recorded on the
trial database which conform to the definition above. One more occurred in a patient
who had already experienced a new primary cancer of the cervix. A further six
contralateral breast cancers were recorded, which did not conform absolutely to the
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strict definition used by the Scottish Cancer Trials Office, but were nonetheless
recorded as new primary breast cancers. Five of these were diagnosed before one year
had elapsed after the initial breast cancer diagnosis. In one case, the patient died from
other causes within one year of the diagnosis of the contralateral breast cancer. These
54 cases have therefore not been classified as metastatic disease and censoring has not
been applied. Where contralateral relapse occurred only in the axilla or supraclavicular
fossa, this has been deemed to be distant disease and censoring has been applied from
the date of occurrence.
4.8.3 Assumptions regarding tamoxifen status
Knowledge of a patient's tamoxifen status at all time-points throughout the follow-up
period is a key feature of the analysis and this requires recording of the tamoxifen
start and stop dates on the analysis database. The dates themselves were not recorded
on the spreadsheet from which trial follow-up data were obtained but tamoxifen
duration, in months, was recorded together with information on whether therapy was
continuing or the year in which it had stopped. In particular, a number of elderly
patients who had been receiving tamoxifen treatment for a number of years had
elected to stop during the period since the last follow-up. A number of assumptions
were implemented in order to deduce the tamoxifen start and stop dates required for
the analysis from the information available. All calculations were to the nearest month
and the 15th day of the month was used in subsequent analyses.
i) If tamoxifen start date and duration of tamoxifen are known, then the
date tamoxifen stopped was calculated from:
(date started + duration).
If the date of last follow-up is before this calculated stop date, date of
last follow-up was used.
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ii) If the tamoxifen duration is known and treatment was continuing at the
last follow-up or the patient had died on therapy, the tamoxifen start
date was calculated from:
(date of follow-up or date of death - duration)
This would be expected to coincide approximately with a recurrence
date for patients in the control arm.
There were a number of cases where tamoxifen therapy of a known duration had
stopped but neither start nor stop dates were recorded on the analysis database. These
cases were reviewed individually and the necessary information obtained from trial
records held by Dr Stewart.
4.9 Glossary
Refer also to main Glossary
SMR1 database ofScottish hospital discharge records
SMR6 database of Scottish cancer registration records
GRO death records death certification as notified to the General Registry Office
combined database combined database of SMR1, SMR6 and GRO records, held at
ISD
linked dataset dataset obtained by linking the combined database with the
Scottish tamoxifen trial database
validated dataset linked dataset after removal of those records, shown by
verification procedures, not to be true matches
analysis database database containing a record for each of the 1312
('Tambase') tamoxifen trial patients, with details of all the endpoints under
study and their dates of occurrence, obtained from
interrogation of the validated dataset
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5.1 Overview of statistical methods
5.1.1 Survival analyses
Survival analysis is a set of statistical techniques used in studies that investigate the
occurrence ofdefined point events in time (or similar linear dimension), sometimes
referred to as failure events. The data for analysis in this study take the general
form of survival data and the failure time is the time from the time origin to the
occurrence of the event under study. The time origin in this case is the date of
randomisation into the study. Thus:
failure time = time of failure event - time origin
It is important that the key variable, failure time, is determined as reliably as
possible. This requires a clear and unambiguous definition of the outcome of
interest and the time origin of the study.
A key feature of the methods of survival analysis is the ability to deal with
incomplete information. This most often occurs because observation has not
continued until all individuals in the study have experienced the failure event; for
example, because follow-up has stopped or because the individual has died from an
unrelated cause. The method for allowing for incomplete information is known as
censoring. This situation is represented in Figure 5.1
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Figure 5.1
Individual








Schematic representation of censoring
Censoring is discussed in more detail in Section 5.1.6.
Survival data can be illustrated by a life table, which allows us to look at the time
course of an event and calculate the probability of an event occurring at a
particular time since the start ofobservation.
Table 5.1 below shows a very simple example of data for 45 women with breast
cancer randomised into a clinical trial (Leathern & Brooks, 1987). The data are
divided into two groups depending on whether the tumour was negatively or
positively staining to a particular histochemical marker. The time origin is the date
of surgery for breast cancer and the outcome of interest is death from breast cancer.
Women who survived to the end of follow-up, or whose survival status was not
known at the end of the study, were given a censored survival time to the date of
last known follow-up. Similarly, women who died from a cause other than breast
cancer were given a censored survival time. Censored survival times are denoted
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by an asterisk (*) in Table 5.1. These data are used to illustrate some of the

























Survival times (months) for women in breast cancer study (Leathern &
Brooks, 1987)
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Table 5.2 illustrates the life table that has been derived from these data and the
calculation ofthe Kaplan-Meier estimate of the survivor function (S(t)). This
method ofestimating the survivor function, also known as the product-limit
estimate, utilises all the information that has been obtained from censored and non-
censored individuals. To determine the Kaplan-Meier estimate of the survivor
function from a sample ofcensored survival data, a series of time intervals is
formed. Each of these intervals is constructed to be such that at least one failure
time is contained in the interval and this failure time is taken to start at the start of
the interval. It is assumed that deaths of individuals in the sample occur
independently of one another. Note that no interval starts with a censored survival
time. Table 5.2 illustrates that censored individuals are no longer at risk of
experiencing the event and the number at risk decreases by the sum of the number
ofdeaths and the number ofcensored individuals.
The estimate of the survivor function, denoted by S(t), is the probability of
surviving to time t and is the product of the probabilities of surviving through all
time periods preceding time t. S(t) is a non-parametric estimator of the true
survivor function; i.e. no assumption is made about the mathematical form of the
'true' curve S(t). It can be shown mathematically that, assuming censoring occurs
at random and survival times are measured exactly, S(t) is a consistent estimator of
the true survivor function and the estimate converges to the true value as the
sample size increases.
The estimated survival function for the probability of surviving
from 0 to t, where tj < t <tj+i
S(t) = 7To<t<j-i (p) x pj
Pj = probability of surviving period j, conditional on having
survived to time j-1, = (1-d/n)
where d = number of deaths in period j, n = number at risk at start of
period j
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Table 5.2
Group 1:
Interval Time At Risk Dead Censored Survivor Function
1 5 32 0 0.96875
2 8 31 0 0.9375
3 10 30 0 0.90625
4 13 29 0 0.875
5 18 28 0 0.84375
6 24 27 0 0.8125
7 26 26 0 0.75
8 31 24 0 0.71875
9 35 23 0 0.6875
10 40 22 0 0.65625
11 41 21 0 0.625
12 48 20 0 0.59375
13 50 19 0 0.5625
14 59 17 0 0.5
16 68 16 0 0.46875
17 71 15 4 0.4375
18 113 10 1 0.39375
19 118 8 0 0.34453
20 143 7 6 0.29531
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Calculation of Kaplan-Meier estimate of survivor function for two groups of
sample data in Table 5.1
These data can also be presented graphically in the form of a survival curve, by
plotting the survivor function against the survival time. The survival curve for the
data for all subjects in Table 5.1 is presented in Figure 5.2
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Survival curve for data in Table 5.1
5.1.2 Log rank test
The most common test for comparing the survival of two groups is the log rank
test, also known as the Mantel-Haenszel test. This test compares the distribution of
failures between two groups across the time-span of the study. It tests the null
hypothesis that there is no difference in the survival experience of individuals in
the two groups. The expected number of failures, assuming survival is the same in
both groups, and the observed number of failures can be calculated for each group
at each failure time. The test statistic is calculated by summing the deviation of
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observed from expected frequencies, over all distinct failure times, and dividing by
an estimate of the standard error of this total deviation. Thus, the test statistic
summarises the extent to which the observed survival times in the two groups
deviate from those expected under the null hypothesis of no group differences. The
null hypothesis is rejected if the calculated value of the chi-square test statistic,
with one degree of freedom, is very unlikely and we can conclude that there is a
statistically significant difference in the survival experience between the two
groups. An example of the calculation of the log rank test is given in Table 5.3 for
the sample data in Table 5.1.
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5 0 13 1 32 1 45 0.2889 0.2054
8 0 13 1 31 1 44 0.2955 0.2082
10 0 13 1 30 1 43 0.3023 0.2109
13 0 13 1 29 1 42 0.3095 0.2137
18 0 13 1 28 1 41 0.3171 0.2165
23 1 13 27 1 40 0.3250 0.2194
24 0 12 1 27 1 39 0.3077 0.2130
26 0 12 26 38 0.6316 0.4205
31 0 12 1 24 1 36 0.3333 0.2222
35 0 12 1 23 1 35 0.3429 0.2253
40 0 12 1 22 1 34 0.3529 0.2284
41 0 12 1 21 1 33 0.3636 0.2314
47 1 12 20 1 32 0.3750 0.2344
48 0 11 1 20 1 31 0.3548 0.2289
50 0 11 1 19 1 30 0.3667 0.2322
59 0 11 1 18 1 29 0.3793 0.2354
61 0 11 1 17 1 28 0.3929 0.2385
68 0 11 1 16 1 27 0.4074 0.2414
69 1 11 15 1 26 0.4231 0.2441
71 0 9 1 15 1 24 0.3750 0.2344
113 0 6 1 10 1 16 0.3750 0.2344
118 0 6 1 8 1 14 0.4286 0.2449
143 0 6 1 7 1 13 0.4615 0.2485
148 1 6 0 6 1 12 0.5 0.2500
181 1 5 0 4 1 9 0.5556 0.2469
Total 5 9.5652 5.9289
Calcu ation of log rank statistic for data in Table 5.1
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The variance, V = d x ni x n2(n-d) / (n2 x (n-1))
The expected failure in Group 1 (Ei), at time t
is calculated from:
(At risk in Groupl/Total at risk) x Total Failures
= (ni/n) x d
Extent of exposure to risk of death = 2 Ei = 9.565127
Chi-square test statistic = (O1-E1)2/ V with 1 df
=(5 - 9.565) / 5.929
= 3.515
P = 0.061
For the data in Table 5.1, describing the survival experience of two groups of
breast cancer patients, the P value is sufficiently small to cast doubt on the null
hypothesis that there is no difference between the survivor functions for the two
groups of women. .However, the results are not statistically significant at the 5%
level (p>0.05)
This is illustrated in the survival curve in Figure 5.2 in which the survival of both
groups is plotted separately. The plot shows that, at any time t, the estimated
probability of survival beyond t is greater for women with negatively staining
tumours.
The log rank test for two groups can easily be extended to the comparison of three
or more variables by calculating the observed and expected failures in each group
at each of the distinct failure times. The test can therefore be used to look at the
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effect of covariates with the limitation that the covariate must be categorised into
groups, (e.g. age less than 45 years and age greater or equal to 45 years).
Continuous variables cannot be incorporated into this model.
5.1.3 Hazard function
The hazard function at time t, h(t), is defined as the probability that an individual
will fail at time t, given that they have survived up to that point. This can be
expressed as:
h(t) = f(t) / S(t) where f(t) = probability of failure at t
S(t) = probability of survival to time t
The hazard is the rate of failure per unit time, and in order to estimate how 'risk'
changes across time for an individual, we can look at the hazard at different points
in time. This is illustrated in the survival curve in Figure 5.2. In the early part of
the study, the survival curve is falling rapidly and the hazard is high. Towards the
end of the follow-up period, the survival curve is virtually flat and the hazard is
near zero.
5.1.4 Proportional hazards model
One model for the analysis of the hazard function of two groups of individuals is
the proportional hazards model, proposed by Cox in 1972 (Cox, 1972). The model
is referred to as a semi-parametric model, as no particular form of probability
distribution is assumed for the survival times, and it provides a powerful and
versatile tool in the comparison of survival between groups and the effect of
prognostic variables on survival.
Implicit in this model is the assumption that the hazard at time t for an individual
in group 1 (hj(t)) is proportional to the hazard at the same time t for an individual
in group 2 (h2(t)); i.e. the ratio between them is independent of time.
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Thus:
hi(t) = vh2(t) where ig is a constant
The value of ig is the ratio of the hazards at any time for an individual in one group
relative to an individual in the other group and is known as the relative hazard or
hazard ratio. If vg < 1, then the hazard at time t for an individual in Group 1 is
smaller than the hazard for an individual in Group 2. If individuals in Group 1 are
on a new treatment and individuals in Group 2 are receiving standard treatment,
then this is indicative that the new treatment is superior to the standard treatment.
Comparison of two groups
The proportional hazards model for the comparison of two treatments can be
expressed as follows. Consider that X is an indicator variable, which takes the
value 0 if an individual is on standard treatment and 1 if the individual is on the
new treatment. If x; is the value ofX for the ith individual, then the hazard function
(hj(t)) for this individual can be written as:
hi(t)=e|!xi h0(t)
where p is the log of the hazard ratio (p = log ig)
and h0(t) is the hazard function for an individual on the
standard treatment
General form of the proportional hazards model
One of the objectives ofmodeling survival data is to determine how explanatory or
indicator variables affect the form of the hazard function. These may be
demographic variables, such as age and sex of the individual, physiological
variables, such as various blood parameters or heart rate, or lifestyle variables such
as diet and smoking history and they may be discrete (factors) or continuous
Page 100
Chapter 5 Statistical Methods - Part A
(variates). The proportional hazards model extends the methodology of the log
rank test, by allowing incorporation into the model ofmultiple explanatory which
may be factors, variates or a combination of the two types. The fundamental
assumption of the model is that the effect of an explanatory variable on the hazard
does not change with time (Tibshrani R, 1982). The effect of time-dependent
covariates is discussed in Section 5.1.5.
As well as the inclusion of factors and variates in the model, it is possible to allow
for the interaction between factors by incorporating an interaction term. This is
necessary when the effect of one factor depends on the value ofanother factor.
The generalised form of the model for the values xj, X2, xp, of explanatory
variables Xi, X2, Xp, can be expressed as
hi(t) = ¥(Xr)h0(t)
where hj(t) is the hazard function for the ith individual
and x is a vector representing the set of explanatory variables
such that x=(xi, x2 xp)'
The hazard function hj(t) can also be expressed as
hi(t) = exp(p1x1i+p2X2i+ +PpXpi) h0(t)
where p-i, p2, pP are the coefficients of the explanatory variables
The function ho(t) represents the particular case where the values of all the
explanatory variables that make up the vector x are zero and is known as the
baseline hazard. No explicit form for ho(t) is required for this model. The p
parameters can be estimated by the method ofmaximum likelihood (Section 5.4).
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5.1.5 Time-dependent covariates
When explanatory variables are incorporated in a model for survival data, the
values taken by these variables are those recorded at the time origin of the study.
The basic assumption of the model is that the value of these explanatory variables
is constant over time. An explanatory variable whose value changes over time and
whose value is known at all times during the course of the study, is a time-
dependent variable or updated covariate. Such variables can be incorporated in
models used in the analysis of survival data such that the most recent value is used
at each specific time in the modeling procedure (Altman 1994).
The general form of the Cox proportional hazards model, when some of the
explanatory variables are time-dependent, can be written as:
j=P
hi(t) = exp {ZPjXji(t)} h0(t)
j=i
The values of the variables Xj;(t) depend on the time, t and so the relative hazard,
h;(t) / ho(t) is also time dependent. In this model, the baseline hazard function,
ho(t), is the hazard function for an individual for whom all the variables are zero at
the time origin and remain at zero through time.
5.1.6 Censoring
As discussed in Section 5.1.1, censoring is a key feature of survival analysis and
allows for the presence of incomplete information. Censoring may be an inherent
feature of the design of a study, for example when the study ends at a pre-specified
point, before failure has occurred in all individuals. This is Type I censoring and
results in right-censored data, where in some individuals, the failure time is known
only to be greater than a specified value. Inadvertent censoring, where the
individual is lost to follow-up, withdraws from a study before failure or dies from
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another unrelated cause also results in right-censored data. An alternative study
design, less common in medical research, uses Type II censoring and the study
ends when a pre-specified proportion of failures has occurred. This also results in
right-censored data. There are also other, more complex types of censoring. In left-
censored data, the failure time is known only to be before the most recent
observation time and in interval-censored data the failure time is known to be at
some time between the present and preceding observation times.
Censoring, like failure, is a point event and it is important that the timing of the
occurrence of censoring is recorded as accurately as possible. An important
assumption in survival analysis is that the censoring process is independent of
individual survival times i.e. the likelihood of censoring is a random process and
does not give any prognostic information about the subsequent survival time of
that individual. This assumption is necessary so that the survival times of non-
censored individuals can be used to estimate the survival times of censored
individuals.
When the fact that censoring has occurred gives prognostic information about the
individual and indicates that either a shorter or longer survival time is likely, this is
described as informative censoring. Informative censoring introduces bias into
the analysis and the standard methods of survival analysis are no longer valid. Care
must be taken when defining censoring criteria that informative censoring is not
being applied.
5.2 Statistical methods in the current study
5.2.1 Censoring
Right-censoring was applied in this study at whichever of the following occurred
first:
• the date of last follow up information, after which no further
information was available on disease or tamoxifen status
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• 31st March 1996, after which no further linkage data were
available.
• the date ofdiagnosis of distant cancer spread
Censoring was applied at the onset of metastatic disease in order to remove the
confounding effect of the treatment of metastatic disease, particularly the use of
chemotherapy, on the analyses of thromboembolic disease. The treatment of
metastatic cancer with chemotherapy is a known, additional risk factor for
thromboembolic events (Saphner et al., 1991). Censoring at metastatic relapse does
not, however, guarantee the exclusion of patients receiving chemotherapy as, for
example, some other cancers including new primary contralateral cancers may be
treated by this modality. However, the number of subjects receiving chemotherapy
and not being censored in the analyses is likely to be very small. Censoring at
metastatic disease was applied in the earlier published studies and it was therefore
deemed appropriate to use the same censoring criteria in this study.
In the original tamoxifen trial database, data on contralateral relapse in the breast,
axilla and supraclavicular fossa was collected separately and arbitrary rules applied
to define whether the disease was a new primary cancer or metastatic from the
original tumour. In this study, 54 cases of cancer occurring in the contralateral
breast have been considered to be new primary cancers and censoring has not been
applied. Where contralateral disease occurrence was only in the axilla or
supraclavicular nodes, these have been counted as distant disease relapse and
censoring applied from the time of its occurrence.
It can be difficult, in the absence of histological evidence, to definitely classify a
cancer, occurring at a site distant from the original breast tumour, as a new primary
tumour rather than metastatic spread of the original breast tumour. This is
particularly so when metastatic spread of the original tumour is already known to
have occurred and therefore censoring at metastatic relapse is relevant when
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considering the incidence of new primary cancers. Censoring at metastatic relapse
with regard to the analyses of fractures and ocular toxicity is discussed further in
Section 5.7.
5.2.2 Ascertainment of events
In this study, a number of analyses have been performed for different failure
events; hospitilisation for myocardial infarction, other IHD, thromboembolism,
CVA, fractures, ocular toxicity and non malignant endometrial pathologies.
Registration of a new primary malignancy on SMR6 is also a failure event. These
failure events were ascertained by interrogation of the validated linked dataset as
already described in Chapter 4. Apart from fatal events, the outcomes being
considered in this study can potentially be experienced by an individual on
multiple occasions. The time origin for the study is the date of randomisation into
the Scottish adjuvant tamoxifen trial and therefore any event occurring prior to
randomisation was not included in the analyses. However, the patient was still
considered to be at risk of experiencing a similar event until censored according to
some other criteria, such as metastatic disease or the end of follow-up. For all
analyses, only the first occurrence after randomisation, of an event was counted
and subsequent episodes were disregarded.
As a result of the problem in differentiating new primary tumours from metastatic
spread, it has been recognised that a diagnosis of cancer is sometimes
inappropriately registered as a new primary cancer on SMR6. In an effort to ensure
that only true new primary malignancies were included and cases of metastatic
spread were excluded, a new primary cancer registration on SMR6 was only
counted as an event provided there was no subsequent metastatic relapse diagnosed
in the following 30 days.
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5.2.3 Data manipulation and creation of variables
The data relating to study endpoints for 1312 patients in the tamoxifen trial were
available in Microsoft Access on the analysis database (Tambase), which has
already been described (Chapter 4, Section 4.7, Appendix 4). All data
manipulations were performed within this database, before export for statistical
analysis. In addition to variables already described a number of calculated
variables were added to Tambase for the purposes of the analyses. These are
described in Table 5.4. The values of these variables were calculated by running
update queries in Microsoft Access and examples of these are attached as Appendix
5. Date of censoring was calculated as a separate variable and this was used,
together with information on the date of occurrence of failure events, to determine
whether the event had occurred (event=l) or the individual was censored
(event=0).
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Date of dcensor Earliest of the following:
censoring Date ofmetastases ifpresent
Date ofdeath if dead with no metastasis (cause
other than study endpoint)
Last follow-up date if alive and disease free (no
further information on disease or tamoxifen status
available)
31st March 1996 ifearlier than any of the above (no
further linkage data available)
Time to start Number of days from randomisation to tamoxifen
tamoxifen start start
Time to stop Number of days from randomisation to tamoxifen
tamoxifen stop stop
Age age Age in years at randomisation calculated from (date
of randomisation - date ofbirth)
Event event Takes the value 1 if the event has occurred and 0 if
the individual is censored
Survival time survtime Number of days from randomisation to occurrence
of the event (event=l) or to censoring (event=0)
Additional variables created in the analysis database
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5.3 Preparation of data for analysis
The variables age, option, start, stop, event and survtime were exported from the
analysis database (Tambase) into an ASCII text file and from there imported into
Arcus Quickstat Biomedical (Research Solutions) for the log rank analysis and
production of survival curves and cumulative log hazard curves. The same ASCII
text file was imported into the software package EGRET (Sere) for the Cox
proportional hazard analyses. Two additional variables, tO and tl were created
during definition of the analysis file in EGRET. The variable tO was set to 0 and tl
was set to 1. These are time-dependent variables that allow changes in tamoxifen
status over time to be included in the statistical model. When an individual changes
tamoxifen status, from no treatment to treatment started to treatment stopped, there
is switching between the two time dependent variables tO and tl. For example, at
entry to the study, before tamoxifen treatment is started, the variable tO, which
always takes the value 0, is invoked. At the start of tamoxifen therapy, the variable
tl which always takes the value 1, is invoked. In the analysis of current tamoxifen
therapy versus not current, the variable switches again to tO when tamoxifen
therapy is stopped.
This is illustrated in hypothetical example in Table 5.5. The number of days
elapsing between randomisation and starting and stopping tamoxifen are shown,
together with the switching of the time-dependent covariate at these time points to
allow the tamoxifen status of each individual at all times during the study to be
defined. Individuals who did not receive tamoxifen therapy have days to tarn start
and stop completed with '9999' and the variable tO is invoked throughout. Failure
time is the number of days from randomisation to the event, or censoring. The
value of the time dependent variable at failure time depends on which analysis
('Ever'/'Never' or 'Current'/'Not current') is being undertaken.
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001 to 58 tl 2178 2178 tl tl
002 to 9999 to 9999 5861 to to
003 to 76 tl 1095 3965 tl to
004 to 9999 to 9999 3643 to to
005 to 9999 to 9999 5856 to to
006 to 547 tl 951 545 tl tl
007 to 0 tl 4280 5854 tl to
008 to 0 tl 1282 1279 tl tl
009 to 27 tl 1812 5843 to to
010 to 9999 to 9999 2724 to to
Description of tamoxifen status and illustration of switching between time
dependent variables tO and tl
tO describes a non user of tamoxifen (never used or stopped use)
tl describes a current user of tamoxifen
5.4 Implementation of the Cox model
The Cox proportional hazards model was implemented in EGRET for each of the
endpoints being studied. Fitting the proportional hazards model to an observed set
of survival data involves estimation the unknown coefficients of the explanatory
variables (P). The values of P can then be used to construct an estimate of the
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baseline hazard function. The failure-time variable indicates the point at which the
individual corresponding to that observation either reached an endpoint or was
censored. The failure-time variable in these analyses is survtime. The
failure/censoring indicator variable, event, indicates whether the failure-time
variable is a study endpoint or whether it is a censored observation.
The method of maximum likelihood was used to estimate the p coefficients. This
method estimates the value of the coefficient that is most likely on the basis of the
observed data. The likelihood function of the sample data is the joint probability of
the observed data as a function of the observed failure times and the unknown P
parameters. The maximum likelihood is the value of the likelihood function when
parameters are replaced by their maximum likelihood estimates. The basic
assumption used in the construction of a likelihood function for the proportional
hazards model is that intervals between successive failure times convey no
information about the effect of the explanatory variables on the hazard of death.
For comparing alternative models fitted to an observed set of survival data, a
statistic which measures the extent to which the data are fitted by a particular
model is required. For a given set of data the larger the value of the maximum
likelihood the better is the agreement between the model and the observed data. In
comparing alternative models it is more convenient to use minus twice the
logarithm of the maximised likelihood (-2 log L). As the maximum likelihood, L,
is the product of probabilities, this statistic will always be < 1. Therefore, -2 log L
will always be positive and for a given data set, the smaller the value of- 2 log L,
the better the model. Two models can be compared on the basis of the difference
between the (-2 log L) statistics by calculation of the Likelihood Ratio Statistic
(LRS):
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Likelihood Ratio Statistic = -2log (L(1)/L(2)}
where L(1) and L(2) are the maximised likelihood
functions for Models 1 and 2 respectively
This statistic has an asymptotic chi-squared distribution with the number of
degrees of freedom being equal to the difference between the number of
parameters being fitted in the two models.
5.5 Statistical Analyses
For each endpoint, three separate analyses were performed:
Analysis 1 As Randomised.
Those randomised to tamoxifen compared with those randomised to
observation.
Analysis 2 'Ever' versus 'Never' use of tamoxifen.
Those ever exposed to tamoxifen (either current or previous)
compared with those who have never had tamoxifen treatment
Analysis 3 'Current' versus 'Not current' use of tamoxifen.
Those who are currently receiving tamoxifen at the time of the
event compared with those who had either stopped or had never
received treatment
Analysis 1 involves the comparison of two randomised groups and it can be
reasonably assumed that the process of randomisation will result in an equal
distribution of prognostic variables, such as tumour size, between the groups.
Further, the study was stratified at randomisation for two important prognostic
variables, axillary node status and menstrual status. The variable option, which
defines the treatment assigned to the individual by randomisation, is entered into
the analysis as a regression term.
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Analyses 2 and 3 are observational and so no assumptions can be made about the
distribution of prognostic variables. In this respect, they are less reliable than
Analysis 1. For Analyses 2 and 3, the tamoxifen status is defined and included in
the analyses for all women at all times up to censoring or failure time, by invoking
the time-dependent covariates tO and tl.
In this study, the time origin for all analyses is the date of randomisation into the
Scottish adjuvant tamoxifen trial.
5.6 Expression of Results
The results of the analyses are expressed as hazard ratios and 95% confidence
intervals. The significance of the most recent model extension is measured by the
likelihood ratio statistic. Where only one term is included in the regression, the
likelihood ratio statistic measures the significance of adding this term to the null
model. The null model is the special case of the proportional hazards model in
which there are no explanatory variables and the hazard function is equal to the
unknown baseline hazard, which is the same for all individuals.
5.7 Supplemental^ Analyses
Effect ofAge
The analyses were all repeated with age, as a continuous variable, being entered
into the model as the first regression term. The model was then extended by
adding the variable option (Analysis 1) or the time-dependent variable describing
tamoxifen status (Analyses 2 and 3). This allows the effect of treatment group and
tamoxifen status to be determined, having taken account of the effect of age on the
various endpoints.
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Ocular Outcomes
There is no rationale for censoring at metastatic relapse when considering the
incidence of ocular events. Therefore, an additional set of analyses of ocular
toxicity was carried out, in which there was no censoring at metastatic relapse.
Fractures
It has been suggested that metastatic breast cancer, to sites other than the skeleton,
is associated with generalised disturbances in skeletal metabolism with an
increased risk of vertebral fracture. A 20-fold increase in the incidence of vertebral
fracture has been seen in patients with soft tissue metastases (Kanis et al., 1999).
Censoring at metastatic relapse for the outcome of fracture can therefore be
considered as informative censoring, where the fact of metastatic disease is itself
associated with the risk of experiencing the failure event. A further set of analyses
was therefore carried out in which censoring at metastatic relapse was not applied
but the presence or absence ofmetastatic disease was included as a time-dependent
covariate. This covariate had the value 0 in the absence of metastatic disease and
the value 1 after the onset ofmetastatic relapse.
Effects on the endometrium and dementias
The causal effect of tamoxifen on endometrial cancer has assumed great
significance in the ongoing debate on the use of tamoxifen in the chemoprevention
of breast cancer. However, endometrial cancer is rare and the number of cases in
this study is small, so these results have not been subjected to statistical analysis
but are described in Chapter 6, Section 6.4. Similarly there are small numbers of
benign endometrial events and dementias and these results are also treated
descriptively.
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6.1 Validation of matched records in linked dataset
6.1.1 Matching scores
The linkage between the Scottish adjuvant tamoxifen trial and the combined database
of SMR1, SMR6 and GRO death records produced an electronic file containing
about 18,500 individual records. All the primary matched records output to the file
had a matching score of at least 15, this being the relative odds that the record
belonged to the same patient as the corresponding record in the trial database. As it
was not possible to predetermine the probability weight required to give favourable
absolute odds that the records belonged to the same patient, all scores of 17, 18, 19,
20, 21, 22 and 23 were checked manually as described in Chapter 4, Section 4.4.
The results of this validation exercise are shown in Table 6.1. The decision had been
taken that when a matching score had less than 5% of true matches, all matches with
a score less than this would be discarded. Conversely, when a matching score had
95% or more of true matches, representing an absolute odds of a true match of 95/5,
all matches with a score greater than this would be accepted. Only 3.2% of matches
with a score of 17 were found to be correct by manual checking and therefore, all
matches with scores of 16 or less were discarded. 97.4% of records with a matching
score of 23 were found to be correct and so all matches with a score of 24 or more
were accepted. In all cases, it was possible to definitely categorise a match as 'true'
or 'false'.
There was one incidental finding of a trial record being matched with a record from
the combined database with a matching score of 24 which was positively confirmed
as an incorrect match, by virtue of having dates of hospital admission after the date
of death of the trial patient. This group of records was therefore removed from the
validated dataset.
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Table 6.1
Matching No. of groups on No. correct after % correct
Score linked dataset validation matches
17 125 4 3.2
18 51 4 7.8
19 36 9 25
20 19 2 10.5
21 9 3 33.3
22 4 2 50
23 39 38 97.4
Note: sample size for a scores of 21 and 22 are very small (9 and 4 groups respectively).
Number and percentage of manually validated records with matching scores of
17-23 inclusive
After verification of the matches as described, the final validated, linked dataset
contained a total of 9,968 records. A total of 1,237 of the 1,312 trial patients had
been matched with a record from the combined database and its associated matched
groups of records. As previously explained, a group of records on the validated
dataset consists of the tamoxifen trial record, the record from the combined database
most likely to match with it and all records in the combined database associated with
this primary matched record.
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6.2 Tamoxifen trial follow-up
Follow-up for patients in the Scottish adjuvant tamoxifen trial was obtained as
already described (Chapter 4, Section 4.8) for all 1312 tamoxifen trial patients.
Follow-up to at least 1996 was available for all but 23 of the alive patients and to
1993 for all but 7 alive patients. At the time of the current analysis, 751 patients
were recorded as having died, 24 were alive with metastatic disease and 537 were
alive and free ofmetastatic disease. The median follow-up for 561 patients recorded
as alive is 178 months with a range of 1-232 months.
6.3 Ascertainment of 'Events'
6.3.1 Numbers of events
The events identified in the validated, linked dataset are shown in Table 6.2, by ICD9
classification and randomised option (tamoxifen or observation). This table shows
both the total number of events ascertained and the number of events included in the
statistical analyses (in parenthesis). Events which occurred prior to the date of
randomisation are not included in Table 6.2.
Each ICD9 code is counted only once for each patient. For example, if a patient
suffered two instances of myocardial infarction (410.9), then only the first
occurrence is included in Table 6.2. This is also true for ischaemic heart disease and
cerebrovascular disease where only the first occurrence of an event in these
classifications is counted. In the case of thromboembolism, the two endpoints of
deep vein thrombosis and pulmonary embolism have been combined and therefore
the number of events in Table 6.2 represents the number of patients experiencing at
least one episode of either of these events.
The situation with regard to fractures and new primary malignancies is different and
patients are included in Table 6.2 more than once if they had multiple occurrences of
the events at different sites. For example, if a patient suffered two fractures at
different sites having different ICD9 codes, then both are tabulated. Similarly for
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new primary malignancies, Table 6.2 therefore shows numbers of tumours rather
than numbers of patients. The ocular endpoints were also ascertained individually
and so multiple occurrences of ocular events are included.
The numbers in parenthesis in Table 6.2 refers to the number of events that are
included in the statistical analyses for each of the outcomes being studied. For the
statistical analyses, only the first occurrence of an event in each Event Description is
recorded for each patient and thus the occurrence of multiple fractures, new primary
malignancies and ocular events occurring in one patient are not accounted for. For
the primary analyses, censoring was applied at the time of metastatic relapse and
events occurring after censoring are not included in the statistical analyses.
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Table 6.2
Event Description ICD9 Code Tam Control
Ischaemic Heart Disease (HID)
acute myocardial infarction (MI) 410 26 (20) 41 (29)
Other IHD (excluding acuteMI)
excluding 412 (old myocardial infarction) 411,413,414 39 (35) 38 (32)
Thromboembolism:
pulmonary embolism, phlebitis, thrombophlebitis 451,415.1 23 (17) 21 (11)
Cerebrovascular Disease
excluding 438 (late effects ofcerebrovascular
disease)
430-437 44 (40) 31 (22)
Skeletal Effects:






87 (59) 70 (45)
Ocular Effects:
Disorders of the eye and adnexa 360-379 62 (49) 34 (26)
Dementias:
Senile and presenile organic psychotic conditions 290 9(7) 9(8)
Benign Endometrial Disorders:
endometriosis - uterus





Total number of events identified from the validated, linked dataset, by ICD9
classification and randomised option.
Number of events included in statistical analyses, after censoring for metastatic disease,
is in parenthesis ( )
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6.3.2 Distribution of events
Table 6.2 shows very similar numbers of events in the two randomised arms of the
trial for the endpoints of ischaemic heart disease, thromboembolism, fractures and
dementia. For the endpoint of myocardial infarction, there are more events in the
observation arm compared with the adjuvant tamoxifen arm (41 and 26 respectively).
The numbers of events for the endpoints of cerebrovascular disease, ocular events
and new primary malignancies are greater in those randomised to receive tamoxifen
than in those randomised to observation. The total number of benign endometrial
events and dementias is small (11 and 18 respectively).
6.3.3 Fractures
Table 6.3 shows a breakdown of the fractures by site. As previously described, a
patient may appear in this table more than once, if they experience fractures at more
than one site. Only the first fracture at any site will be included in the statistical
analysis. The overall number of fractures in Table 6.4 is similar in both arms of the
trial, as is the distribution at each of the individual sites. The greatest number of
fractures occurring at a singe site is fractures of the femur, with 47 recorded cases.
6.3.4 New primary malignancies
Table 6.4 shows a breakdown of the incidence of new primary malignancies,
excluding breast cancer, by site. Overall there are 87 new primary malignancies in
patients randomised to receive tamoxifen compared with 70 in the observation arm.
There is the suggestion of an increased incidence of new primary malignancies of the
digestive organs in patients randomised to receive adjuvant tamoxifen (26) compared
with those randomised to observation (14). This is also true of endometrial cancers (8
in the tamoxifen arm compared with 3 in the observation arm) and, but the total
number of these events is very small. The group of genitourinary cancers, excluding
endometrium, is also very small, but there is a suggestion of fewer occurring in those
patients randomised to tamoxifen (6 compared with 11 in the observation arm).
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Table 6.3
Site of fracture ICD9 Code lam Comtrol
Face bones 802 0 1
Vertebral column 805 4 0
Ribs, sternum, larynx, trachea 807 2 2
Pelvis 808 6 5
Humerus 812 1 3
Radius and ulna 813 4 3
Carpal bone 814 0 1
Femur 820,821 22 25
Tibia, fibula 823 2 4
Ankle 824 6 5
Tarsal, metatarsal bones 825 2 2
TOTAL 49 51
Fractures identified in the validated, linked dataset, by ICD9 classification of
site and randomised option
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Table 6.4
Site of primary malignancy ICD9 Tam Control
Lip and oral cavity 140 - 149 1 1
Digestive organs 150-159 26 14
Respiratory and intrathoracic 160 - 165 15 16
Bone, connective tissue and skin 170 - 173 18 21
Genitourinary
(ex. Endometrium - 182)
179-189 6 11
Endometrium 182 8 3





New primary malignancies identified in the validated, linked dataset, by ICD9
classification of site and randomised option
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6.3.5 Ocular toxicity
Table 6.5 shows the breakdown ofocular events by cause. As with fractures and new
primary malignancies, patients are included more than once in this table if they have
experienced different ocular endpoints with different ICD9 codes. In the statistical
analysis only the first ocular event experienced by a patient is included. Generally,
the number ofocular events identified is low and there is a similar distribution of
events between the two randomised arms of the study. There was however a high
incidence ofocular cataracts (ICD9 Classification 366) with a total of 56 events
being identified. The majority of these occurred in patients randomised to receive
tamoxifen (38 events compared with 18 events in the observation arm). The recorded
incidence of low vision and visual disturbances (ICD9 Classification 368, 369) is
higher in the tamoxifen group than the observation group (6 compared 3) and there
are more cases ofglaucoma in the observation group (7 compared with 4). However
the number of these events is small.
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Table 6.5
Description ICD9 Code Tam Control
Retinal detachments and defects
Other retinal defects
361,362 3 0
Disorders of the iris and ciliary body 364 1 0
Glaucoma 365 4 7
Cataract 366 38 18
Visual disturbances 368 2 1
Blindness and low vision 369 4 2
Keratitis 370 2 1
Disorders of conjunctiva 372 2 0
Inflammation ofeyelids
Other disorders of eyelids
373, 374 2 2
Disorders of lacrimal system 375 2 1
Strabismus and other disorders of
binocular eye movements
378 1 1
Other disorders of eye 379 1 1
TOTAL 62 34
Ocular events identified in the validated, linked dataset, by ICD9 classification
and randomised option
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6.4 Statistical Analyses
6.4.1 Log rank analysis by randomised option
Table 6.6 shows the hazard ratios, 95% confidence intervals and p values for the log
rank analysis by randomised option (adjuvant tamoxifen versus tamoxifen at first
relapse) for the failure events ofmyocardial infarction, other ischaemic heart disease,
thromboembolism, cerebrovascular accident, new primary cancers, fractures and
ocular toxicity.
Unlike Tables 6.2 to 6.5, which derive their data from the validated, linked dataset,
the data for statistical analysis are derived from the analysis database (Tambase), in
which only the first occurrence of an event corresponding to an Event Description in
Table 6.2 (e.g. IHD, fracture, new primary malignancy) is recorded. The date of the
event is the date of admission to hospital for the first occurrence of the event, or the
date ofdeath if the event is noted only as a cause ofdeath.
Results are statistically significant when p<0.05 and the 95% confidence interval of
the hazard ratio does not include unity. The p value is that obtained from the
likelihood ratio statistic and it should be noted that it is theoretically possible, using
this method, to have a p value of < 0.05 but a confidence interval which crosses
unity. The use of the log rank test to compare the failure times of the adjuvant and
observation groups is equivalent to the use of the Cox proportional hazards model
with the randomised option as a single covariate. Survival curves are given for these
analyses in Figures 6.1 — 6.7.
Page 124
Chapter 6 Results - Part A
Table 6.6
Outcome No. of events
Control Tarn
HR* 95% CI P
MI 29 20 0.580 0.331 - 1.017 0.058
IHD 32 35 0.900 0.556- 1.456 0.666
Thromb 11 17 1.319 0.627-2.773 0.472
CVA 22 40 1.533 0.930-2.527 0.105
Cancer 45 59 1.112 0.756- 1.635 0.592
Fracture 33 31 0.775 0.474-1.268 0.306
Ocular 26 49 1.605 1.019-2.527 0.049
Log rank analysis comparing the survival experience of the tamoxifen group
with the observation group, as randomised
*Hazard Ratio (HR) is for tamoxifen arm compared with control
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Figure 6.1
Failure Times (Days)
Survival curves showing rate ofMI in the two randomised groups
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Figure 6.4
Failure Time (Days)
Survival curves showing rate of CVA in the two randomised groups
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Figure 6.5
Failure Time (Days)
Survival curves showing rate of new primary cancers in the two randomised
groups
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Figure 6.6
Failure Time (Days)
Survival curves showing rate of fracture in the two randomised groups
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Figure 6.7
Failure Time (Days)
Survival curves showing rate of ocular outcomes in the two randomised groups
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The results show no significant differences between those randomised to receive
tamoxifen and those randomised to observation for any of the failure events studied,
except a borderline significantly increased incidence of hospital admission for ocular
events in those patients randomised to tamoxifen (p=0.049).
6.4.2 Cox porportional hazards analyses
Table 6.7 presents the results, using the Cox proportional hazards method, of the
analyses by randomised option, 'Ever' vs Never' and 'Current' vs 'Not current' use
of tamoxifen. For the analyses by randomised option the results show some
differences compared with the log rank method for the outcomes ofMI, THROMB,
CVA and OCULAR. These results are discussed further in Chapter 7, Section 7.1.
The results of the analyses of the 'Ever' vs 'Never' and 'Current' vs 'Not current'
use of tamoxifen show a significantly reduced risk of admission to hospital for
myocardial infarction in those patients currently receiving tamoxifen compared to
those who have either stopped or never received tamoxifen (p=0.034). There is no
significant difference in risk between the 'Ever' and 'Never' use groups. There is no
significant difference in any of the analyses in the risk of admission for IHD other
than myocardial infarction.
The risk of admission for a thromboembolic event (pulmonary embolism or deep
vein thrombosis) is significantly increased in those currently receiving tamoxifen
compared to those not receiving current treatment (p=0.038). There is no difference
in thromboembolic events between 'Never' and 'Ever' use groups.
In the analyses of CVA, there is a significant difference between 'Ever' and 'Never'
use groups (p=0.007). However, these results were not maintained in the analysis of
current tamoxifen therapy compared with previous therapy or no exposure. There
were no significant differences evident in any of the analyses relating to the
endpoints of fracture or new primary malignancy.
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In the analyses of ocular toxicity there was a significantly increased incidence of
hospital admission for patients randomised to tamoxifen compared to those in the
observation arm (p=0.049) in both the analysis by the log-rank method and that by
the proportional hazards method (p=0.024). A similar, but more pronounced effect
was seen in the comparison of those currently receiving tamoxifen compared with
those who had stopped, or had never received, treatment (p=0.006).
The number of endpoints for the events of endometrial cancer, benign endometrial
events and dementia are small and have therefore not been subjected to statistical
analysis. These results are described in Section 6.4.
In all of the analyses one record is rejected as being a non-positive survival time.
This was identified as a patient who was inappropriately entered into the tamoxifen
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6.4.3 Effect of age
In order to determine the effect of age on the endpoints being studied, the three
analyses were repeated for all the failure events, using age at randomisation as the
first covariate in the model and then extending the model, by adding either option or
one of the time-dependent covariates ('Ever'/'Never' or 'Current'/'Not current' use
of tamoxifen), as appropriate for the particular analysis. The results are tabulated in
Table 6.8 and the p value is that derived from the difference between the values of (-
2 Log L) for the model containing only age and the extended model, using the chi-
squared test statistic with one degree of freedom.
The results indicate a significantly increased incidence of all the failure events
studied, except myocardial infarction and thromboembolism, with increasing age.
However, the results are essentially similar to those obtained when age is not
included in the model. There is some strengthening in the level of significance seen
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6.5 Other failure events
6.5.1 Endometrial cancer
There were 11 diagnoses of endometrial cancer within the study, 3 in the observation
arm and 8 in the adjuvant tamoxifen arm. Two patients (1 adjuvant, 1 observation)
were recorded as having a previous uterine cancer and 1 patient randomised to
adjuvant tamoxifen had metastatic disease recorded one day after the date of
diagnosis of endometrial cancer. In these 3 cases, in the absence of histological
confirmation, there must be some doubt as to whether they were truly new primary
malignancies. Of the 8 patients in the adjuvant arm, 5 were still receiving tamoxifen
therapy when their endometrial cancer was diagnosed. Median exposure of the 8
patients was 93 months. Tamoxifen status, duration of exposure and time since










Observation None - -
Observation None - -
Observation None - -
Tamoxifen Current 131 -
Tamoxifen Stopped 107 2
Tamoxifen Current 75 -
Tamoxifen Current 63 -
Tamoxifen Stopped 56 17
Tamoxifen Current 79 -
Tamoxifen Stopped 144 1
Tamoxifen Current 139 -
Tamoxifen status, duration of exposure and time since stopped in 11 cases of
endometrial cancer
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6.5.2 Benign endometrial disease
Eleven cases of benign endometrial disease were ascertained. These were 3 cases of
endometrial cystic hyperplasia, 2 cases of polyp of the corpus uteri and 6 cases of
endometriosis. All 11 patients had exposure to tamoxifen, 2 of these were in the
observation arm and being treated for recurrence. The median duration of tamoxifen
therapy was 58 months with a range of 11 - 147 months.
6.6 Supplementary analyses
6.6.1 Ocular endpoints
In the analyses of ocular events without censoring at metastatic relapse, there were a
total of 83 hospital admissions for ocular outcomes available for analysis (52
tamoxifen, 31 observation) The results of the 3 analyses by Cox proportional hazard
method are shown in Table 6.10 and show little difference from the results obtained
where censoring was applied (75 cases) with only a slightly reduced level of
statistical significance in the 'Current' vs 'Not current' analysis.
Figure 6.10
Analysis HR 95% CI P
Tamoxifen vs
Observation 1.049 1.020-1.079 0.024
Ever vs Never 1.399 0.879-2.227 0.149
Current vs
Not current 1.647 1.058-2.562 0.028
Results of comparison of incidence of ocular endpoints, with no censoring at
metastatic relapse, between randomised groups, 'Ever' vs 'Never' and
'Current' vs 'Not current' use of tamoxifen
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6.6.2 Fractures
The additional analyses carried out for the incidence of fractures at any site, where
censoring was not applied at metastatic relapse, included a total of 86 cases of
fracture (41 tamoxifen, 45 observation). This compares with 64 cases in the censored
analysis. The inclusion of the presence or absence ofmetastases, as a time-dependent
covariate, shows a strongly significant association between the presence of
metastases and the incidence of fractures (HR 5.099, 95% CI: 3.132 - 9.300,
p<0.001). The results of extending this model to compare the incidence of fracture in
those randomised to tamoxifen compared with the observation group, 'Ever' vs
'Never' use of tamoxifen and 'Current' vs 'Not current' use of tamoxifen are shown
in Table 6.11. These indicate that, when censoring at metastases is not applied,
current users of tamoxifen have a significantly reduced risk of fracture compared
with not current users.
Table 6.11
Analysis HR 95% CI P
Tamoxifen vs
Observation 0.961 0.623-1.482 0.857
Ever vs Never 0.753 0.473 - 1.201 0.237
Current vs
Not Current 0.579 0.357-0.939 0.022
Results of comparison of incidence of fracture between the randomised groups,
'Ever' vs 'Never' and 'Current' vs 'Not current' users of tamoxifen, adjusted
for the presence or absence of metastatic disease
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7.1 Statistical Aspects
The results obtained for the analysis by randomisation, using the Cox proportional
hazards model, differ substantially from the results obtained by comparing the survival
curves of the two groups using the log-rank method, for the outcomes of MI,
thromboembolism and CVA {Tables 6.6 and 6.7). There is also a difference for the
ocular endpoint, although in this case the result is significant, and in the same
direction, by both methods. The results for these outcomes using the proportional
hazards model have hazard ratios very close to unity, with narrow confidence
intervals and a statistically significant result. Interestingly, the hazard ratio for MI is
highly significant (p=0.002) in favour of the control arm, which is in the opposite
direction than is to be expected. These differences obtained by different methods
suggest that the proportional hazards assumption may fail such that it is inappropriate
to model the data in this way.
If the hazards are not proportional over time then the linear component of the model
varies with time. This can be tested by determining the Kaplan -Meier estimate of the
survivor function of the two groups. A plot of the negative logarithm of the estimated
survivor function against the logarithm of the survival time (log-cumulative hazard
plot) will yield parallel curves if the hazards are proportional across the two groups.
The log-cumulative hazard plots for all the outcomes being studied are shown in
Figures 7.1-7.7. The plots for MI and ischaemic heart disease {Figures 7.1 and 7.2)
in particular show a tendency to converge as survival time increases, suggesting that
the proportional hazard assumption is no longer valid at longer follow-up times and
that the hazard associated with one or both ofthe groups is changing over time.
An extreme example of this is illustrated in Figure 7.4, where the curves for
cerebrovascular disease cross and in Figure 7.5 where the curves for new primary
cancer are tending to cross towards the end of the follow-up period. . In Figures 7.3,
7.6 and 7.7 the plots for PE/DVT, fractures and ocular disease remain essentially
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parallel throughout the follow-up period, indicating that these data fulfil the criteria
for proportional hazards. Thus with some doubts as to the validity of the results of the
randomised comparison by the Cox method (Chapter 6, Tables 6.7 and 6.8), the
'genuine' results of the randomised comparisons should be based on the log rank test
{Chapter 6, Table 6.6).
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Cumulative log hazard for randomised groups with respect to MI
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Cumulative log hazard for randomised groups with respect to other IHD (other
than MI)
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Figure 7.3
Cumulative log hazard plot for randomised groups with respect to PE/DVT
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Cumulative log hazard for randomised groups with respect to CVA
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Cumulative log hazard for randomised groups with respect to new primary
malignancies
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Cumulative log hazard for randomised groups with respect to ocular toxicity
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In his original paper, Cox suggested testing the interaction between the effect of a
covariate (or set of covariates) and time (Cox, 1972). If a time dependency of the
effect of a covariate on risk is established, a model with time-varying coefficients can
be used (Abrahamowicz et al., 1996). An alternative approach is to divide the follow-
up time into intervals and determine differences between the relative risks in each
interval evaluated (Moreau et al., 1985). The disadvantages of this method are that
the selection of intervals is arbitrary and the assessment ofwhether a time dependency
is present is subjective. The use of these two models to test the proportional hazards
assumption in a population-based study of acute myeloid leukaemia has recently been
described (Bourdais-Mannone et al., 1999).
In principle, all of the methods available for testing the assumption of proportional
hazards can be applied to the situation where the value of a covariate varies over time
(as in the 'Ever/Never' and 'Current/Not current' analyses discussed in Chapter 5,
Section 5.5) (Altman & De Stavola, 1994), but they are much more complex to
implement. The concept of the value of a covariate varying over time should not be
confused with that of the value of a coefficient (i.e. the effect on risk) varying over
time. Both are often referred to as time-dependent covariates. Despite all the
methodologies available for model checking, the overall power to detect departures
from the proportional hazards assumption is generally low because of the semi-
parametric nature of the model. Investigators are often reluctant to test the
assumption because of the difficulty in estimating and interpreting the effect of a
prediction once the hypothesis ofproportional hazards has been rejected.
Use of the proportional hazards model in situations where the impact of a variable
may change during follow-up can introduce a bias in the estimation of the predictor's
effect. Further, if the effect of the variable inverts during the course of follow-up, a
false conclusion ofno difference between the groups may be made. The use ofother
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statistical methods, such as non-parametric survival analysis methodology) was
beyond the scope of this dissertation. This said, it is important that the possible
limitations that have been identified in the validity of the model should be borne in
mind when considering and interpreting the results of the study. Some of these
alternative approaches may be considered relevant for future work, particularly if a
reanalysis of these data, with further follow-up, is planned.
7.2 Risk/Benefit assessment of tamoxifen
The benefit of tamoxifen treatment for patients with breast cancer is now undisputed.
Current studies are addressing the issues of optimal duration of treatment, combining
tamoxifen therapy with chemotherapy or other hormone therapies and the
effectiveness of tamoxifen in the chemoprevention of breast cancer. Long-term
morbidity is particularly important in the context of extended duration of treatment
and the medication of young, healthy women considered to be at high risk of
developing breast cancer. Long-term morbidity is however, as yet, poorly described
with judgements to date being based on relatively short durations of treatment, of up
to 5 years. This study provides important data relating to key outcomes in the study
of tamoxifen morbidity in women who have received up to 18 years of treatment and
therefore serves to fill a gap in our current knowledge.
The additional follow-up in this study (01/01/93 - 31/03/96) compared to the
previous (Appendix 2) has provided an additional 12 cases of myocardial infarction,
25 cases of other ischaemic heart disease, 17 cases of cerebrovascular disease and 3
cases of thromboembolism. The results obtained for the individual outcomes studied
are discussed below.
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7.3 Myocardial infarction and ischaemic heart disease
The cardioprotective action of tamoxifen is undoubtedly a key element in discussing
the likely risk to benefit ratio of tamoxifen treatment and has probably received the
greatest attention in the medical literature. The results of the current study suggest
that this effect is limited to a reduction in the incidence of acute myocardial infarction
in current tamoxifen users compared with previous or non-users (HR=0.511, 95% CI:
0.267 - 0.976, p=0.034). Thus the previous results obtained for the 'Current/Not
current' comparison are confirmed with an additional 3 years and 3 months of follow-
up while the results for the 'Ever/Never' comparison are no longer statistically
significant. The introduction of age into the model indicates that, as would be
expected, the incidence ofall ischaemic heart disease increases with increasing age but
the effect of tamoxifen does not change when age is taken into account.
The results obtained suggest that the protective effect of tamoxifen is only apparent
while receiving treatment and is lost on the cessation of treatment. This concurs with
findings that the beneficial effects of tamoxifen on lipid profile are not maintained
after cessation of treatment (Dewar et al., 1992) (Cuzick et al., 1993). The interaction
of tamoxifen with membranes and lipoprotein particles and the resulting antioxidant
and cardioprotective action is also unlikely to be maintained once exposure to
tamoxifen has been stopped.
There is no evidence from the current study that tamoxifen therapy protects against
ischaemic heart disease other than MI, such as coronary failure, coronary
insufficiency, angina pectoris or atherosclerotic heart disease.
Two large clinical trials of adjuvant tamoxifen therapy have reported results for
cardiac mortality and morbidity. The Stockholm adjuvant tamoxifen trial looked at the
incidence of hospital admissions due to cardiac disease and the relative hazard for
those randomised to receive tamoxifen compared with the control arm, at a median
Page 152
Chapter 7 Discussion - Part A
follow-up of 6 years, was 0.68 (95% CI: 0.48 - 0.97, p=0.03). There was also a
statistically significant difference in the comparison of 2 years of tamoxifen versus 5
years of tamoxifen (relative hazard 0.37, 95% CI: 0.15 - 0.92, p=0.03). Cardiac
disease in this study included myocardial infarction, other types of ischaemic heart
disease and miscellaneous cardiac disease. There was no significant difference
between the treatment arms for the subgroup of myocardial infarction (Rutqvist &
Mattson, 1993).
The NSABP-B14 study reported a non-significant reduction in cardiac mortality for
tamoxifen-treated patients (8 deaths) compared with those receiving placebo (12
deaths) with a relative hazard of 0.66 (95% CI: 0.27 - 1.61). The mean follow-up
time was 8.9 years. When possible coronary deaths were included in the analysis, the
relative hazard was 0.85 (95% CI: 0.46 - 1.58) (Constantino et al. 1997). The
analyses for both the Stockholm and NSABP B-14 analyses were on an 'intent-to-
treat' (ITT) basis, comparing the groups as they were randomised regardless of
whether the treatment was received. This tends to provide a more conservative
estimate of risk and biases the result towards the null hypothesis, especially if the
hypothetical benefit is for current use of tamoxifen.
Other studies have failed to show an effect of tamoxifen on cardiac morbidity and
mortality. The results from the 1995 meta analysis by the EBCTCG showed no
difference in the cardiac mortality in the tamoxifen treated patients compared with
controls (Early Breast Cancer Trialists' Collaborative Group, 1998) and there was no
difference in the rate of ischaemic heart disease between the tamoxifen and placebo
groups in the US breast cancer prevention trial (BCP Trial) (Fisher et al., 1998).
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Coronary heart disease in premenopausal women is rare and there is no evidence from
this or any other published study to date that tamoxifen increases the risk of cardiac
morbidity in younger women. This is an important observation with regard to the use
of tamoxifen as a prophylactic in healthy, premenopausal women. One of the
postulated mechanisms by which tamoxifen exerts a cardioprotective effect is by an
action on arterial status similar to that exerted by oestrogen. Oestrogen is known to
act as an arterial vasodilator and decrease the pulsatility index (PI), which is a
measure of impedance to blood flow within the artery. This has been demonstrated in
uterine and cerebral arteries in women (Penotti et al., 1998) and the action is the
expression of a generalised effect on arterial vessels. However studies have shown
that tamoxifen does not exhibit this effect and this has implications with regard to the
cardioprotective actions of tamoxifen. The authors suggest that its use in healthy
women should therefore be reviewed.
7.4 Thromboembolic disease
The results of the current study with regard to thromboembolic disease again
reinforce those obtained in the previous study of morbidity within the Scottish
adjuvant tamoxifen trial. They suggest that patients currently receiving tamoxifen are
more than twice as likely to suffer an incident of pulmonary embolism or deep vein
thrombosis than those who have stopped, or never received, treatment (HR 2.229,
95% CI: 1.040 - 4.777, p=0.038). In the BCP Trial there is also evidence of an
association of tamoxifen treatment with an increased risk of thromboembolism.
Seventeen cases of pulmonary embolism occurred in the tamoxifen arm compared
with 6 on placebo and there were 30 cases of deep vein thrombosis in the tamoxifen
group compared with 19 in the placebo group (Fisher et al., 1998).
The Stockholm adjuvant tamoxifen trial was unable to show a difference in the
incidence of hospital admission for thromboembolic causes between those randomised
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to tamoxifen and the control group (Relative Hazard 1.06, 95% CI: 0.71-1.60). This
study included cerebral thrombosis in the thromboembolic group, differential
diagnosis between thrombotic and haemorrhagic CVAs being performed routinely in
Sweden on admission to hospital. As discussed in relation to cardiac morbidity, the
ITT analysis used in this study is likely to be less able to detect a difference between
the groups, particularly if current use is an important factor.
The mechanism of a possible effect of tamoxifen on thromboembolism is not clear and
is likely to be multifactorial. Changes in coagulation factors which have been noted on
tamoxifen therapy, such as a decrease in levels of antithrombin III, are small and
unlikely on their own to account for the results observed. Activated protein C
resistance due to Factor V Leiden is a significant inherited prothrombotic defect in
European populations. A case-report has identified 3 cases of thromboembolic
complications in women receiving tamoxifen therapy all of whom were determined to
be heterozygous for Factor V Leiden. The authors suggest that patients should be
screened for Factor V Leiden before commencing tamoxifen therapy (Weitz et al.,
1997).
7.5 Cerebrovascular disease
The results obtained for the incidence of cerebrovascular disease indicate a significant
increase in the incidence of CVA in those patients who have ever received tamoxifen
compared with never users. The 'Current' versus 'Not current' comparison indicates
no difference between the groups indicating that, for incidence of CVA, it is ever use
of tamoxifen rather than current use which may be important. These results differ
from those obtained in the previous study, where no significant differences were
observed in any of the analyses performed, with respect to CVA. This may be a
reflection of the increased follow-up time and increased number of events (from 45 to
62). It should be remembered that the curves in the log-cumulative hazard plot for the
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randomised comparison crossed towards the end of the follow-up period, indicating
that these results may not be reliable, particularly towards the end of the follow-up
period (Figure 7.4).
Cerebrovascular disease includes both thrombotic and haemorrhagic events and
current tamoxifen use does appear to increase the risk of thrombotic events (Section
7.4). The increased incidence of CVA in patients who have received tamoxifen may
therefore be a reflection of an increased number of thrombotic events in these
patients. Of the cerebrovascular events identifiable by ICD9 code as either as
haemorrhagic (430, 431, 432) or thrombotic (433, 434), there were 5 in the former
group and 10 in the latter group. However, the majority of cerebrovascular events are
classified as 'ill-defined' and no conclusions can be drawn about their thrombotic or
haemorrhagic nature. The BCP Trial reported an increased rate of stroke in the
tamoxifen group (38 events) compared with placebo (24 events), although this was
not significant (RR 1.59, 95% CI: 0.93-2.77) (Fisher et al., 1998).
7.6 New primary malignancies
The carcinogenic potential of tamoxifen is particularly important in view of the very
widespread use of tamoxifen in women with a high cure rate and long life expectancy,
and in healthy women in the context of breast cancer chemoprevention. A
hepatocarcinogenic effect has been clearly demonstrated in rats (Chapter 3, Section
3.3.3). In fact, only one case of liver cancer was identified in the current study, in a
patient who had received tamoxifen therapy for 66 months. This low incidence was in
spite of the extended duration of exposure and supports the reassuring data obtained
from other studies. One reason for the apparently low incidence of primary fiver
tumours may be that histology is rarely available to allow the differential diagnosis of
primary tumour as opposed to metastases from breast carcinoma to be made. Overall
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in the current study, there was no significant difference in the total number of new
primary malignancies by any of the analyses performed.
The number of endometrial cancers detected was higher in the tamoxifen arm than in
the observation arm but the number of cases overall was low and insufficient for
statistical analysis, reflecting the fact that this is a rare condition. Nevertheless, the
results offer limited support for the considerable volume of data already available
indicating that women on long-term tamoxifen treatment are at a higher risk of
developing endometrial cancer. In the BCP Trial, thirty-three (33) women on
tamoxifen developed endometrial cancer compared with 14 women on placebo. The
relatively rare incidence of endometrial carcinoma must, however, be put in
perspective in relation to hundreds of thousands of women who have benefited from
tamoxifen treatment.
One of the criteria in developing new endocrine treatments for breast cancer is to find
an effective treatment that does not exhibit the carcinogenic effects of tamoxifen.
Toremifene is a chlorinated derivative of tamoxifen (Figure 7.8) and is marketed as
Fareston® for the treatment of metastatic breast cancer. A number of preclinical
studies have shown that toremifene does not appear to have the same carcinogenic
potential as tamoxifen. A comparison of the hepatoproliferative effects of tamoxifen
with toremifene has been investigated in rats using a 32P-postlabelling assay.
Administration of tamoxifen at 45 mg/kg for 7 days produced liver DNA nucleoside
modifications, but no detectable modified bases in rat liver DNA were produced by
toremifene (Hard et al., 1993). Also, unlike tamoxifen, toremifene does not show
activity in the rapid induction of hepatocellular altered foci (HAF) in rats (Williams et
al., 1997). To further evaluate toremifene for possible genotoxicity, 3 standard in
vitro assays were performed in which toremifene failed to exhibit genotoxicity or
myelotoxicity. However the action of toremifene on the endometrium in an athymic
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ovariectomised mouse model is identical to that of tamoxifen. In contrast, the
steroidal antioestrogen
ICI 182780 {Figure 7.9) inhibited tamoxifen stimulated endometrial cancer, both in
the presence and absence of oestrogen, in this model (O'Regan, et al, 1998). ICI
182780 is a 'pure' antioestrogen and as such, does not exhibit any oestrogen agonist
activity. To date, the clinical use of toremifene has been in the treatment of advanced
breast cancer and there are few clinical data on its use in the adjuvant setting. A large
ongoing study being co-ordinated by the Finnish Breast Cancer Group is comparing
toremifene and tamoxifen as adjuvant therapies in breast cancer patients. An interim
safety analysis on 500 patients with a mean follow-up of 18 months has shown no
differences between tamoxifen and toremifene in terms of efficacy or side effects
(Holli, 1998).
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Figure 7.8
Figure 7.9
Structure of ICI 182780
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7.7 Effects on the skeleton
The results of the randomised, 'Ever/Never' and 'Current/Not current' comparisons,
where censoring has been applied at metastatic relapse, indicate a similar rate of
fracture incidence in the groups being compared. Thus, there is no indication from
these results that tamoxifen has an effect on the pathogenesis of fracture in patients
with breast cancer. In the supplementary analyses, in which censoring at metastatic
relapse was not applied, there is a clear and not surprising association between the
presence of metastatic disease and the incidence of fracture (p<0.001). In this
analysis, a significant reduction in fractures in current users of tamoxifen compared
with not current users is also seen (p=0.022). This observation could be related to a
reduced incidence ofmetastatic disease in current users of tamoxifen.
One other study has reported on the occurrence of fracture in breast cancer patients
receiving tamoxifen. Linkage of data, pertaining to patients randomised within a trial
of adjuvant tamoxifen in breast cancer run by the Danish Breast Cancer Co-operative
Group, with the Danish National Registry of Patients indicates that there is no
significant difference in the incidence of femoral fracture between the two groups (64
in the tamoxifen treated group and 51 in the control group, HR = 1.08, 95% CI: 0.74
- 1.55, p=0.70). There was a slight excess of trochanteric fractures in the tamoxifen
group (27) compared with controls (11) and this was statistically significant (HR 2.12,
95% CI: 1.12 - 4.01, p=0.022) (Kristensen et al., 1996). These results could not be
explained by a longer survival in the tamoxifen group nor by the presence of bone
metastases resulting in pathological fractures.
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These results differ from those obtained in the BCP Trial where a clear reduction in
hip, radius (Colles') and spine fractures associated with tamoxifen administration is
evident. There were a total of 71 fractures in the placebo group compared with 47 in
the tamoxifen arm (Fisher et al., 1998). This effect of tamoxifen in healthy women
concurs with evidence of a protective effect in healthy women of exogenous
oestrogens on bone density and a decreased fracture risk. This has been
shown for postmenopausal oestrogen use (Christiansen & Lindsay, 1990)
(Michaelsson et al., 1998). The results of a Swedish case-control study in 130 cases
and 562 controls suggest that OC use late in reproductive life may also confer a
reduction in the risk ofhip fracture (Michaelsson et al., 1999).
Thus, there is therefore some evidence of an oestrogen-mediated reduction in
fractures in healthy women and effects are seen in women with breast cancer which
depend on the fracture site. These various findings are difficult to interpret and the
results obtained are likely to be influenced by a number of factors. For example, there
are data which show a 5 times increased risk of vertebral fracture in patients with
breast cancer compared with healthy controls (OP = 4.7, 95% CI: 2.3 - 9.9),
suggesting that the presence of breast cancer itself can cause changes in skeletal
metabolism (Kanis et al., 1999). This concurs with data showing a decrease in bone
mineral density in postmenopausal women with breast cancer compared to normal
women (p<0.001) (Kostoglou-Athanassiou et al., 1994). There are also apparent
differences in the effect of tamoxifen on the skeleton which depend on the hormonal
environment. In the Royal Marsden pilot chemoprevention trial, postmenopausal
women receiving tamoxifen showed a mean annual increase in BMD of 1.17% in the
spine and 1.71% in the hip compared with a non-significant loss for women on
placebo. However, in premenopausal women receiving tamoxifen there was a mean
annual loss ofBMD in the spine of 1.44% compared with a small annual gain (0.24%)
for the placebo group (Powles et al., 1996).
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The answer to the exact actions of tamoxifen on the skeleton may be found at the
level of the bone cells. As yet, the effect of tamoxifen on osteoclasts and osteoblasts is
largely unknown but the oestrogenic effect may be dependent on the presence of
oestrogen receptors on the cells (Ernst et al., 1991). Oestrogen receptors have been
detected in some osteoblastic cell lines, usually in low concentrations (Keeting et al.,
1991). It is therefore clear that an effect of tamoxifen therapy on fracture incidence
has not been clearly established and further prospective studies are required before
any firm conclusions can be drawn.
7.8 Ocular effects
The current study provides evidence of a very significant association between
tamoxifen use and hospitilisation for ocular problems, both in the comparison of the
randomised groups and the 'Current' 'Not current' use groups. This effect is
independent of the effect of age, which itself is highly significant. The majority of the
episodes of hospitilisation identified were for cataract (59 out of 96 events). Almost
twice as many cataracts were recorded in patients randomised to receive tamoxifen
compared with those in the observation arm. The results did not change materially
when the data were re-analysed without censoring at metastatic relapse.
Cataract is the commonest cause of visual impairment in persons aged 75 years or
older. In a population-based study of the incidence of age-related cataracts in 3,271
participants aged from 40 to 98 years, the overall prevalence of any type of cataract
that had not been surgically corrected was 18% (McCarty et al., 1999). Another
population based study collected data between 1988 and 1995 and reported a
cumulative incidence of nuclear cataract, in persons aged 75 years or older, of 40%
with women more likely than men to be affected, after adjusting for age (Klein et al.,
1998). Further, the Rotterdam Study has examined the prevalence and causes of
blindness and visual impairment in 6,775 subjects and concluded that age-related
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cataract is primarily responsible for the increased prevalence of visual impairment
(Klaver et al, 1998).
The results of the current study concur with those obtained in the TOES study
(Chapter 3, Section 3.5.2) in which the 'previous tamoxifen use' group had a
significantly increased incidence of posterior subcapsular opacities (OR = 4.02,
p=0.046) compared with untreated controls. There was also an increased incidence in
the 'current tamoxifen use' group which failed to reach statistical significance (OR =
4.07, p=0.067). The similar prevalence of posterior subcapsular opacities in the two
tamoxifen treatment groups suggest that any effect is occurring within the first 5 years
of drug exposure. In contrast, the survival curves for ocular outcomes in the current
study suggest that separation between the two groups is not occurring until about
Year 8 (Figure 6.7). The BCP Trial has also reported a significant increase in cataract
in the tamoxifen group. The development of cataracts since randomisation relied on
self reporting and was marginally statistically significant (RR 1.14, 95% CI:1.01-
1.29). However, the incidence of cataract surgery was verified and documented by
examination of medical records. There was an increased risk of developing cataract
and undergoing surgery in the tamoxifen group compared with the placebo group (RR
1.57, 95% CI: 1.16-2.14) (Fisher et al., 1998).
The observed clinical results support the observations made in tissue culture
experiments in bovine lenses (Chapter 3, Section 3.5.). Similar experiments using the
steroidal antioestrogen (ICI 182780) (.Figure 7.2), which is a pure antioestrogen with
no oestrogenic effects, showed that this did not block volume-regulated chloride
currents in three cultured cell lines and required 10-fold higher concentration to
induce significant opacification of bovine lenses in vitro (Zhang et al., 1995). Studies
in rats have shown that treatment with tamoxifen for 2 years results in increased in
cataract formation (Greaves et al., 1993). There is also some evidence that
postmenopausal oestrogen replacement therapy can increase the prevalence of
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posterior subcapsular cataracts. The Blue Mountains Eye Study has shown that the
prevalence of posterior subcapsular cataract is increased in current users of hormone
replacement therapy who had had a non-surgical menopause (adjusted OR = 2.1 (95%
CI: 1.1 - 4.1) (Cumming & Mitchell, 1997).
Other factors which may predispose to the formation of cataracts include long-term
corticosteroid use and the presence of diabetes mellitus. It is not possible in this study
to adjust for these factors although they would be expected to be evenly distributed
within the two randomised groups and therefore not affect the randomised
comparison, which also showed a borderline significant increase ofall ocular toxicities
(p=0.049).
It should be remembered that the cases of cataract determined in the study were all
related to an episode of inpatient hospitilisation and were likely to be cases
undergoing surgery for removal of the lens and implantation of an artificial intraocular
lens. The association between tamoxifen therapy and the rate of hospitilisation due to
cataract observed in the current study, could potentially have implications for the
provision of ophthalmic services and future requirements for cataract surgery.
Screening for ocular toxicity
Based on the current evidence available on the incidence of ocular toxicity associated
with tamoxifen use, views on whether screening for ocular disorders is merited in
women receiving tamoxifen therapy are mixed. Extensive ocular examination of 135
visually asymptomatic tamoxifen treated patients with a mean cumulative dose of 17.2
g, revealed two patients with intraretinal refractile crystals. The authors conclude that
the relatively uncommon finding of ocular toxicity does not merit special screening
(Heier et al., 1994). This view was supported in a study of retinal changes and visual
impairment in 290 patients taking tamoxifen for durations of between 6 months and
12 years (Tang-R et al., 1997). A study of 61 patients found 2 with retinopathy, one
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with corneal deposits and one with optic neuritis. Based on these results the author
recommends an ophthalmological assessment in the case of visual complaints for
those patients taking tamoxifen (Therssen et al, 1995). The same conclusion was
drawn following a review of the medical literature published in 1994 where case
reports and clinical studies citing adverse ocular effects in tamoxifen treated patients
were identified (Heier et al., 1994). Routine ophthalmo logical screening examinations
are considered as being ofpotential benefit because many of the lesions identified are
reversible on the cessation of treatment (Ah-Song & Sasco, 1997). The conclusion
drawn from the TOES study is that women should have a thorough baseline
ophthalmic evaluation within the first year of starting treatment and subsequently
receive appropriate follow-up evaluations (Gorin et al., 1998).
7.9 Benign endometrial disease
This study provided little evidence of an effect of tamoxifen therapy on the
development of benign endometrial lesions. This is not surprising when it is
considered that the majority of benign endometrial changes reported elsewhere have
been detected in asymptomatic women. Transvaginal ultrasonography is used to
measure endometrial thickness and in the most recent results from the Royal Marsden
pilot chemoprevention study a persistent endometrial thickening of 8 mm or more was
identified in 56 (24%) of the 235 women on tamoxifen compared with only 5 (2%) of
228 women on placebo (Powles et al., 1998). This endometrial thickening, and a
consequent risk of developing endometrial cancer, was limited to postmenopausal
women and recently amenorrheic women with a low level of circulating oestradiol.
The results lead the authors to conclude that women who develop amenorrhea on
tamoxifen, especially in the presence of endometrial thickening, low oestradiol levels
with or without gynaecological symptoms warrant further investigation (Chang et al.,
1998).
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There has been much controversy and lively discussion about the level ofmonitoring
required ofwomen on long-term tamoxifen therapy. It is not possible to predict which
postmenopausal women will develop pathological endometrial changes and some have
suggested routine periodic endometrial sampling for patients on tamoxifen (Cohen et
al., 1993) or regular monitoring by less invasive means, such as transvaginal
ultrasonography (Kedar, 1994). However, other groups do not agree with this
approach and the issue is still a controversial one (Bisset, 1994, Seoud et al., 1994). A
study at the Edinburgh Breast Unit investigated endometrial thickness in 487 women
with breast cancer. Three hundred and fifty seven (357) women treated with
tamoxifen for between 5 and 191 months had significantly thickened endometria
measured by transvaginal ultrasound compared with 130 controls (p<0.0001). Further
assessment of thickened endometria by hysteroscopy revealed a 46% false positive
scan rate suggesting that this method of screening in asymptomatic women is
unjustified (Love et al., 1999).
7.10 Dementias
This study was unable to demonstrate any association between tamoxifen use and the
incidence of dementia in the 18 cases that were detected. There is, as yet, no clear
unambiguous evidence of the benefit of oestrogen, although there are plausible
biological mechanisms by which oestrogen might lead to improved cognition and
reduced demential risk. These include the promotion of cholinergic and serotonergic
activity in specific brain regions, maintenance of the network of neurones, favourable
effects on lipoprotein profile and prevention of cerebral ischaemia. Meta analyses of
10 observational studies suggest a 29% decreased risk of developing dementia among
oestrogen users but the findings of the studies are heterogenous. Thirteen studies
addressing the effects of oestrogen on cognitive function have failed to show a clear
benefit. Studies of oestrogen therapy in Alzheimer's disease have generally had
positive results but have been small trials of short duration, non-randomised and
uncontrolled (Yaffe et al., 1998).The results of a three year, multicentre, double blind,
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placebo controlled trial of various oestrogen/progestin interventions in 875
postmenopausal women showed no effect on cognitive function (Greendale et al.,
1998).
There are, to date, no data available describing the effect of tamoxifen on cognitive
function or incidence or severity of dementia. Large placebo-controlled trials are
required to determine whether tamoxifen has a role to play in this area.
7.11 The tamoxifen life-cycle
The original intended use of tamoxifen was as a 'morning-after pill' for contraception
but this was shown to be inappropriate. Now tamoxifen is the first line endocrine
treatment of choice in women with breast cancer and its use in this indication is
widespread. Early use was for the palliation advanced breast cancer and then, having
been shown in numerous clinical trials to be a safe and effective therapeutic option, its
use was extended to treatment in early disease. Its effectiveness in the
chemoprevention of breast cancer is currently being studied and tamoxifen is now
licensed in the US for this indication in women at high risk of the disease.
Table 7.1 summarises the risk to benefit profile of tamoxifen as it is currently
understood from this study and those preceding it. Work is still required to clarify
many of the questions for which there are, as yet, no definitive answers.
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Table 7.1
Risks Benefits
Increased incidence ofPE/DVT Increased beast cancer survival
Increased incidence of stroke Decreased incidence of contralateral
breast cancer
Increased cataract formation Possible decreased breast cancer
incidence in women at high risk
Increased endometrial cancer
associated with extended duration
ofexposure
Decrease inMI incidence in current
tamoxifen users
Maintenance ofBMD
Possible effect on the incidence of
fractures
Possible improvement in cognitive
function 4
Summary of risk to benefit profile of tamoxifen in healthy women and those
with breast cancer
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Progress in understanding the basic and clinical pharmacology of tamoxifen and its
mode of action as an oestrogen agonist and antagonist, and elucidation of the cell-
signaling processes involved in the interaction with the ER, have resulted in the
development of a new generation of compounds with wider applications and has
heralded a new era in preventative therapeutics that could revolutionize womens'
health (Jordan, 1997). The nature and use of these new pharmaceuticals is discussed
more fully in Chapter 12.
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8.1 Introduction
It has long been recognised that postmenopausal hormone replacement therapy (HRT)
and oral contraception (OC) are associated with a spectrum of both risks and benefits.
Both therapies involve the use of exogenous oestrogen, either alone or in combination
with progestagens. The well-documented profile of benefits associated with
postmenopausal oestrogen use includes reduced cardiovascular disease and protection
of the skeleton against osteoporosis. Concerns about the risks associated with
exogenous oestrogen exposure have focused on areas such as thromboembolism and
cancer risk. The published literature is reviewed in the following sections of this
chapter, with some of the most recent published data being discussed in Chapter 11.
Many of the most common cancers occur in sites that are under hormonal regulation
by the steroid sex hormones. For women, these include the breast, ovary,
endometrium and, possibly, the colon. The use of oestrogens and progestagens for
contraception and postmenopausal hormone replacement therapy has provided
indirect information on the effect ofexogenous hormone exposure on the incidence of
these cancers.
The evidence of cancer risk associated with exposure to exogenous oestrogens is
conflicting, with apparently increased risk at some sites and protection at others. The
risk appears to differ according to menstrual status and levels of endogenous
oestrogens. The most intensive debate on the possible increased cancer incidence
associated with exogenous oestrogen exposure as HRT or OC has always centered
around the risk of breast cancer. Small studies often show no effect but they have low
statistical power and are therefore unreliable. For example, no increase in the
incidence of breast cancer was observed in 142 women receiving combined OC for 7
years, compared with controls. The same study showed no increase in breast cancer
Page 170
Chapter 8 Other Health Effects ofHRT and OC
incidence in 98 postmenopausal women who received HRT with oestrogens and
progestagens for the same period of time (Tzingounis et al., 1996).
The preference of researchers is to perform large-scale epidemiological studies,
involving many thousands of women and long-term follow-up. Meta analyses of
published data are also used in an attempt to quantify the risks and benefits associated
with oestrogen use. Duration of oestrogen exposure, whether exposure is current or
previous and time since last exposure are important variables to be taken into account
as part of these investigations. Some of the epidemiological studies that have been
carried out in this field are described below, and the results are discussed in the
relevant sections that follow.
8.2 Epidemiological studies of exogenous oestrogen use
8.2.1 The Nurses' Health Study
The Nurses' Health Study is a large prospective cohort study initiated in the US in
1976. 121,700 female registered nurses of between 30 and 55 years of age completed
a mailed questionnaire concerning their medical history. This included information on
oral contraceptive use, menopause, cardiovascular disease and cancer. Follow-up is
biennial, by mailed questionnaire, at which time further information on exposures and
newly identified cases of major illness is sought. The study has maintained a high
follow-up rate, with >90% of participants responding to each of the follow-up cycles
between 1988 and 1997. More recently the study has been extended to address other
emerging issues in women's health (Colditz et al., 1997).
8.2.2 Royal College of General Practitioners' Study
The Royal College of General Practitioners initiated a cohort study in the UK in 1968
into which 23,000 women taking OC and 23,000 women who had never used them
were recruited. Details of morbidity and mortality are reported every six months by
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general practitioners and the study had 25 years of follow-up when reported in 1999.
The primary aim of the study was to describe the long-term effects of OC use on
mortality (Beral et al., 1999). Over the 25 year follow-up period, 1599 deaths have
been reported. For women who had stopped OC use 10 years or more previously,
there were no significant excesses or deficits, either overall or for any specific cause
of death. Among current and recent (within 10 years) users, a decrease in the relative
risk of death from ovarian cancer has been reported along with increased risk of death
from cervical cancer, likely to be attributable to absence of barrier contraception use,
and cerebrovascular disease.
8.2.3 World Health Organisation Collaborative Study of Cardiovascular
Disease and Steroid Hormone Contraception
This hospital based case-control study was undertaken in 21 centres in 17 countries.
Cases and up to three controls, matched by 5-year age band, were interviewed while
in hospital with a standard questionnaire, which included information on medical and
personal history and lifetime contraceptive use. Cases were those admitted with a
diagnosis of acute myocardial infarction, pulmonary embolism or deep vein
thrombosis between February 1989 and January 1995 (WHO Collaborative Study of
Cardiovascular Disease and Steroid Hormone Contraception, 1997) (WHO
Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception,
1995).
8.3 Hormone Replacement Therapy (HRT)
8.3.1 HRT and breast cancer
The risk of breast cancer associated with postmenopausal hormone use in the Nurses'
Health Study was reported in 1995 (Colditz et al., 1995). The data showed a
significantly increased risk ofbreast cancer in women currently using oestrogen alone
(RR 1.32, 95% CI: 1.14-1.54). The addition ofprogestins to oestrogen therapy did not
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reduce the risk of developing breast cancer (RR 1.41, 95% CI: 1.15-1.74). The
relative risks associated with 5-9 years of exposure and 10 or more years were
similar (RR=1.46), but the increased risk associated with 5 or more years of
postmenopausal therapy was greater among older women (RR 1.71, 95% CI: 1.34-
2.18 for women of 60-64 years). The increased risk of developing breast cancer was
translated into a significantly increased risk of death from breast cancer among
women who had taken oestrogen therapy for five or more years (RR 1.45, 95%
CI: 1.01-2.09).
These data suggesting a positive relationship between the use of oestrogens after the
menopause and an increased risk of breast cancer are supported by a large number of
other observational studies which have been published in the literature. Duration of
exposure appears to be an important factor and a reanalysis of data from 51 studies,
including more than 52,000 patients with breast cancer and more than 100,000
women without breast cancer indicates that, for each year a woman uses
postmenopausal hormones, her risk of breast cancer increases by 2.3% (95% CI:
l.l%-3.6%, p=0.0002) (Collaborative Group on Hormonal Factors in Breast Cancer,
1997). A review of the literature relating to postmenopausal hormone use and breast
cancer development was published in 1998. This includes reports on cell
proliferation and endogenous hormone levels as well as epidemiological studies.
The authors conclude that there is evidence of a causal relationship between
postmenopausal oestrogen and progestin use and breast cancer (Colditz, 1998).
7,944 women who participated in a mammography screening programme for breast
cancer in Finland were followed-up from 1987 to 1995. Information on health events
and oestrogen use was obtained from biennial questionnaires and by data linking with
a number of national registers. Risk ofbreast cancer did not increase with current use
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of HRT (RR 0.57, 95% CI:0.27-1.20). Oestrogen use was classified as 'never',
'former' or 'current' and the incidence per 1000 women years was 1.8 (95% CI: 1.5-
2.3), 1.6 (95% CI: 0.75-2.8) and 1.0 (95% CI: 0.47-1.9) in these groups respectively
(Sourander et al., 1998). One mechanism by which it is postulated that excess
endogenous and exogenous oestrogens increase the risk of breast cancer development
is by increasing the proliferation of epithelial cells which have undergone partial
malignant transformation (Thomas, 1984).
8.3.2 HRT and other cancers
Endometrial cancer
The endometrium is more responsive to the tumour-promoting effects of oestrogen
than the breast and it is widely accepted that unopposed oestrogen therapy increases
the risk of developing endometrial cancer in postmenopausal women. In the Finnish
mammography study {Section 8.3.1) there was a significantly increased risk of
endometrial cancer in current hormone users (RR 2.1, 95% CI: 1.2-3.3, p<0.001)
(Sourander et al., 1998).
A meta analysis of 30 published studies summarised the relative risk of endometrial
cancer among HRT users receiving either unopposed oestrogen or oestrogen plus
progestin. Users of unopposed oestrogen had an elevated risk of developing
endometrial cancer (RR 3.3: 95% CI 2.1-2.5) and an increased risk of death (RR 2.7:
95% CI 0.9-8.0). The increased risk rises to a RR of 9.5 for 10 or more years of use
and persists for several years after discontinuation of oestrogens. Data on the risks
associated with oestrogen therapy combined with progestin were conflicting (Grady
et al., 1995). This increased risk of endometrial cancer has always been associated
with higher dose formulations of replacement oestrogens. However, a case-control
studied published in 1999 involving 789 cases of endometrial cancer and 3368
population controls has reported a two-fold increase in endometrial cancer in women
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using low dose oestrogen replacement, compared with women who had never used
oestrogens (Weiderpass et al., 1999).
Colorectal Cancer
There is now considerable evidence for a possible role for hormonal or reproductive
factors in the development of large bowel cancer in women. It has been suggested
that this may be due, at least in part, to the differential effects of endogenous and
exogenous oestrogens on the bile acid pool. Endogenous oestrogens are associated
with lower plasma cholesterol, increased high density lipoprotein (HDL) cholesterol
and increased bile acid production. Pregnancy, progestins and high dose oral
contraceptives lower plasma HDL cholesterol concentrations and reduce bile acid
production (Furner et al., 1989).
A case-control study was set up to investigate the conflicting role of endogenous and
exogenous hormonal factors and their relationship to large bowel cancer. Female
cases (n=90) and controls (n=208) were selected from an ongoing large bowel cancer
study. Postmenopausal oestrogen use was found to be protective with respect to the
subsequent development of large bowel cancer with an odds ratio of 0.6 (95% CI
0.33-0.99). Subsite analysis revealed the protective effect to be greatest for rectal
cancer (Furner et al., 1989).
Three hundred and ninety seven (397) colon cancer deaths were observed in a cohort
of 422,373 postmenopausal female participants in the Cancer Prevention Study-II
initiated by the American Cancer Society in 1982. Use of exogenous oestrogen
therapy as HRT was associated with a significantly decreased risk of fatal colon
cancer (RR 0.71: 95%CI 0.40-0.76) and there was a significant trend (p=0.0001) of
decreasing risk with increasing years ofuse (Calle et al., 1995).
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A case-control study was conducted in Northern Italy between 1985 and 1992 and
enroled 709 women with incident colorectal cancer and 992 controls admitted to
hospital for a wide range of acute, non-neoplastic, non-digestive tract and non-
hormone related disorders. For women ever using HRT, the multivariate odds ratio
was 0.40 (95% CI:0.25-0.66), with the lowest risk being associated with more than 2
years ofuse (Fernandez et al., 1996).
8.3.3 HRT and cardiovascular morbidity
Coronary heart disease
A review of 23 studies which was published in 1988 supports the hypothesis that
reductions in cardiovascular morbidity would be expected in women receiving
postmenopausal oestrogen therapy because of the effect that oestrogen has on
reducing LDL cholesterol and increasing HDL cholesterol (Rnopp, 1988). In the
same year a study was published that showed a reduced incidence of death from
myocardial infarction in oestrogen users compared with non-users (RR 0.59,
p=0.002) and also a reduced hospitilisation rate for oestrogen users (RR 0.2, p=0.03)
(Henderson, 1988).
The Finnish mammography study described in Section 8.3.1 also looked at
cardiovascular morbidity (Sourander et al., 1998). Current use ofHRT was associated
with significantly decreased cardiovascular mortality (RR 0.21, 95% CI:0.08-0.59,
p<0.001). There was a non-significant reduction in the absolute risk of sudden cardiac
death from acute MI (RR 0.45, 95% CI: 0.11-1.2, p=0.197).
The relation between postmenopausal hormone use and mortality in the Nurses'
Health Study was reported in 1997. Included were 3,637 deaths that had occurred
between 1976 and 1994 (Whitehead, 1996). The most marked reduction in deaths,
adjusted for a number of confounding variables, was that due to coronary heart disease
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in current hormone users (RR 0.47, 95% CI: 0.32-0.69). The reduction in mortality
associated with hormone use disappeared within 5 years after stopping use and there
was no increasing benefit with increasing duration of use.
This beneficial effect ofpostmenopausal oestrogen is less well defined where there is
pre-existing coronary disease. A randomised trial was conducted to determine if
oestrogen plus progestin therapy alters the risk of coronary heart disease (CHD)
events in postmenopausal women with established coronary disease (Hulley et al.,
1998). A total of 2,763 women were randomised to combined oestrogen progestin
therapy or placebo. The primary outcome measures were the occurrence of non-fatal
MI or CHD death. During an average follow-up of just over 4 years, there were no
significant differences between groups in the primary outcome measures.
Thromboembolism
Evidence of an association between current use of HRT and venous
thromboembolism is not clearly established. Three studies published in the same issue
of the Lancet in 1996 demonstrated an increased risk of thromboembolism in
postmenopausal oestrogen users. A hospital based case-control study recruited 103
cases with a diagnosis of venous thromboembolism and 178 matched controls. The
adjusted odds ratio for venous thromboembolism in current users of HRT compared
with non-users was 3.5 (95% CI 1.8-7.0, p<0.001). No association was found with
past use and risk appeared to be highest among short-term current users (Daly et al.,
1996). The second study was also hospital based and looked at the association of
postmenopausal oestrogen use with admission for venous thromboembolism. An
analysis of 42 cases and 168 matched controls yielded a relative risk estimate of 3.6
(95% CI: 1.6-7.8) for current oestrogen users compared with non-users. This estimate
was strongly dose dependent (Jick et al., 1996). A prospective study documented 123
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cases ofPE and reported an increased risk for current oestrogen users of 2.1 (95% CI:
1.2-3.8) (Grodstein et al., 1996). Overall, the absolute risk of venous
thromboembolism was low and these increases resulted in only a modest increase in
morbidity.
CVA
The effect of postmenopausal HRT on the incidence of stroke is as yet unclear. The
covariate adjusted difference in stroke mortality in the Finnish mammography study
(Section 8.3.1) was of borderline significance (RR 0.16, 95% CI: 0.02-1.18, p=0.049).
Results from a large case-control study utilising the Danish National Patient Registry
showed no significant associations between unopposed oestrogen or combined
oestrogen-progestagen regimens and the risk of non-fatal haemorrhagic or
thromboembolic stroke in women aged 45-64 years (Pederson et al., 1997). The study
adjusted for several factors which are thought to have confounded previous analyses,
such as smoking, treatment for hypertension and previous OC use.
8.4 Oral contraception (OC)
8.4.1 OC use and cancer
A meta analysis 79 epidemiological studies of cancer risk associated with oral
contraceptive (OC) use which had been reported in the literature between 1980 to
1994 was reported in 1995. Relative risk of cancer was estimated as a function of
duration and recency of OC use. Only very small differences in cancer incidence in
OC users compared with non-users were detected and the author concluded that, from
a population perspective, the net effect is negligible (Schlesselman, 1995).
Breast cancer
The increased risk of breast cancer associated with OC has long been a major concern
and a number of large epidemiological studies have tried to address this issue. A
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report of the Nurses' Health Study in 1997 looked at the risk of breast cancer
associated with OC use (Hankinson et al., 1997). There was no evidence of an
increased risk of breast cancer associated with OC use in 3,383 cases of breast cancer
in 1.6 million person-years of follow-up. This included data from women reporting
more than 10 years ofOC use (RR 1.11, 95% CI: 0.94-1.32) and five or more years of
use prior to a first full-term pregnancy (RR 0.96, 95% CI: 0.65-1.43). The Royal
College of General Practitioners' Study also reported no difference in the risk of
breast cancer between 'ever' and 'never' users of OC ((RR 1.1, 95% CI:0.8-1.4)
(Beral et al., 1999). However concern has been raised that this may provide false
reassurance. The study began in 1968 when most women using the pill were married
and the use of OC was relatively short-term. It does not address the issue of
widespread use of the pill for many years in young unmarried women, which mimics
the situation of a long gap between menarche and first pregnancy - a recognised risk
factor for breast cancer (McPherson, 1999).
Ovarian cancer
Oral contraception is known to protect against ovarian cancer and this has been
confirmed by the finding of a decreased relative risk of death from ovarian cancer in
the Royal College ofGeneral Practitioners' Study in current and recent OC users (RR
0.2, 95% CI: 0.1-0.8, p=0.01) (Beral et al., 1999). A small case-control study has
looked at the effect of OCs on the 10% of ovarian cancers which are hereditary.
Women with mutations in either the BRCA1 or BRCA2 gene have a high lifetime
risk of ovarian cancer (45% and 25% respectively). 207 women carrying a gene
mutation were enrolled into the study together with 161 who were their sisters. The
adjusted odds ratio for ovarian cancer associated with any past use of OC was 0.5
(95% CI: 0.3-0.8) and there was a significant trend for decreased risk with increasing
duration of use (Narod et al., 1998).
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Cervical cancer
A nested case-control design was used to study the association between cervical
neoplasia and oral contraceptive use within a cohort of 17,000 women. After 22 years
of follow-up of women in the Oxford Family Planning Association contraceptive
study, the elevated risk associated with OC use appeared to be largely confined to
current or recent (last use in the past two years) long-term users (OR 3.34: 95% CI
1.96-5.67). When all OC users were considered, the odds ratio was highest for
invasive carcinoma (OR 4.44: 95% CI 1.04-31.6). The results suggest a possible
effect of OC use on the later stages of cervical carcinogenesis, although the authors
stress that residual confounding due to sexual factors or human papillomavirus
infection (HPV) cannot be ruled out (Zondervan et al., 1996). For the same sexual
practices, OC users are unlikely to use barrier contraception and therefore be more at
risk of HPV. An increased relative risk of death from cervical cancer has also been
reported in current and recent users in the Royal College of General Practitioners'
Study (RR 2.5, 95% CI: 1.1-6.1, p=0.04) (Beral et al., 1999).
Colorectal cancer
The evidence of a reduced risk of colon cancer associated with postmenopausal
exogenous oestrogen use is paralleled by a reduced risk associated with exogenous
oestrogen use as oral contraceptives. The Nurses' Health Study reported on colorectal
cancer in 1997. Data collected between 1980 and 1992 involving 1,012,280 person
years of follow-up, indicate a reduced risk of colorectal cancer in women who had
used oral contraceptives for 96 months or longer (RR 0.60: 95%CI 0.40-0.89)
(Martinez et al., 1997). The case-control study conducted in northern Italy {Section
8.3.2) also found a reduced risk of colorectal cancer in women who had ever used
OCs (multivariate odds ratio 0.58 95% CI:0.36-0.92 (Fernandez et al., 1996).
Page 180
Chapter 8 Other Health Effects ofHRT and OC
8.4.2 OC use and cardiovascular disease
Oral contraceptives were introduced into clinical practice in the 1960's and it was not
long before the first case reports of thromboembolism in women taking them were
received. A number of relatively small case-control and cohort studies estimated a
relative risk of thromboembolism associated with OC use in the range of 2 to 11.
Since then, the doses of oestrogen and progestagen in these products has been
reduced and prescribing practice has changed towards the preferential use of OCs by
younger women without other risk factors for cardiovascular disease. In spite of this,
the results of the WHO Collaborative Study show an increased risk of venous
thromboembolism associated with OC use in Europe (OR 4.15, 95% CI: 3.09-5.57).
This increased risk was apparent within 4 months of starting OCs, was unaffected by
duration of use and had disappeared within 3 months of stopping (WHO
Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception,
1995).
Leiden factor V mutation is a hereditary prothrombotic disorder present in 4-5% of
the population and this increases the risk of thromboembolism in oral contraceptive
users. A study to investigate the incidence of the relatively rare condition of cerebral
sinus thrombosis in oral contraceptive users found an odds ratio of 30 in women who
were OC users and carried this hereditary risk factor relative to women who had
neither risk factor (de Bruijn et al., 1998).
The WHO Collaborative Study has also reported on the incidence of acute myocardial
infarction in women receiving OCs. As with thromboembolism, there was early
evidence of an association between OC use and myocardial infarction. Many
subsequent case-control studies suggested that the association was causal. The WHO
study included 368 cases and 941 matched controls. The overall odds ratio for acute
myocardial infarction associated with current OC use in Europe was 5.01 (95% CI:
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2.54-9.07). However, this increased risk was shown to be among women with known
cardiovascular risk factors such as increased blood pressure and smoking. Very few
cases were identified among women with no cardiovascular risk factors and who
reported that their blood pressure had been checked before starting OC use (WHO
Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception,
1997).
The association between OC use and MI risk seen in the WHO study has not been
confirmed in a UK case-control study published in 1999. The study compared 448
women who had suffered an MI with 1,728 controls and the adjusted odds ratio for
current OC users was 1.40 (95% CI:0.78-2.52). There was thus no evidence of a
significant association between oral contraception and myocardial infarction (Dunn
etal., 1999).
Other reports linking cardiovascular disease with OC use include a report of the
Nurses' Health Study in 1997 which indicated a non-significant reduction in death
from stroke (RR 0.68, 95% CI: 0.39-1.16) representing a relatively small number of
cases (Grodstein et al.1997). In 1999 The Royal College of General Practitioners'
Study reported an increased risk of death from cerebrovascular disease in current and
recent OC users (RR1.9, 95% CI: 1.2-3.1, p=0.009) (Beral et al., 1999).
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9.1 Types of epidemiological studies
9.1.1 Cohort studies
Cohort studies, often referred to as prospective studies, involve the selection of a
group of individuals with exposure documented at the outset as exposed or non
exposed, and the follow-up of both groups enables investigators to compare the
incidence of a particular outcome. If a positive association exists between exposure
and the outcome we would expect to see a greater incidence of the outcome in the
exposed compared with the non exposed individuals. A cohort study is indicated
when there is good evidence of an association between exposure and the outcome
and, as follow-up is usually over a long period, loss to follow-up must be minimised.














Design of a cohort study
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Other types of cohort studies include, for example, dietary studies where all
individuals are exposed but at different levels and studies which follow only an
exposed cohort and compare it to the general population. The null hypothesis in a
cohort study is that there is no association between the exposure and the outcome.
9.1.2 Case-control studies
Case-control studies, known also as retrospective studies, provide an alternative
means to the cohort study of examining the possible relationship of a certain disease,
or other outcome, with a particular exposure, such as a drug or an environmental
factor. The key design feature of a case-control study is the selection of a group of
individuals with the disease (cases) and a group of people without the disease
(controls) and comparison of the two groups with respect to the exposure of interest.
The proportion of cases and controls exposed can be determined by a variety of
means such as interview, examination of case records or biochemical assay. The
design of a case-control study is shown schematically in Figure 9.2.
Figure 9.2
Design of a case-control study
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As with a cohort study, the null hypothesis in a case-control study is that there is no
association between the exposure and the outcome.
The design of a case-control and that of a cohort study differ fundamentally. The
former compares a group of cases and a group of controls with respect to exposure
while the latter compares exposed and non-exposed individuals with respect to
outcome. Because case-control studies start after the outcome event, they provide an
opportunity to assess multiple causes relating to one event. They are also highly
efficient in terms of the number of subjects required. However, the fact that the
outcome has already occurred results in one of their disadvantages; information
relating to exposure and other factors has to be collected after disease status is
determined. This can lead to bias, especially interviewer bias and recall bias.
9.1.3 Nested case-control studies
The nested case-control study is a hybrid design in which a case-control study is
nested within a cohort study. In this type of design a population is identified and
baseline exposure data are collected, but not processed. The population is then
followed over a period of time, usually years, and a percentage will experience the
outcome under study and the majority will not. A case-control study is carried out in
which those who experience the outcome are cases and a sample of those not
experiencing the outcome are selected as controls. This is shown schematically in
Figure 9.3.
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Design of a nested case-control study
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This design is free from information bias, in the same way as cohort studies are. It
was developed to reduce the resource costs of cohort studies and is particularly
efficient when complex analyses of biological samples are required to process the
baseline data.
9.2 Methodology of case-control studies
9.2.1 Selection of cases
There are a number of basic criteria that should be applied to the selection of cases.
These can be summarised as follows:
• Cases should be truly 'a case' and have had the outcome under
study. Clear case definition is critical and misclassification of case
status will bias the results of the study towards the null hypothesis.
• Cases should be newly incident cases. The use of prevalent cases,
where the disease has been present for some time, is likely to
mean that a larger number of cases are available for study.
However, any risk factors identified in such a study may be
related more to survival than to disease incidence. Also, the time
sequence between exposure and disease will be unclear.
• Cases should be a representative sample ofall arising in a defined
eligible population.
• It must be possible to determine exposure and other related factors
in cases.
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9.2.2 Selection and number of controls
The essential characteristics of the control group follow logically from those of the
cases and may be defined as:
• Controls must be truly 'non-diseased'. Definition is required of
the tests to which they have been subjected.
• Controls should be representative of the population from which
the cases are derived.
• Controls must be available for study so that necessary information
on exposure and other factors can be determined.
The ratio of the number of cases to the number of controls is determined arbitrarily.
Multiple controls of the same type are used to increase the power of the study where
the number of cases is limited and cannot be increased other than by extending the
recruitment period of the study. A noticeable increase in power is gained only up to a
case:control ratio of about 1:4. The decision on the number of controls to use for
each case is therefore based on a balance between the power requirements of the
study and the availability of suitable controls.
While it is normal practice to use all available cases in a study, the number of
controls available is often vastly in excess of that required. In these circumstances, a
sampling procedure is undertaken to ensure that each eligible control has an equal
chance of selection. Sampling should be random but may, in practice, be systematic.
In random sampling, a method of random number generation is used whereby each
possible control has a fixed and determinate probability of selection. One method of
systematic sampling is to select controls sequentially separated by a fixed interval.
Both methods require enumeration of the eligible controls.
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9.2.3 Error and bias
Errors result in the value of a variable being used in the study differing from the true
value of that factor. These may be non-differential, such that the inaccuracies are
similar in both cases and controls with only a small possibility of there being
systematic differences between the groups. Such errors include those resulting from
random and biological variation and they can also be introduced during
measurement, recording or computation of a variable. These result in a systematic
deviation towards the null of the results.
Bias is an inaccuracy that differs in size or direction between the cases and controls.
It can influence the results of a study in any direction and can produce measurements
ofassociation which are exaggerated. A number of common sources of bias can arise
in a case-control study and these include:
• Recall bias, arising from a subject's recall of exposure
information.
• Selection bias, arising from the way in which cases and controls
are selected from the target population.
• Observer bias, where the means of obtaining information on
exposure and other details differs between cases and controls.
Bias also includes other areas, such as interpretation bias, publication bias and
disclosure bias to name but some. In order to design a study so that bias is
minimised, the choice of outcome and exposure measures must be relevant,
objective, reproducible and robust. The same methods should be used under the same
circumstances by the same observers for cases and controls involved in the study.
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9.2.4 Confounding
One of the main problems in epidemiological studies is that of confounding.
Confounding is the distortion of an exposure-outcome association brought about by
the association of another factor with both outcome and exposure. These associations
are independent of one another. This situation is represented schematically in Figure
9.4.
Figure 9.4
Schematic representation of confounding
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The problem of confounding can be addressed in a number of ways, either at the
level of study design or during the statistical analysis. Strategies to deal with
confounding include restriction, matching, stratification and adjustment and these are
discussed below.
Restriction
Restriction involves excluding those subjects, at either the design or analysis stages,
who exhibit the confounding factor, For example, if smoking is a confounding factor,
all patients who smoke can be excluded. This effectively leaves no possibility of
confounding but reduces the generalisability of the study in that results cannot
subsequently be applied to smokers.
Matching
Matching of cases and controls can be undertaken to avoid the situation where cases
and controls differ in characteristics other than that being studied. This may be by
group matching, where controls are selected such that the proportion with a certain
characteristic is similar to the proportion in the cases, or by individual matching. In
individual matching, for each case in the study, a control is selected with a similar
profile of the specific variables being matched. It is important only to match on
variables that are known to be risk factors for the outcome being studied and are not
part of the causal pathway being investigated. Overmatching can result in difficulty
in finding sufficient controls fulfilling the criteria and odds ratios artefactually close
to unity. Another problem is that once controls have been matched to cases according
to a particular characteristic, that characteristic cannot subsequently be studied.
An appreciable gain in precision is only realised by matching for a confounding
variable that is strongly related to the exposure of interest. For less strongly related
confounders, matching leads to only modest gains in precision while complicating
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the study design. In the situation where the matching variable is related to exposure
but not to the risk of the outcome under study, then matching reduces the efficiency
of the study. In practice, age is usually a very strong confounder and case-control
studies are frequently matched for age.
Stratification
As an alternative to matching, where confounding is dealt with as part of the study
design, the problem can be addressed during data analysis by means of stratification.
Stratification involves analysing the data in strata corresponding to different values
of the confounding variable. If the association being studied is true and not due to
confounding, then we would expect to see this association in each of the strata in the
analysis. Problems can arise as a result of small numbers in strata and the consequent
instability of estimates. In these circumstances it is necessary to produce a summary
measure of association, in the form of a weighted average of the stratum-specific
estimates.
Adjustment
An alternative method for dealing with confounding variables is to analyse the data
by means of a mathematical model that takes the outcome under consideration as the
dependent variable and includes both the postulated causal factor and confounding
factors in the equation. The covariates may be continuous, dichotomous or
categorical and the logistic regression model can be applied, or conditional logistic
regression if a matched design is being used. This allows the effect of the exposure
of interest on the incidence of the studied endpoints to be determined having adjusted
for confounding variables.
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9.3 Analysis of observational studies
9.3.1 Estimating risk
The incidence of a disease in a population is known as the absolute risk. Absolute
risk is an indicator of the magnitude of the risk in a group of exposed people, but it
does not take into account the risk of disease in non exposed individuals. It therefore
cannot indicate whether or not exposure is related to an increased risk of the disease.
To determine whether such an association exists between exposure and the disease,
we consider the ratio of the risk of disease in exposed individuals over the risk of
disease in non-exposed individuals. This ratio is the relative risk.
Relative risk = Risk in exposed / Risk in non-exposed
The relative risk can be calculated directly in cohort studies but in case-control
studies the incidence of disease in the exposed and non-exposed population is not
known and the relative risk cannot be calculated directly. An alternative measure, the
odds ratio, is therefore calculated in case-control studies.
In general terms, the odds of an event can be defined as the ratio of the number of
ways that the event can occur to the number of ways the event cannot occur. If the
probability of an event occurring is P, then the odds that the event will occur are
defined as P/(l-P). In a case-control study, the odds ratio is defined as the ratio of the
odds that the cases were exposed to the odds that the controls were exposed. If the
exposure is not related to the disease, the odds ratio will be 1. If the exposure is
positively related to the disease, the odds ratio will be greater than 1. If the exposure
is negatively related to the disease, the odds ratio will be less than 1.
Calculation of relative risk and odds ratio is shown schematically in Figure 9.5 for a
cohort study.
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Relative Risk = Risk in exposed
Risk in non exposed
= a/(a + c)
Odds Ratio =
b/(b + d)
Odds that exposed person develops disease





Calculation of the Relative Risk and Odds Ratio
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When the disease outcome is rare, the odds ratio is a good approximation of the
relative risk in the population. Cases and controls must be representative, with regard
to exposure, of people with and without the disease respectively in the population
from which they were drawn and sampling fractions must not depend on exposure.
The relationship between odds ratio and relative risk for different disease frequencies
is illustrated in the following calculations for two hypothetical cohort studies





Relative Risk = (50/100)/(25/100)
= 2
Odds Ratio = (50x75)/(25x50)
= 3











Relative Risk = (200/10000)/(100/10000)
= 2
Odds Ratio = (200x9900)/(100x9800)
= 2.02
Comparison of OR and RR in a cohort study where disease is rare
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9.4 Design of current study
9.4.1 Introduction
The current study was designed as an observational study comprising a number of
case-control studies, nested in cohorts formed from the target population. Baseline
data with respect to the exposures of interest (exogenous oestrogens) were obtained
routinely for the hospital case-notes from the patient at presentation. A strong feature
of the study design is that cases and controls are derived from the same target
population. This comprised all women who had presented to the Edinburgh Breast
Unit between 1989 and 1994 inclusive, and for whom there is a computerised data
record. This record was extracted from the database and included in the dataset
which was linked with the SMR6 cancer registration and GRO death records. Output
from the linkage procedure consisted of two datasets; one dataset consisted of
records from the EBU database which had not been linked with a SMR6 or GRO
record and the other consisted ofEBU records and one or more SMR6 records and/or
a GRO record with which they had been linked.
The exposures of interest were exposure to exogenous oestrogens, as oral
contraception (OC) or hormone replacement therapy (HRT), both of which were
classified at the time of presentation as current, previous or never. Information on
duration of exposure was available for some, but not all of cases. A single exposure
category (oestrogen exposure/no oestrogen exposure) was used in the analyses.
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9.4.2 Selection of cases and controls
Cases were drawn from the set of linked records and were those subjects:
i) who had died and the registered cause cited on the death certificate, as
either the underlying cause or a secondary cause, was ischaemic heart
disease (IHD), cerebrovascular disease or thromboembolic disease
according to the ICD9 classifications in Table 9.1.
Table 9.1
Cause ofDeath ICD9 Classification




Note: where an ICD9 code is given to 3 digits, all further subclassifications are included e.g.
451 includes 4510-4519 inclusive
Causes of death endpoints for study
Page 198
Chapter 9 Case-control Study: Methods and Analysis
ii) who were registered on SMR6 with a new primary cancer, since entry
to the study, at a site identified as being potentially relevant to








Sites of new primary malignancy as endpoints
Breast cancer was not included as an outcome for the current study as it was
considered that inclusion of the incidence ofbreast cancer in a population presenting
to a Breast Unit would require careful consideration of, and adjustment for, other
variables known to be risk factors for the development of breast cancer. These
include age at menarche, parity and family history. Hodgkin's disease has been
included as an endpoint because there are epidemiological data which suggest an
Involvement of reproductive, and thus hormonal factors, in its pathogenesis in
women (Bourdais-Mannone et al., 1999).
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Whether or not a case had a diagnosis of breast cancer at presentation was
determined by referring back to the dataset of linked records and cross-checking the
date of presentation with the date of diagnosis of breast cancer, if this was present.
This enabled distinction between subjects who presented with a diagnosis of breast
cancer and those who developed breast cancer at a later date.
Controls were a sample ofwomen, individually matched with cases for year of birth
and the presence or absence of a diagnosis of breast cancer at presentation, who had
none of the above endpoints. Separate groups of controls were selected for each of
the endpoints. The populations from which the controls were drawn are illustrated in
Figure 9.8.
Controls without a diagnosis of breast cancer at presentation were drawn from the set
ofEBU records that had not been linked with an SMR6 or a RGO record. Thus, the
non breast cancer control set was already available as a result of the linkage process.
Controls with a diagnosis of breast cancer at diagnosis were drawn from the set of
linked records. To be eligible as a breast cancer control, a subject was required to be
alive with a diagnosis of invasive breast cancer within one month of a single
presentation to EBU between 1989 and 1994. No other malignancy or hospital
admission should be present. This process could only be carried out by manual
checking of the entire set of linked records, marking those that satisfied the criteria
and copying the marked set to a new table. This was the set of breast cancer controls.
The irregular structure of the records made it impracticable to use programming
methods to select the control set.
A similar process was implemented to randomly select the controls from each of the
two control datasets. Consider the situation where 5 breast cancer cases have the year
of birth 1945. For a case to control ratio of 1:2 it is necessary to randomly select 10
controls from the set of breast cancer controls with the year of birth 1945. The
following procedure was adopted:
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• A query was run in Microsoft Access to select all records in the
breast cancer control set with the year of birth 1945.
• If this process yielded, say, 40 possible controls (numbered
sequentially from 1 to 40) the random number generator in
Microsoft Excel was implemented to randomly select 10 numbers
between 1 and 40.
• These numbers identified the 10 controls required.
If matching by year of birth failed to yield sufficient possible controls, additional
controls were selected from the next following year. The selected casercontrol ratio
of 1:2 was that considered to be the optimum value in terms of power of the study
and practicality of obtaining the relevant information from the EBU database within
the required timeframe.
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with only a diagnosis
of invasive breast
cancer









Schematic representation of populations from which cases and controls were
selected
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9.4.3 Discussion of method of selection of controls
Age has a strong association with the outcomes and exposures and is therefore, by
definition, a confounding factor. Frequency matching of cases and controls within 5
year age bands is one option for taking this confounding effect into account.
However, for logistic reasons related to the structure and subsequent manipulation of
the linked data as supplied by ISD, the decision was taken to match cases and
controls individually on year of birth. Date of presentation was not available on the
listings of cases (Section 9.5.4) and therefore age was not used as a matching
variable. For the same reason, cases and controls were not matched on duration of
follow-up and therefore controls were not defined to be free of disease when the case
was diagnosed.
Cases and controls were also matched on the presence or absence of breast cancer.
This was important because of the effect the presence of breast cancer may have on
the endpoints being studied and was implemented by matching the controls to the
cases on breast cancer diagnosis as described. Had all the controls been selected from
the set of unlinked records then, by definition, none of the controls would have had a
diagnosis of breast cancer at presentation. The diagnosis of breast cancer was
restricted to invasive breast cancer.
Exclusions
Cases and controls identified in the target population were excluded from the eligible
population for analysis for any of the following reasons:
i) The subject did not have a record on the EBU database. This was the
case when a mismatch had occurred between the EBU database and
the ISD combined database.
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ii) A record was present on the database but no presentation details were
recorded.
iii) For a new primary cancer endpoint, if a previous malignancy at any
site was noted prior to presentation at EBU this case was excluded.
Previous malignancies did not exclude cases from the analysis of the
other cause of death endpoints, as this would have required checking
every case for an entry on the cancer registration database (SMR6).
9.4.4 Sources of bias
Selection bias was minimised within the study by selecting all available cases with
the outcomes of interest ascertained from the data linkage with cancer registration
and death registration databases. Controls, individually matched with cases by year
ofbirth and presence or absence ofbreast cancer diagnosis, were randomly selected
from the relevant control sets. Information bias was excluded by the prospective,
nested case-control design.
9.5 Data linkage
9.5.1 Preparation of data for linkage
Ascertainment of cases in the study was by means of record linkage of the target
population with the cancer registration database (SMR6) and the GRO death
registration records held on the combined database at ISD. The background and a
detailed discussion of the record linkage procedure are given in Chapter 3. The
linkage with the EBU data was carried out by ISD in February/March 1999, at which
time death registration on the combined database was complete to March 1998 and
cancer registration on SMR6 was complete to the end of 1996.
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The data for linking with the combined database were extracted from the EBU
database for patients presenting in the years 1989 to 1994 inclusive. The records
were extracted into a Microsoft Excel file by a member of staff at EBU (PD). The
variables which were extracted for each presentation are shown in Table 9.3.
Postcode is formatted into 2 variables in the EBU database and these were combined








Variables extracted from EBU database for linking with SMR6 and GRO
records
The total number of data records included in the linkage was 27,089, corresponding
to the number of presentations at EBU between 1989 and 1994 inclusive. It is not
uncommon for subjects to present for the unit on more than one occasion. Before the
linkage with SMR6 and GRO records in the combined database was undertaken, staff
at ISD performed an internal linkage to remove instances ofduplicate presentations.
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A total of 19,410 individual patients were then available for linking. Some
manipulation of the data was required prior to linkage to correct inconsistencies in
the formatting ofpostcode and dates of birth in the spreadsheet. This was also carried
out by staff at ISD.
Linkage of the data to hospital inpatient statistics (SMR1) was not carried out in this
part of the study because only mortality data and new primary cancers were of
interest.
9.5.2 Matching score
During the linkage procedure at ISD, the data were reviewed to determine the level
ofweighted probability which gave as near 100 to 1 absolute odds that the matched
records belonged to the same individual. Inspection revealed that weighted
probabilities above 27 indicated true matches, those under 23 were mismatches and
those between 23 and 27 represented a combination of true and mismatches. All
scores of 23 and above were included in the linkage output. All records selected as
cases or controls had their data records accessed on the EBU database and the
validity of the match was thus checked at this stage.
9.5.3 Output of linked data
The linked data were compressed by ISD into an ASCII file onto a 3.5" disk. On
receipt by the author the file was expanded and exported into a Microsoft Access
database. The ISD output included two files; unlinked EBU records and linked EBU
records with the corresponding SMR6 and/or GRO records. This second file of
linked records comprised information relating to 4,122 patient records. All fields in
the imported file were text fields. The structure of the records differed depending on
the source of the record (EBU, SMR6, GRO). This is illustrated in Table 9.4.
4
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Table 9.4
Field No. Description Size Format/Source
1 Linkno 8 Unique identifier allocated to all records
by linkage procedure
2 Record Type 2 00=EBU, 06 = SMR6, 09=GRO
3 Presentation Date 6 EBU record
Registration Date 6 SMR6 record
Date ofDeath 6 RGO record
4 Surname 12 Text
5 Forename 12 Text
6 Maiden Name SMR6 and RGO records
7 Date ofbirth 6 DDMMYY
8 Sex 1 2 = Female
9 Postcode 7
10 Case Reference No. 10
11 Linkage weight 4 EBU record
Cancer site code 4 SMR6 record
Primary cause ofdeath 4 RGO record
12 Secondary causes 14 RGO record
Structure of linked dataset showing records from 3 different sources - EBU,
SMR6, GRO
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9.5.4 Ascertainment of cases and selection of controls
Queries were run on the Microsoft Access database of linked records to identify the
endpoints defined in Table 9.1. Listings were obtained for each of the cause ofdeath
endpoints being studied and for all new, non-breast primary cancers. These data
listings comprised the population from which the cases in the study were drawn.
Queries in Microsoft Access were run on both the linked and not linked datasets to
select the controls for the study, as described in Section 9.2.2 above.
9.5.5 Data collection
Data collection was carried out by the author at the Western General Hospital where
access to the EBU database was available. Cases and controls were identified on the
EBU database by name and date of birth, the relevant information obtained from the
presentation screen and entered directly into a Microsoft Access database which had
been previously created on a laptop computer. A description of this database is given
in Table 9.5. Age at presentation was calculated from the date of presentation and
date ofbirth.
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Table 9.5
Field Name Description
Linkno Unique linkage no assigned by ISD









oc Exposure to OC: 1=CURRENT
2=PREVIOUS
3=NEVER
oc_dur Duration of exposure to OC
hrt Exposure to HRT: 1=CURRENT
2=PREVIOUS
3=NEVER
hrtdur Duration of exposure to HRT
Diagnosis Diagnosis: 1=BREAST CANCER
2=BEN1GN
Oestrogen Oestrogen exposure: l=EXPOSED
2=NOT EXPOSED
9=NOT KNOWN
Structure of database for entering exposure data obtained from EBU database
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During data collection it was noted that the recording of the presence or absence of
hysterectomy (Hx) and oophorectomy (Ox) on the EBU database was inconsistent
The following consistency rules were implemented at data entry:
• IfHx -NO and Ox is missing, then Ox = NO
• If Hx=YES (1 or H) and Ox is MISSING, then Ox - NOT
KNOWN
• If Hx is MISSING and Ox is MISSING, then Hx is NOT
KNOWN and Ox is NOT KNOWN
Menstrual status is recorded on the EBU database as REGULAR, IRREGULAR,
STOPPED. For the purposes of this study, REGULAR AND IRREGULAR were
both coded as PREMENOPAUSAL.
9.5.6 Data checking procedures
Linkage validation
No systematic validation of the linkage process was undertaken. However, the
process of accessing the record on the EBU database to obtain the necessary
information relating to oestrogen exposure was, in effect, a method of validation. The
search was by name as recorded on the ISD combined database and the appropriate
record would not be found on the database unless this was identical to the name as it
was recorded on the EBU database. Date of birth was always verified to ensure that
the correct record had been accessed. If a record could not be found on the EBU
database, possible alternative spellings were tried, to ensure that a true match was not
being missed - e.g. Miller for Millar, Johnston for Johnstone, Ann for Anne,
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McDonald for Macdonald. If a record was not identified on the database at the first
attempt a further attempt was made at a later date as an additional check that it was
not present on the EBU database. If, after following these procedures, a record was
not identified on the EBU database, it is reasonable to assume that this was an ISD
record that had been mismatched with an EBU record.
Consistency checks
When data collection was complete, a number of queries were run on the Microsoft
Access database to identify records with inconsistent or implausible data. Such
inconsistencies may arise from data entry errors or from errors on the database. Data
for records identified by this procedure were re-checked with the EBU database. The
consistency checks performed were as follows:
• Age <21 or > 100 years
• Age > 60 years and premenopausal
• Premenopausal but current or previous HRT
• Postmenopausal but current oral contraception
• Duration ofHRT or OC recorded but status = NEVER
The results of the data checking procedures are described in Chapter 10.
9.6 Statistical methods
Various calculated fields were created before the data were subjected to statistical
analysis. These are described in Table 9.6. Matching of cases and controls had been
implemented by year of birth (or the following year) and breast cancer status at
presentation and a single matching variable for the analysis was created by
combining the 5 year age-band stratification and the presence or absence of breast
cancer at presentation. This variable took the value 1-22. The data were exported as
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separate text files for each of the outcomes under study and were thus presented in
the appropriate matched sets (by 5 year age band and breast cancer status) for each
analysis.
Table 9.6
Calculated Field Name Description
Age Age calculated from (d_pres - dob)






Outcomeihd 0 = control for IHD
1 = case for IHD
Outcomet 0 = control for PE/DVT
1 = case for PE/DVT
Description of calculated fields for the case-control analyses
Statistical analysis was by standard methods of analysis for matched case-control
studies using conditional logistic regression, which enables the investigation of the
relationship between one or more predictors and a binary outcome/response. For
each outcome studied, a point estimate of the odds ratio (i.e. relative odds of that
outcome for exposed versus non exposed individuals) was determined, together with
a confidence interval around that estimate The logit model assumes a binomial error
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distribution and allows information about the relationship between outcome and
exposure to be obtained.
Odds =p/(1-p)
Logit = log odds = log[p/(1-p)]
Where p = proportional response
Logit 1 - Logit 2 = log[p/(1-p)] - log[p2/(1-p2)]
= log [(p1/(1"P1) / (P2/(1-p2))]
= Odds Ratio
The logistic regression equation takes the form:
Log[p/(1-p)] = a + biXi + b2X2 + b3X3
Where the x variables represent exposure factors and
the b terms are the coefficients
The conditional logistic regression model is used to analyse data where controls have
been matched to cases. In this model the results are analysed in terms of case-control
sets rather as individual subjects. The method avoids having to estimate a large
number of fixed effect parameters corresponding to the baseline responses for the
sets induced by the matching. Statistical analysis was implemented in the
Conditional Logistic Regression module of the Egret® (Sere) statistical software.
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9.7 Changes to study design
The study was originally planned such that, after the identification of cases and
controls, hospital case-notes would be reviewed to obtain the information recorded at
presentation which was to be included as covariates in the analysis. The variables
which it was planned to study were:
* Menstrual status
* Occurrence of hysterectomy/oophorectomy
Smoking history
Previous relevant medical histoiy
* Oestrogen exposure as OC / HRT
* Duration of oestrogen exposure
Occurrence ofprevious cancer at any site
In the event, it transpired that only a very small percentage of case-notes were
available and these related exclusively to cancer patients. This was largely due to the
fact that hospital policy is now to destroy case-notes of discharged patients with
benign disease after a period of 3 years has elapsed since death.
Therefore the only available source of the information required was the EBU
database. This was known to be incomplete for parameters other than menstrual
status (periods regular, irregular or stopped) and use of OC and HRT (current,
previous, never) for the years of interest in the study (1989 - 1994). The data
collected for the study had to be restricted to the variables in the above list marked
with an asterisk (*). Information on duration of OC/HRT use and the presence of
hysterectomy and oophorectomy was scanty but was nevertheless collected where
available.
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10.1 Results of linkage of EBU data with SMR6 and GRO records
After inspection of the linked data file by the operator from ISD, it was determined
that a probability weight of over 27 corresponded to a 100/1 absolute odds of a true
match, a probability weight of less than 23 corresponded to a mismatched record and
probability weights of between 23 and 27 were a combination of true matches and
mismatched records. All records linked with a probability weight of 23 or over were
output to the linked dataset. No specific action was taken at this stage to validate
whether or not matches were correct. Using these criteria, the linkage procedure
resulted a total of in 9,137 data records comprising EBU records for 4,022 women
and the SMR6 cancer registration and GRO death records with which they had been
matched.
10.2 Number of events
The number of deaths identified from linkage with GRO records and corresponding
to the causes of death considered for inclusion in the study are shown in Table 10.1.
The number ofall new primary malignancies identified from linkage with SMR6 are
presented, classified by site of cancer, in Table 10.2. Patients developing new
primary cancers at more than one site during the follow-up period will appear in
more than one site classification. Breast cancer has been excluded as an endpoint in
the current study.
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Table 10.1
Event ICD9 Classification No. of events
Ischaemic Heart Disease 410,411,413,414 153
Cerebrovascular Disease 430-439 141
Thromboembolism
(PE/DVT) 451, 4151 43
Number of events identified from linkage of EBU data with GRO records
Table 10.2
Site of primary malignancy ICD9 No. of Events
Lip and oral cavity 140 - 149 3
Digestive organs 150- 159 103
Respiratory and intrathoracic 160- 165 64
Bone, connective tissue and skin 170- 173 158
Ovarian 184 14
Endometrium 182 36





Number of new primary malignancies at all sites (excluding breast) identified
from linkage of EBU data with SMR6 records
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The broad classification of sites of new primary malignancy noted in Table 10.2 are
further broken down in Table 10.3 into those sites which are thought to be most
influenced by endogenous and exogenous oestrogen exposure and which are







Colorectal cancer 153, 154 79
Liver cancer 155 2
Hodgkin's disease 201 0
Endometrial cancer 182 36
Ovarian cancer 183 65
Number of new primary malignancies at sites of interest for the current study.
10.3 Scope of the current study
Unforeseen delays in the preparation of the data for linkage and the processing of the
linkage procedure itself resulted in time constraints necessarily being placed on the
analyses to be undertaken. Access to the EBU database was also difficult with
computer terminals rarely freed up from routine use. The scope of the study was
therefore confined to those outcomes considered to be the most relevant. Decisions
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on the outcomes to be analysed were made before data collection was started. With
regard to cause of death, ischaemic heart disease and thromboembolism were
selected for study. The number of cases of liver cancer and Hodgkin's disease was
negligible and the analysis of new primary malignancies was restricted to
endometrial cancer.
10.4 Data validation
Table 10.4 presents the results of the consistency checks that were run on the data
collected from the EBU database. These results indicate that there were 14 records
where the recording ofmenstrual status can be considered unreliable.
Table 10.4
Detail Number of Records
Age <21 or > 100 years 0
AGE > 60years but PREMENOPAUSAL 7
PREMENOPAUSAL but HRT =
PREVIOUS or CURRENT 7
POSTMENOPAUSAL but OC =
CURRENT
0
Duration ofHRT given but HRT =
NEVER
0
Duration ofOC given but OC = NEVER 0
Data inconsistencies identified in EBU database
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10.5 Overview of results of data collection
The following sections consider only the results for the mortality endpoints of
ischaemic heart disease and thromboembolism. Results with respect to the incidence
ofendometrial cancer are presented in Section 10.9.
The linkage procedure and selection of controls (Chapter 9, Section 9.4.2) identified
a total of 196 cases and 320 controls for the endpoints of ischaemic heart disease and
thromboembolism. However, as data collection progressed, it became clear that not
all of the cases and controls selected had data recorded on the EBU database. Two
main reasons for this were identified:
i) A subject identified by the linkage as experiencing an event
did not have a record on the EBU database. This was
indicative of an incorrect matching between the EBU database
and the combined SMR6/GRO database and serves as an
internal validation of the matching procedure.
i) A subject was registered on the EBU database and the record
was identified but no presentation data were present and
therefore no information on oestrogen exposure was available.
The reason for these data not being recorded was not apparent.
A total of 21 records could not be found on the EBU database, indicating that they
were not valid matches between the ISD combined database and the EBU database.
A further 16 records identified on the EBU database had no presentation details
associated with them. Thus, a total of 170 cases and 309 controls were available for
data collection and inclusion in the statistical analyses. As a result of the procedure
for selecting controls, 31 patients had been selected as controls for both endpoints.
The effective number of controls available for study was therefore 340 giving an
overall casexontrol ratio of 2, although of course each analysis proceeded
Page 219
Chapter 10 Results - Part B
independently. The number of cases for inclusion in the analyses of the two cause of
death endpoints is presented in Table 10.5.
Table 10.5
Cause ofDeath No. of Cases




Number of cases available for analysis on the EBU database
Table 10.6 presents an overview of the data that were available for the 479 cases and
controls and also indicates where data are missing. The percentages in the final
column refer to the percentage of the total for which data are available.
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Overview of data collected from EBU database
% refers to percentage of available data, excluding missing values
Page 221
Chapter 10 Results - Part B
10.6 Power of the study
10.6.1 Definition of power
The power of a study is the probability that the study can demonstrate a significant
association, given that an association exists. Power is defined as 1-p, where p is the
probability of not detecting a significant difference where a true difference exists, p
is thus the risk of a false negative result and is known as the Type II error. Several
factors affect the power of a study:
• The strength of the true association - the larger the true difference
between groups the easier it will be to detect.
• The frequency of outcome, as given by the number of cases and
controls.
• The prevalence of exposure among cases and controls. The
maximum power is achieved when about one half of all the
subjects are exposed.
In calculating the sample size for a study, the power is often set at 0.8. This means
that the study is designed so that the chance of detecting a significant difference, if
the true difference exists, is 80% and we accept that we will miss the true difference
20% of the time and get a false negative result. Another factor of relevance when
considering sample size is the significance level, a. This is the cut-off point used to
determine whether the association found is statistically significant and is most
frequently set at the p=0.05 level, a is called the Type I error and is the probability of
detecting a 'significant difference' when no true difference exists - i.e. a represents
the risk ofdetecting a false positive result.
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10.6.2 Calculation of power in the current study
Estimations of the ability of the current study to detect an association between
exposure and risk of the outcomes under study were derived for each of the
endpoints from the number of cases available for analysis. Table 10.6 indicates that
52 of 256 controls (20.3%), for whom the information was available, were exposed
to oestrogen as either OC or HRT. This exposure level has been used in the power
calculations. The calculation has been carried out for case-control studies in which
there are two matched controls for every case and for a range of values of the
correlation coefficient of exposure between cases and controls (0.25, 0.5 and 0.75)
The calculation was performed using Arcus Quickstat Biomedical (Research
Solutions), and the figures obtained represent the minimum number of cases required
to have an 80% chance of detecting a true effect with a Type I or alpha error (risk of
false positive result) of 0.05, for a range ofOR between 2 and 10.
Table 10.7





Minimum Number of Cases
2 160 240 480
3 61 96 203
4 38 61 135
5 28 46 106
6 23 38 90
7 19 33 80
8 17 30 73
9 15 27 68
10 14 25 64
Minimum sample size required in terms of detectable odds ratio for exposed
compared with non exposed individuals for different correlation coefficients of
exposure between cases and controls
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Thus, from Table 10.7 it can be seen that for the endpoint of ischaemic heart disease
(130 cases), under the conditions described, the study has an 80% power to detect an
odds ratio of 2 to 4 between exposed and non exposed individuals. For the outcome
of thromboembolism (40 cases), the study is sufficiently powered to detect an odds
ratio of 4 and 6 respectively for exposure correlation coefficients of 0.25 and 0.5
respectively. However, Table 10.7 also shows that for an exposure correlation
coefficient of 0.75, the number of thromboembolic events is insufficient to detect an
odds ratio of exposed to non exposed individuals of 10.
10.7 Results for ischaemic heart disease
Table 10.8 presents the results for ischaemic heart disease in a simple 2x3 table of
numbers of cases and controls and their exposure status to exogenous oestrogen, as
either HRT or OC. Note that 38 cases and 48 controls were excluded from the
statistical analysis because the EBU presentation data did not include the necessary
information on oestrogen exposure.
Table 10.8
Cases Controls Total
Exposed 23 37 60
Not exposed 69 177 246
Not Known 38 48 86
Total 130 262 392
Numbers of exposed, non exposed and exposure unknown cases and controls for
the endpoint of ischaemic heart disease
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Ninety two cases of ischaemic heart disease with known oestrogen exposure status
were included in the final analysis together with 214 controls. Cases and controls
were matched in the analysis by 5 year age band and breast cancer status at
diagnosis. The data as presented for statistical analysis are attached as Appendix 6.
Statistical analysis was by the conditional logistic regression module of the statistical
package Egret® (Sere). Menstrual status was not used as a covariate because the
consistency checks carried out on the database had indicated that the recording of
this variable on the EBU database was unreliable. The covariate under investigation
was that relating to oestrogen exposure. It is worth remembering that when the
conditional logistic regression model is used to estimate the odds ratio, the only
matched sets that participate in the estimation of the odds ratio for a covariate, V, are
those in which two subjects differ in their values for V.
The analysis of the influence of exogenous oestrogen exposure on death from
ischaemic heart disease yielded an odds ratio of 1.001 (95% CI: 0.991-1.012,
p=0.822) for exposed compared with non exposed individuals. Thus the results show
no indication of an association between oestrogen exposure and death from IHD in
this study.
10.8 Results for thromboembolism
Table 10.9 presents the results of the oestrogen exposure status for the cases and
controls for the endpoint of thromboembolic death, defined as PE or DVT.
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Table 10.9
Cases Controls TOTAL
Exposed 6 15 21
Not exposed 28 51 79
Not Known 6 12 18
TOTAL 40 78 118
Numbers of exposed, non exposed and exposure unknown cases and controls for
the endpoint of thromboembolism
Six cases and 12 controls were excluded from the statistical analysis because
oestrogen exposure data were not available. Thus of 40 cases and 78 controls
identified, 34 cases and 66 controls were available for the analysis. As before, a
matching variable was created from the age stratification and the breast cancer status
at presentation. The data for analysis are attached as Appendix 7.
Statistical analysis by conditional logistic regression yielded an odds ratio of 0.411
(95%CI: 0.097-5.223, p=0.737) for exposed compared with non exposed individuals
and does not indicate an effect of oestrogen exposure on death from
thromboembolism, as PE or DVT, in this study.
10.9 Results for endometrial cancer
A total of 34 of the 36 cases of endometrial cancer which were identified from the
data linkage had a data record on the EBU database. However, it became apparent
during the collection ofexposure data that a significant number of these cases related
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to endometrial cancers which had a date of onset preceding the date of presentation
to the EBU. The linked dataset contained all primary cancer registrations for an
individual and was not limited to those occurring from 1989 onwards. Those cases
of endometrial cancer with a date of onset preceding the date of presentation to the
EBU were not eligible for inclusion in the analysis. Thus a total of 17 cases were
excluded, leaving only 17 available for analysis. This number was insufficient to
justify proceeding with statistical analysis at this time.
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11.1 Study power: comparison with published studies
The calculations of study power which are presented in Chapter 10, Section 10.6.2
suggest that the current study is sufficiently powered to detect an odds ratio of
between 2 and 4 at the 5% level of significance, between individuals exposed and not
exposed to oestrogen as HRT or OC, for a maximum correlation coefficient of
oestrogen exposure in cases and controls of 0.75. Published studies of the relative
risk ofmyocardial infarction in users ofHRT indicate that the greatest benefit is seen
in current users who have pre-existing cardiovascular risk factors (OR 0.51, 95%
CT0.45-0.57) (Grodstein et al., 1997). A striking decrease in cardiovascular mortality
was observed in a population study of 7,944 women (adjusted risk ratio 0.21, 95%
CI:0.08-0.59) (Sourander et al., 1998). One important difference between the current
study and many of the published studies is that data are not available on smoking
history and cardiovascular risk factors and these are therefore unmeasured
confounders.
The sample size calculations for the current study (Table 10.7) indicate that the
number of cases of death from ischaemic heart disease identified in this study should
be sufficient to detect differences of the order ofmagnitude seen in previous studies.
A preliminary estimate of the expected number of IHD deaths suggested that there
may be over 300 deaths from IHD in the study (Scottish Health Statistics, 1993. ISD
Publications, Volume 35). The lower number of deaths seen is likely to be due to the
relatively young age of the population presenting to EBU and to the fact that 10% of
the population are breast cancer patients with a correspondingly higher breast cancer
death rate.
For cause of death due to thromboembolism, the power calculations suggest that the
number of cases available is sufficient to detect odds ratios of between 4 and 6 for
exposed compared with non exposed individuals, for a correlation coefficient of
exposure between controls and cases of 0.25 and 0.5 respectively. The WHO
collaborative study of the risk of venous thromboembolic events associated with OC
use showed an odds ratio of 4.15 (95% CI:3.09-5.57) for a hospital based case-
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control study in Europe (WHO Collaborative Study of Cardiovascular Disease and
Steroid Hormone Contraception, 1995). In this study, the prevalence of current OC
use among the cases and controls was 61.2% and 34.1% respectively. The level of
exposure in cases and controls is clearly an important factor in determining study
power.
There are a number of factors in this study which compromise its statistical power to
detect differences between exposed and non exposed individuals. Firstly, the number
of cases and controls available for the analyses is less than the number identified as
eligible for statistical analysis in the linked dataset and this is due to missing
exposure data on the EBU database. Secondly, the level ofexposure of the controls is
relatively low at 20.3%. Maximum study power is obtained with control exposure
levels of 40-50% (Breslow and Day). It is worthy of note that the exposure levels in
cases (IHD -25%, thromboembolism-20%) does not differ greatly from that in
controls (20.3%) and this results in a correlation coefficient of exposure between
cases and controls which approaches unity.
The levels of oestrogen exposure observed in this study may reflect a true situation.
However the possibility cannot be ignored that they might be the result of incorrect
data entry and coding on the EBU database resulting in non-differential errors in
exposure assessment. This would be the case if OC and HRT use had been recorded
as NONE when the true value is MISSING. Problems with the classification of
menstrual status on the database have already been identified and other errors cannot
be ruled out. Further, it is known that during the time frame covered in this study
(1989-1994), significant problems were experienced with the EBU computer system,
particularly on two occasions when data were transferred from one system to
another. Problems of system incompatibility resulted in loss of data during these
transfer processes.
Thus, the lack of association between exogenous oestrogen exposure and death from
ischaemic heart disease or thromboembolism seen in this study may be attributable to
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a lack of power and is not necessarily indicative that such an association does not
exist. The combining ofHRT and OC use into a single exposure category may also
dilute the results of the study; the literature appears to point to effects of exposure to
HRT and OC acting in opposite directions. Whereas much of the published data on
postmenopausal oestrogen use point to a protective effect, the evidence is clearly
indicative of an increased risk of myocardial infarction associated with exposure to
exogenous oestrogens as oral contraception. A further factor is that, according to
published data, the effects seen are limited to current oestrogen use and by
combining current and previous use into a single exposure category, any effects may
be diluted out.
11.2 Recent published data of oestrogen exposure and cardiovascular disease
Although a lower rate of coronary heart disease in postmenopausal women who take
oestrogen is well documented and discussed in Chapter 8, these data relate to
observational studies and have not been confirmed in clinical trials. More recently,
two large clinical trials have been published and the data challenge this premise. The
HERS (Heart and Estrogen/progestin Replacement Study) study randomised 2,763
women with established coronary disease to combined OC or placebo. The main
outcome measure was the occurrence of non fatal MI or death from coronary heart
disease and over a follow-up of 4.1 years, there was no difference in the number of
coronary events in the two groups. Further there was a statistically significant trend
to more events occurring in the active treatment group in the first year (Hulley et al.,
1998).
The second study involved women starting HRT with a pre-existing heart condition
and suggests that women with previous heart disease should not be prescribed HRT.
These data emerged from a further analysis of the 1996 CARS trial (Coumadin-
Aspirin Reinfarction Study) which collected data on 8,803 heart disease patients
including 1857 postmenopausal women. The results showed that of 111 women who
started HRT after a heart attack, 32.5% were hospitalised for unstable angina within
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a year. This compares with 21% of 413 women who had used hormones before their
first attack and continued to use them during the study and 17% of 1,333 women
who had never used hormones.
11.3 Suggestions for future work
11.3.1 Validation of exposure data
Based on the findings of the current study, a number of extensions to this work can
be proposed. Firstly, it would be of value to audit the EBU database to determine the
accuracy and validity of the data, particularly those data relating to oestrogen
exposure. As has already been discussed, the source data (hospital case-notes) for
this study tend not to be available for patients with benign disease who have died.
However, notes for all cancer patients are available and checks in this group would
be feasible and would allow the accuracy of the database to be audited against the
source data. An estimate of the error rate in data recording for various parameters in
this sample could be obtained. If this exercise confirmed the validity of the levels of
oestrogen exposure recorded then it is clear that, because of the similar exposure
levels in cases and controls, a considerable increase in the number of cases would be
required to reliably detect an association. The number of events could be increased
by increasing the length of follow-up and re-running the linkage procedure. Now that
the linkage between the EBU database and the ISD combined database has been
established and the methodology is in place, this is a straightforward operation. A
modification to the method used to select controls in the current study, whereby
controls are selected who are free of the endpoint when the case is diagnosed should
be implemented in any future study.
11.3.2 Extensions to the current study
Provided that the validity of the EBU data was confirmed, a number of extensions to
the current study can be proposed. Linkage of the EBU database has only been
undertaken with SMR6 and GRO death records. This could be extended to include
linkage with SMR1 enabling a comprehensive study of all morbidity, resulting in a
period of hospitilisation, to be undertaken. Such an extension to the study is likely to
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provide large numbers of cases but these could be adequately processed by the
electronic methods that have been established. Potential therapeutic areas for study
are discussed below.
Cognitive function
There are plausible mechanisms by which oestrogen may affect cognition but studies
of the effects of oestrogen replacement on cognitive function and dementia in
postmenopausal women have produced heterogeneous results. There have been
positive results in studies of verbal memory and oestrogen has been shown to cause
changes in brain activation patterns in regions of the brain associated with short-term
memory function. The changes seen appear to reinstate the patterns seen in younger
women (Shaywitz et al., 1999). A meta analysis of 10 observational studies
investigating the risk of developing dementia suggested a 29% reduction associated
with postmenopausal oestrogen use but concluded that further large studies are
required. A recently published case-control study involving 222 cases and 222
matched controls has produced further evidence of a reduction in the risk of
postmenopausal women developing Alzheimer's disease associated with hormone
replacement therapy (odds ratio 0.42, 95% CI: 0.18-0.96, p=0.04) (Waring et al.,
1999).
Fractures
There is no doubt that sustained administration of oestrogen to postmenopausal
women maintains skeletal bone density and protects against fracture, although many
questions remained to be answered about the optimal use of this treatment. A case-
control study of 1,327 postmenopausal women with hip fracture and 3,262 controls,
which was published in 1998, concluded that recent use of HRT is required for
optimum fracture protection and that the protective effect increases with duration of
use. Current users had an odds ratio of 0.35 (95% CI:0.24-0.53) for hip fracture
(Michaelsson et al., 1998). The same group have also published data showing a 25%
reduction in the risk of hip fracture associated with OC use (OR 0.75, 95% CI:0.59-
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0.96) (Michaelsson K et al., 1999). Extension of the current linkage to include SMR1
would allow identification of those women admitted to hospital for fracture and
would enable a study of the association of fracture with exposure to oral
contraceptives and postmenopausal oestrogens.
Colorectal cancer
A number of studies have been published which suggest a reduced incidence of
colorectal cancer in postmenopausal women receiving oestrogen replacement. In the
current study, 79 colorectal cancers were identified and 60 of these have a date of
onset of 1989 or later. The majority of these are likely to be eligible as cases (date of
onset after date ofpresentation to EBU). Provided that the exposure data on the EBU
database were verified, an analysis of these data would be of interest.
11.3.3 New study design
If source data verification of a sample of cases and controls indicated that the details
of oestrogen exposure recorded on the EBU database are unreliable, then there is
little to be gained from pursuing the extensions to the study discussed above. The
question of morbidity and mortality associated with exogenous oestrogen exposure
would best be addressed by a designing an alternative study. One option would be a
prospective, cohort study with baseline data, including oestrogen exposure, being
recorded at study entry (presentation to EBU). The same linkage methodology that
has been established for the current study could be used to determine the number of
cases occurring in exposed and non exposed individuals. The design of such a study
is illustrated in Chapter 9, Figure 9.1. A prospective study of this type would require
a number of years of follow-up but there would be some advantages in adopting this
approach. For example, there would be the opportunity to set up methods for the
reliable collection of all covariates at baseline, including smoking status, previous
medical history and other risk factors. There would also be the opportunity to study
HRT and OC as separate exposures, to look at the effect of duration of exposure and
to look separately at current and previous exposure.
Page 233
Chapter 12 Final Discussion
12.1 Study Conclusions
The results obtained from the updated data linkage of the Scottish adjuvant
tamoxifen trial database with the ISD combined database provide further substantial
evidence for the protective effect of current tamoxifen use against ischaemic heart
disease and for an increased risk of thromboembolism associated with current use.
The study has therefore achieved its aim of strengthening the evidence base of the
risks and benefits associated with tamoxifen use in relation to these particular
parameters, which are among the most intensively studied. The incidence of ocular
toxicity associated with tamoxifen use has, in general, provoked less discussion than
the cardiovascular effects but the results of this study, which indicate a substantially
increased risk of cataract development with tamoxifen are particularly striking. The
data obtained are in accordance with recent published data from the US Breast
Cancer Prevention Trial (Fisher et al., 1998) and this is an area worthy of
consideration when prescribing tamoxifen therapy for prolonged periods.
The data for the risk of fracture in this study does not provide clear evidence for a
beneficial effect but does emphasise the need for further prospective studies of this
complex area. The study provides further evidence for the endometrial
carcinogenicity of long-term tamoxifen, although numbers are small and statistical
evaluation was not feasible. Claims of carcinogenicity at other sites, such as
colorectal, have not been substantiated.
The attempt to apply the data linkage methodology to answer related questions
regarding the effects of exposure to exogenous oestrogens, using the Edinburgh
Breast Unit database failed to produce informative results for reasons discussed in
Chapter 11. Further, no attempt has been made to ascertain the risk of breast cancer
development associated with oestrogen use. However, the study has established the
methodology for data linkage of this database with SMR1, GRO records and also,
although not used in the current study, SMR1. The study has also performed a
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valuable audit of the Edinburgh Breast Unit database and opened the way for fixture
studies.
12.2 New agents for hormone replacement therapy
Tamoxifen remains the treatment of choice as first-line endocrine therapy in women
with breast cancer. As understanding of its mode of action increased, particularly
with reference to its tissue specific actions as both an oestrogen agonist and
antagonist, it was inevitable that the potential of agents with a similar profile of
action would be investigated as possible hormone replacement therapies. The
development of tamoxifen has been instrumental in the development of a new
generation of pharmaceuticals offering significant potential benefits for women's
health, beyond the treatment ofbreast cancer.
Although tamoxifen was itself never seriously considered as an oestrogen
replacement therapy, such a role was tentatively discussed when evidence of its
oestrogen agonist activity on the skeleton and cardiac system, together with its
oestrogen antagonist action on the breast started to accrue. Here was a molecule
which performed the functions of oestrogen on the skeleton and the heart but did not
carry an increased risk of breast cancer, but rather may be associated with a reduced
risk (Jackson, 1997). This led to a search for other candidate molecules and this
search gathered pace as the evidence for the clinical benefit of tamoxifen in
postmenopausal cardiac disease and loss of bone density became apparent. The
potential of these compounds as long-term hormone replacement interventions to
prevent some of the age-related problems seen in postmenopausal women as well as
harnessing the potentially beneficial effect of chemoprevention of breast cancer is
very significant.
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12.3 Selective Oestrogen Receptor Modulators (SERMs)
The group of compounds known as selective oestrogen receptor modulators, or
SERMs, has been undergoing development over the past few years. These are a
structurally diverse group of compounds which, like oestrogen, interact with the
nuclear receptor but are distinguished from oestrogen by their ability to act as either
an oestrogen agonist or antagonist depending on the target tissue and the hormonal
milieu. The SERM profile is therefore distinct from that of pure oestrogens and pure
oestrogen antagonists. SERMs of different structural types, such as tamoxifen and
raloxifene, can be distinguished from each other by their different activity profile in
specific tissues, for example in the uterus. It is the tissue selectivity ofSERMs which
has led to their being developed as oestrogen replacement therapies for the treatment
of otherwise healthy, postmenopausal women.
12.4 SERMs as oestrogen replacement therapies
Hormone replacement therapy has the potential to prevent many of the diseases
associated with oestrogen deficiency in postmenopausal women. However, there is a
lack of data on optimum dose duration and, in particular, on when to initiate therapy.
Currently, hormone replacement therapy is given as oestrogen or combined
oestrogen-progestin preparations. Problems of unwanted side-effects result in lack of
compliance and make them unsuitable for long-term use. There have been many
studies investigating the risk of breast cancer associated with HRT use. The
reanalysis in 1997 of 51 such studies reaffirmed that the risk of having breast cancer
diagnosed is increased in women receiving HRT and the risk increases with
increasing duration of use (Collaborative Group on Hormonal Factors in Breast
Cancer, 1997). In the Nurses' Health study of long-term HRT, the lower
cardiovascular mortality seen was cancelled out after 10-years treatment by an
increase in breast cancer mortality (Grodstein et al., 1997). Continuing concern about
the increased breast cancer risk means that many clinicians are reluctant to use
oestrogen-based HRT in the preventative setting.
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Two structural classes of SERMs have been identified - the triphenylethylene
derivatives and the benzothiophene derivatives. The mechanisms by which these
molecules elicit tissue-specific responses are currently the subject of intensive
investigation. It is postulated that the structural differences may influence the
conformations of their respective receptor-ligand complexes and this, in turn, may
affect which oestrogen-responsive genes are modulated in various tissues (Grese et
al., 1997).
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12.5 Triphenylethylene derivatives
The triphenylethylene tamoxifen may be considered, in retrospect, a first-generation
SERM because of its ability to exert antioestrogenic action on breast tissue and an
agonist action on, for example, the cardiovascular system and skeleton. A number of
triphenylethylene derivatives have subsequently been developed and the structure of
some of these are shown in Figure 12.1. The best known of these is toremifene,
which is a monochloro-derivative of tamoxifen, the structure of which has already
been described in Figure 7.1. Toremifene is licensed as Fareston® for use in the
treatment of advanced, tamoxifen-resistant breast cancer. However, as already
described in Chapter 7, Section 7.5, toremifene does have a stimulatory effect on the
endometrium and is associated with increased endometrial thickness. Early evidence
also suggests that this molecule is less effective than tamoxifen in protecting against
loss in bone mineral density in postmenopausal breast cancer patients (Marttunen et
al., 1998). Toremifene is currently undergoing evaluation as a therapy for breast
cancer in the adjuvant setting and as an agent for the prevention of breast cancer.
Studies in rats have shown a favourable activity profile for idoxifene with protection
against bone loss, a reduction in total cholesterol and a lack of growth promoting
activity in the uterus (Nuttall et al., 1998). However Phase III clinical trials for the
prevention of osteoporosis were prematurely stopped because of the high number of
gynaecological events, including endometrial thickening, pelvic organ prolapse and
polyps, seen in an interim safety review after one year of therapy (SCRIP, No.2431,
April 23rd 1999, Page 21). Phase II studies of idoxifene in the treatment of advanced
breast cancer are continuing. Droloxifene is currently in Phase III trials for the
prevention of osteoporosis. Cell culture work with this molecule suggests that
induction of apoptosis may be a mechanism for both its oestrogen agonist effects in
bone and its antagonist effects in breast tissue (Grasser et al., 1997).
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Another triphenyethylene derivative, clomiphene, is marketed as Serophene® and is
used to initiate or augment ovulation by antagonising oestrogen at the hypothalamus
and pituitary.
12.6 Benzothiophene derivatives
Raloxifene (LY139481 HC1) is a benzothiophene derivative and the structure is
shown in Figure 12.2. This molecule was the first compound to be given the label of
SERM and is the product in the most advanced stage of clinical development.
Preclinical studies in ovariectomised rats showed that raloxifene can prevent bone
loss and lower serum cholesterol, without stimulating proliferation of the
endometrium (Black et al., 1994). This unique SERM profile encouraged
investigation of its clinical use in healthy postmenopausal women as an oestrogen
replacement therapy.
A clinical study involving 390 healthy, postmenopausal women showed that
raloxifene favourably alters biochemical markers of biochemical risk, with
reductions in LDL cholesterol, fibrinogen, lipoprotein a, and an increase in HDL2
cholesterol (Walsh et al., 1998). A placebo controlled trial in 601 postmenopausal
women also showed reductions in LDL and total cholesterol in the raloxifene group.
This study also demonstrated significant increases, from baseline values, in BMD of
the lumbar spine, hip and total body compared with the placebo group, in which
there were decreases in BMD. These benefits were seen after 24 months of treatment
and there was no evidence at any time during the study of stimulation of the
endometrium and increased endometrial thickness (Delmas et al., 1997).
Page 241
Chapter 12 Final Discussion
Figure 12.2
Raloxifene
The structure of a benzothiophene derivative
Raloxifene was launched in the UK in September 1998 for the prevention of
postmenopausal osteoporosis and is marketed under the tradename of Evista.
Meanwhile further long-term clinical studies are currently underway. The MORE
study is looking at, amongst other parameters, the effect of raloxifene therapy on the
incidence of bone fractures and its effectiveness in the prevention of breast cancer.
Preliminary data have recently emerged from this study indicating that raloxifene
may have a role in the treatment, as well as in the prevention, of osteoporosis. 6,828
women who had already developed osteoporosis were followed up with vertebral
radiography at 36 months. At least one new vertebral fracture was found in 10.1% of
the women given placebo, in 6.6% of those given 60 mg raloxifene daily and in 5.4%
of those given 120 mg daily. The relative risk for spinal fracture in the low and high
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dose groups compared with placebo were 0.7 (95% CI: 0.5-0.8) and 0.5 (95% CI:
0.4-0.7) respectively (Ettinger et al., 1999). This study has also reported on the
incidence of breast cancer development. Thirteen cases of breast cancer have been
confirmed among the 5,129 women randomised to raloxifene compared with 27
cases among 2,576 women randomised to placebo (RR 0,24, 95% CI: 0.13-0.44,
p<0.001) (Cummings et al., 1999). The main adverse effect reported within the
MORE study is an increased risk of venous thromboembolism associated with
raloxifene (Ettinger et al., 1999).
Two other large randomised studies of raloxifene are ongoing. In the STAR study
raloxifene is being tested against tamoxifen as a chemopreventative agent in breast
cancer and the RUTH study is investigating the cardiovascular effects of raloxifene.
12.7 Conclusions
Clearly, SERMs hold much promise in the amelioration of signs and symptoms of
postmenopausal oestrogen deficiency. However much work still requires to be done
to unleash the potential of these, so called, 'magic bullet' molecules and to develop
the ideal hormone replacement therapy. The ideal SERM will have antiestrogenic
effects in the breast and uterus and act as an oestrogen agonist on bone and lipids.
Many pharmaceutical companies' attempts to find the ideal SERM have been
unsuccessful. Pfizer has recently dropped development of droloxifene for breast
cancer therapy, although it is still investigating the product for osteoporosis.
SmithKline Beecham and GlaxoWellcome have also discontinued SERM
development. Lilly is however developing a third generation SERM, arzoxifene,
which has shown a 25,000-fold greater affinity for the oestrogen receptor than
tamoxifen with no pathological endometrial thickening at any of the doses tested.
Hopefully, the many studies currently ongoing will answer some of the questions and
the new therapies being developed will gain widespread clinical acceptance by
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Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial
C C McDonald, H J Stewart for the Scottish Breast Cancer Committee
Abstract
Objective—To investigate the incidence of fatal
myocardial infarction in women in the two random¬
ised arms of the Scottish adjuvant tamoxifen trial.
Design—Retrospective review of hospital notes
to determine with the greatest possible certainty
women who had died of an acute myocardial infarc¬
tion.
Setting—Scottish Cancer Trials Office, the Uni¬
versity of Edinburgh.
Patients—1070 postmenopausal women with
operable breast cancer who were randomised to
receive either adjuvant tamoxifen for five years or
until.relapse (539 patients) or tamoxifen for at least
six weeks on the confirmation of first recurrence (531
patients).
Main outcome measures— Incidence of fatal myo¬
cardial infarction in women with no known or
suspected systemic cancer.
Results—Of the 200 women who died in the
adjuvant tamoxifen arm of the trial, 44 were free of
cancer at death and 10 of these died of myocardial
infarction. In the observation arm 251 women died,
of whom 61 showed no evidence of systemic
cancer and 25 had a fatal myocardial infarction.
The incidence of fatal myocardial infarction in the
two groups was significantly different (x:=6-88,
p=0-0087).
Conclusion—Tamoxifen given for at least five
years as adjuvant therapy for breast cancer seems to
have a cardioprotective oestrogen-like effect in
postmenopausal women.
Introduction
Tamoxifen is a non-steroidal antioestrogen and is
considered to be the front line endocrine treatment for
breast cancer. It is widely used in postmenopausal
women both as treatment for advanced disease' and as
adjuvant treatment in early disease, when it has been
shown to delay recurrence and increase survival.1
Increasing numbers of premenopausal women are also
now receiving tamoxifen as adjuvant treatment.1
Although tamoxifen was given for up to two years in
most early clinical trials, evidence is growing that
better results may be obtained with longer treatment.1
Studies in animals have shown that the effect of
tamoxifen on breast carcinoma cells is rumorostatic
rather than tumoricidal. The growth ofMCF-7 tumour
cells can be reactivated by supplementation with
oestrogen after up to six months' treatment with
tamoxifen,'7 suggesting that long term or indefinite
treatment should be advised. A trial has been proposed
to investigate whether five years' treatment with
tamoxifen has any preventive effect on the develop¬
ment of breast cancer in women considered to be at
increased risk.
Increased length of exposure to tamoxifen raises the
question what are the lona term effects of the treatment.
Acute toxicity is known to be low,' but the possibility
that prolonged exposure may result in premature
osteoporosis and cardiovascular disease as a result of
antioestrogenic action must be considered, oestrogens
being essential for maintaining bone density and a
favourable lipid profile. Various oestrogen-like actions
of tamoxifen have been shown, including effects on
the liver resulting in increased concentrations of sex
hormone binding globulin and thyroxine binding
globulin.' Laboratory studies have shown that tamoxi¬
fen has a favourable effect on bone density,10 and
clinical results have been encouraging." "
The Scottish adjuvant tamoxifen trial was set up to
compare the effect on survival of adjuvant tamoxifen
for five years with that of tamoxifen for recurrent
breast cancer. We compared the incidence of fatal
myocardial infarction in postmenopausal women
randomised within this trial.
Patients and methods
Between 1978 and 1984, 1323 women with operable
breast cancer were entered into four randomised
controlled trials of adjuvant tamoxifen. Patients were
randomised to receive tamoxifen either immediately
after mastectomy (20 mg/day for five years or until
confirmed relapse) or for a minimum of six weeks on
confirmation of first recurrence. Eleven women were
withdrawn from the trial within the first month
because of major protocol violations, leaving 1312
evaluable cases. Fatal myocardial infarction was not
recorded in any premenopausal woman, and this
analysis is confined to the 1070 women who had not
had a menstrual period for more than one year at entry
to the study. Of these women, 539 were randomised
to receive adjuvant tamoxifen and 531 to receive
tamoxifen at first relapse.
Those patients who had not had a recurrence and
were still taking tamoxifen after five years were con¬
sidered eligible for rerandomisation to stop tamoxifen
or to continue until relapse or death. As a result 176
patients continued treatment beyond five years, either
after rerandomisation or electivelv.
Information on disease state, possible new primary
tumours, and details of tamoxifen and other treatments
was collected annually and at death. After a woman
died the records were carefully checked, with par¬
ticular importance being placed on establishing, with
the greatest possible certainty, the cause of death. Any
doubt about the presence or source (from breast or
other confirmed or suspected primary tumour) of
metastatic disease was recorded (table I).
We analysed the results using Pearson's y; test and a
survival analysis in which women who had died of
myocardial infarction were treated as events and
women who had died of other causes or who were
still alive were censored. The hazard ratio and 95%
confidence interval were calculated with Cox's propor-
rionnl hn7nrrK r^r^cion mrw-F»l
Kesuits
Table I shows the cause of death in the 451 women
who died (200 from the adjuvant arm and 251 from the
observation arm). Evidence from postmortem exami¬
nation was available for 38 women. We restricted the
analysis to those who had a fatal myocardial infarction
in the absence of known or suspected systemic cancer.
Ten women in the adjuvant tamoxifen arm of the
trial were recorded as having died of acute myocardial
infarction. The median age of these women was
71 (range 65-77) years and the median duration of
exposure to tamoxifen was 29 (9-93) months. Nine of
the women were still receiving tamoxifen at the time of
death and one had stopped treatment two months
before her death.




Cause of death (n=200) (n= 251)
Breast cancer present at death:
Breast cancer 137 163
Breast cancer and myocardial infarction 2 7
Breast cancer and vascular disease* 6 10
No breast cancer present at death:
Myocardial infarction 10 25
Vascular disease* 14 13
Second primary* cancer 12 15
Other causes 8 8
Disease state at death uncertain:
Unproved systemic spread 6 7
Cancer but source uncertain 5 3
•Includes cerebrovascular accident, congestive cardiac failure, chronic
ischacmic heart disease, and mitral valve disease.
In the observation arm 25 women died of acute
myocardial infarction at a median age of 73 (59-80)
years. Twenty one of these women had had no known
exposure to tamoxifen. The four other women were all
receiving tamoxifen when they died: one had received
adjuvant tamoxifen for four months in error, two
women had been successfully treated for local or
regional recurrence with local therapy and tamoxifen
for 12 and 13 months, and one woman had received
tamoxifen for 14 months after excision of a contra¬
lateral primary breast tumour. Table II shows the
distribution of duration of treatment of women in the
adjuvant and observation arms.
TABLE II—Duration of treatment with tamoxifen in women who died
ofmyocardial infarction in adjuvant and observation arms of trials
Duration of Adjuvant arm Observation arm





Women in the adjuvant arm were significantly less
likely to die ofmyocardial infarction than were women
in the observation arm (y.-'=6-88, p=0-0087). Women
receiving adjuvant tamoxifen have a significantly
increased survival" and hence a longer time at risk of
dying from a cause other than breast cancer. Thus, the
beneficial effect of tamoxifen on myocardial infarction
could be greater than is apparent from these data.
Survival analysis using death from myocardial infarc¬
tion as the end point confirms the significance of this
result (p=0-0054, Mantel-Cox); the hazard ratio was
0-37 (95% confidence interval 0-18 to 0-77).
Twenty seven women died of vascular diseases,
which included cerebrovascular accident, congestive
cardiac failure, chronic ischaemic heart disease, and
mitral valve disease. We found no difference in the
distribution of these various causes within the adjuvant
and observation arms of the trials.
Discussion
Tamoxifen exhibits a range of complex pharmaco¬
logical properties, and may behave as an oestrogen ot
an antioestrogen depending on the target site."
Studies in which the serum concentrauons of lipids
and lipoproteins in pauents receiving tamoxifen have
been monitored have shown an oestrogenic effect,
with decreases in total and low density lipoproteir
cholesterol concentrauons and an increase in high
density lipoprotein cholesterol concentration."*"'
Cholesterol and lipoproteins are implicated as risk
factors for cardiovascular disease, and the author:
of these studies conclude that tamoxifen exerts i
favourable effect on the lipid profile over 12 months
treatment. Addiuonal studies are needed to determine
if the effect is maintained beyond 12months' treatmen
and the effect of stopping tamoxifen.
We found a significant reducrion in the incidence
of fatal myocardial infarcrion in women receiving
adjuvant tamoxifen, which provides clinical evidence
to support the above biochemical findings. A simila:
reducuon in deaths from myocardial infarcuon ii
postmenopausal women receiving oestrogen replace
ment therapy was observed in a study in southeri
California." Among 8841 women aged 44-101 year
followed up for six years, 55 women who wer
receiving oestrogen therapy died ofmyocardial infarc
tion compared with 94 women who were not give:
oestrogens (reladve risk=0-59, p=0-002)."
Bourne el al have shown that administering trans
dermal oestradiol to postmenopausal women reduce
arterial impedance and decreases vascular tone
which would be an alternative explanation for th
effect of tamoxifen on myocardial infarction." Othe
mechanisms, such as effects on insulin metabolisn
should not be overlooked."
Reduced concentrauons of anuthrombin III ha\
been reported during treatment with tamoxifen," an
Dahan el al have suggested that tamoxifen coul
increase the risk of thromboembolism.-" We found r
such increased risk, and a recent study has shown th
the decrease in anuthrombin III concentrauon
paralleled by a greater decrease in fibrinogen co
centrauon'; the rario of fibrinogen to anuthromb
III concentrauon is thus decreased and the risk
thrombosis reduced.
Further follow up may provide information <
whether the reduced incidence of fatal myocard
infarction in the adjuvant arm reverts to that found
the observarion arm in those women who stopp
treatment at five years. We are currendv invesugau
whether adjuvant tamoxifen has a similar effect on t
incidence of non-fatal myocardial infarcuon.
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Objective—To determine whether length of delay
before treatment; specialty and grade of the surgeon;
and use made of surgery, radiotherapy, and chemo¬
therapy influenced the survival of patients with
cancer of the bladder, after adjusting for case
severity.
Design—Retrospective cohort study.
Setting—South East and South West Thames
health regions.
Patients—609 men aged under 75 resident in the
South Thames regions who had been registered as
new cases of bladder cancer in 1982, 35 of whom
were excluded, leaving 574 eligible patients. Analysis
was based on 75% retrieval rate for case notes.
Main outcome measures—Duration of survival
from date ofdiagnosis of the bladder tumour.
Results—10 prognostic variables were used to
adjust for case severity. The median delay from
referral to first treatment was 48 (interquartile range
27-84) days. Treatment after a short delay was
associated with shorter survival because of the early
treatment ofmore severe cases. Consultants treated
68% of patients, trainee surgeons treated less severe
cases. Initial treatment was by a urologist in 67% of
cases, but the specialty of the surgeon was not
associated with prognosis. The associations of
radiotherapy, cystectomy, and systemic chemo¬
therapy with survival were interpreted in terms of
selection bias as well as therapeutic effect.
Conclusions—Case severity was the most
important influence on survival and influenced length
of delay before treatment, grade and specialty of the
surgeon, and main treatment allocation. After
adjusting for case severity, variations in these
processes of care were not strongly associated with
variations in survival.
Introduction
In England and Wales there are substantial varia¬
tions in mortality from conditions which should be
amenable to medical treatment''; variations in survival
with cancer have also been reported." Cancer of the
bladder is one of the most common cancers,s and health
care is thought to influence the prognosis.' An analysis
of cancer registry data for the South Thames regions
showed systematic variation in the survival of patients
with bladder cancer according to district health
authority of residence (A Walker et al, unpublished
data). One explanation for this observation could be
that the quality of health care varied sufficiently to
influence survival of these patients.' The outcome of
treatment for cancer of the bladdermight be influenced
by several characteristics of health care, including the
length of delay before treatment6; the grade and
specialty of the surgeon"; and the use made of surgery,
radiotherapy, and chemotherapy.'" Thesewere relevant
factors to investigate, given current problems with
long waiting times," staffing and surgical specialties,"
and organisation of cancer treatment services." This
study aimed at determining whether, after allowing for
the severity of the underlying disease, survival of
patients with cancer of the bladder in the South
Thames regions was influenced by these processes of
Patients and methods
The patients in the study were men aged below 75,
resident in the South Thames regions, and registered
with cancer of the bladder at the Thames Cancer
Registry in 1982. The registry supplied a list of 609
names believed to fulfil the entry criteria. We excluded
35 men after examining their hospital records: seven in
whom a diagnosis of bladder cancer had not been
confirmed, four who were not resident in the South
Thames regions at the time of diagnosis, and 24 whose
disease was not first diagnosed in 1982. Thus 574
patients were eligible for further investigation. After
consultants' approval had been obtained we abstracted
data from the patients' hospital notes and radiotherapy
records at 71 hospitals and 11 radiotherapy centres
with standard data collection forms.
The patient's age was calculated as 1982 minus the
year ofbirth and was included as a continuous variable.
The presence of associated disease was noted from the
record of the first hospital admission. The categories
none, cardiac, respiratory, renal, and other (specify)
were reduced for analysis to "comorbidity present"
and "comorbidity absent." The histological extent of
tumour invasion was classed according to the Inter-
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Objective—To determine any cardiac or vascular
morbidity associated with long term treatment with
tamoxifen given aftermastectomy for primary breast
cancer.
Design—Cohort study using linkage between
database of a randomised trial and statistics of
Scottish hospital inpatients to identify episodes of
cardiac and vascularmorbidity.
Setting—NHS hospitals in Scotland.
Subjects—1312 women who had undergone
mastectomy for breast cancer and who were ran¬
domised either to a treatment group to receive
adjuvant tamoxifen or to a control group to be given
tamoxifen only on first relapse of disease. Maximum
duration of tamoxifen treatment was 14 years. Total
woman years of follow up were 9943.
Main outcomemeasures—Randomised and obser¬
vational comparisons of risk (expressed as hazard
ratios) ofmyocardial infarction, other cardiac event,
cerebrovascular disease, or thromboembolic event
according to treatment allocated and between non-
users, former users, and current users of tamoxifen.
Results—Use of tamoxifen was associated with
lower rates of myocardial infarction. Hazard ratio
for women in control group was 1-92 (95% con¬
fidence interval 0-99 to 3*73) compared with women
allocated to adjuvant treatment. The association
was stronger for current use: hazard ratio for non-
users was 3-49 (1-52 to 8-03) compared with current
users. Current users of tamoxifen, however, had
higher rates of thromboembolic events: hazard ratio
for non-users was 0-40 (0T8 to 0-90) compared with
current users.
Conclusions—Our results provide further
evidence that tamoxifen reduces the risk of
myocardial infarction. Thromboembolic events
should be carefully monitored in trials of tamoxifen,
particularly those of prophylactic treatment, in
which tamoxifen is given to healthywomen.
Introduction
Tamoxifen, an oestrogen receptor antagonist, is
widely used as an adjuvant treatment for primary
cancer of the breast. The optimal duration of adjuvant
treatment has not been established, and, although
present indications suggest that five years of treatment
is better than two years or less, it is possible that this
should be life long. Several large trials of tamoxifen as
a prophylactic treatment are also now under way.
As these expose large numbers of healthy women to the
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drug, it is essential to assess the long term effects of
treatment.
We previously reported that in the Scottish adjuvant
tamoxifen trial women given long term adjuvant
tamoxifen treatment showed a significant decrease in
the number of deaths from myocardial infarction
compared with those randomised for no adjuvant
treatment.' There was no significant difference in the
incidence of other fatal vascular events between the
two arms of the trial.
In order to take account of non-fatal myocardial
infarctions and other forms of cardiac and vascular
disease, we now report the incidence of several poten¬
tially relevant events requiring admission to hospital in
both arms of the trial population. These have been
ascertained by linkage between the database of the
tamoxifen trial and the Scottish Health Service com¬
puterised inpatient record scheme at the Information
and Statistics Division. As this scheme records the
diagnosis for all acute admissions to NHS hospitals in
Scotland, we have been able to identify all relevant
admissions to Scottish hospitals of trial patients after
their mastectomy. Admissions to mental health
institutions and obstetric units are not covered by
the scheme.
Patients and methods
Between 1978 and 1984, 1312 eligible women with
primary operable breast cancer were entered into the
Scottish adjuvant tamoxifen trial.-' Of these, 242 (18%)
were premenopausal, being within one year of their last
menstrual period. Women in the treatment arm of the
trial received tamoxifen 20 mg daily for five years after
their mastectomy (or until earlier relapse); women in
the control arm did not receive adjuvant tamoxifen,
but this was to be given for treatment of later relapse of
disease. Women in the treatment arm who were alive
and still free of relapse at five years were offered further
randomisation either to stop tamoxifen treatment or to
continue taking it until relapse or death. Information
on recurrence and death was sought annually.
No baseline data were available for factors not
considered relevant to survival from breast cancer.
In particular information on smoking, blood lipids,
weight, and blood pressure (important factors in
cardiovascularmorbidity) was not collected.
In designing the present study, we decided to
include all eligible women rather than just postmeno¬
pausal women as previously1 because our intention was
to examine a range of potential health related effects
and the inclusion of younger women would not in¬
crease the incidence ofmyocardial infarction itself.
data linkage
A computerised linkage program at Information and
Statistics Division attempted to identify episodes in the
computerised inpatient record scheme for all trial
patients for the period from 1 January 1978 to 31
December 1992. Surname, forename, date of birth,
date ofmastectomy, and date of death (if appropriate)
were used as matching items. A probability based score
was used to measure the likelihood of two records
matching. The odds of a correct match were calculated
for each variable and multiplied together to give the
TAHi.fi i—Causes of hospital admissions included in study and numbers of cases analysed and of cases
rejected because ofpresence ofsystemic cancer
International Classification ofDiseases, Ninth Revision' No of cases
Description Code Analysed Excluded
Myocardial infarction 410
Cerebrovascular disease 430-437
Pulmonary embolism or phlebitis and thrombophlebitis 4151,451









overall probability that the two records belonged to the
same person. The threshold value was kept low to
minimise the risk of true matches being rejected.
In the Scottish cancer trials office each matching pair
of records was checked. For each confirmed match, the
date of admission and code of cause' (other than those
related to breast cancer) were added to the existing
trial database. This included dates of patients' birth,
randomisation, local and systemic relapse, and death.
Allocated treatment and its duration were entered for
all trial subjects. From the resulting database all the
above items except locoregional relapse alone were
extracted for the analysis. Table I shows the causes of
hospital admissions considered in this report. These
categories were defined before the data were inspected.
Because of the small numbers involved, deep vein
thrombosis and pulmonary embolus were analysed as a
single group of thromboembolic events. Most of the
subjects admitted to hospital for both deep vein
thrombosis and pulmonary embolism had identical
dates for the two; when they differed the earlier of the
two dates was taken as the date of the thromboembolic
event.
statistical analysis
To avoid the possible confounding effect of systemic
recurrence of breast cancer and consequent treatment,
each subject was considered to be at risk for the
analysed events from the date of randomisation up to,
but not beyond, that of any systemic recurrence.
Statistical evaluation was by the Cox proportional
hazards method using the egret package, with censor¬
ing at date of systemic relapse, death, or at follow up to
31 December 1992. Results are given as hazard ratios
and 95% confidence intervals. A hazard ratio greater
than 1 indicates a benefit from tamoxifen, which is
significant if the confidence interval does not overlap
unity. All analyses were adjusted for age at entry.
table ii—Woman years at risk in treatment and control arms ofstudy
by exposure to tamoxifen





Before use of tamoxifenf 224 3982
While using tamoxifen 3750 431
After stopping tamoxifen use 1457 99
Total 5431 4512
*Time from entry to trial to end of follow up period or to first systemic
relapse.
fThis is "never used tamoxifen" category.
The primary analysis investigated the main effect of
treatment allocated by randomisation. As this did not
take account of stopping treatment in the treatment
arm or giving tamoxifen for locoregional relapse in
controls (table II), additional analyses were carried
out with time dependent covariates to examine risk
according to actual tamoxifen use. Specifically, two
factors were introduced: firstly, for comparison of
women who never used tamoxifen with those who ever
used it, women took the value 1 (never) until they
were prescribed tamoxifen, after which the value
changed to 2 (ever). The second factor, for current use
of tamoxifen, had the value 2 at times of prescribed
tamoxifen treatment (current user) and 1 at other times
(not a current user). The values of these factors were
known at all times for women in the trial. A third
factor, the results of which are not reported in detail,
took three values (never, current user, former user)
defined in a similar way. Since the number of events
available for analysis was small, the potential for
checking the model's assumptions was limited. Details
of the complexity of time dependent covariate analysis
have been described elsewhere.'
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Results
Subjects in the two arms of the study were well
matched for age and menstrual status. The mean age in
the treatment arm was 58-6 years (range 30-79) while
that in the control arm was 59-1 years (27-79). In the
treatment arm 18-5% of women were premenopausal,
and 18-4% were premenopausal in the control armd
HOSPITAL ADMISSIONS
The incidence of hospital admission for myocardial
infarction (fatal and non-fatal) was lower in the
treatment arm of the study than in the control arm,
and this difference was of borderline significance
(table III, fig 1). There was also an apparent reduction
in the incidence of other ischaemic cardiac episodes in
the treatment arm, but this did not reach significance.
There was a slight increase in the number of hospital
admissions for thromboembolic events in the treat¬
ment arm, but there were no differences in admissions
for cerebrovascular events (table III, fig 1).
table in—Number and rale of adverse events and hazard ratio for women in control arm ofstudy compared
with those in treatment arm
Event
No ofevents (crude rate/1000 years at risk)
Treatment arm (n = 661) Control arm (n=651)
Hazard ratio
(95% confidence interval) P value
Myocardial infarction 14 (2-6) 23 (5-1) 1-92 (0-99 to 3-73) 0 051
Cerebrovascular disease 25 (4 6) 20 (4-4) 0-96 (0-53 to 1 73) 0-89
Thromboembolic event* 15(2-8) 10(2-2) 0-76(0-34 to 1-70) 0-50
Other ischaemic heart disease 18(3-3) 24 (5-3) 1-56 (0-85 to 2-87) 0-15
"Deep vein thrombosis or pulmonary embolism.
fig 1—Survival curves for women randomised to adjuvant tamoxifen treatment or to control for the four
study end points
table rv—Number and rate of adverse events and hazard ratio for women who never used tamoxifen
compared with those who ever used it
Event
No of events (crude rate/1000 years at risk)
Ever used tamoxifen Never used tamoxifen
Hazard ratio
(95% confidence interval) P value
Myocardial infarction 15(2-6) 22 (5-2) 2-03 (1-05 to 3-92) 0-033
Cerebrovascular disease 28 (4-9) 17(4-0) 0-87 (0-47 to 1 59) 0-65
Thromboembolic event* 17(3-0) 8(1-9) 0-61 (0-26 to 1 42) 0-24
Other ischaemic heart disease 20 (3-5) 22(5-2) 1-55 (0-84 to 2-84) 0-16
"Deep vein thrombosis or pulmonary embolism.
table v—Number and rate of adverse events and hazard ratio for women who were not current users of
tamoxifen compared with current users
Event
No of events (crude rate/1000 years at risk)
Current users Not current user*
Hazard ratio
(95% confidence interval) P value
Myocardial infarction 7(1-7) 30(5-2) 3 49 (1-52 to 8-03) 0-001
Cerebrovascular disease 15(3-6) 30(5-2) 131 (0-69 to 2-46) 0-40
'ITiromboembolic eventf 15(3-6) 10(1-9) 0-40 (0-18 to 0-90) 0-025
Other ischaemic heart disease 12 (2-9) 30 (5-2) 1-73 (0-87 to 3-43) 0-10
"Never used tamoxifen or former user. fDeep vein thrombosis or pulmonary embolism.
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fig 2—Numbers ofwomen by category of tamoxifen use and time since
randomisation
TAMOXIFEN USE
The patterns of tamoxifen use were complex (fig 2).
In the event of a relapse of disease women in the
treatment arm stopped taking tamoxifen whereas
women in the control arm started taking tamoxifen.
In addition a secondary randomisation altered the
duration of tamoxifen use in the treatment arm.
When actual tamoxifen use was taken into account,
the effect on risk of myocardial infarction was
increased for the comparison of those who had ever
used tamoxifen with those who had never used it
(hazard ratio 2-03 (95% confidence interval 1-05 to
3-92)) (table IV) and for the comparison of current
users with not current users (hazard ratio 3-49 (1-52 to
8-03)) (table V). Further analysis, comparing all three
categories of tamoxifen use, showed that patients
who had never received tamoxifen had a risk of
hospitalisation for myocardial infarction (hazard ratio
3-36 (1-43 to 7-88) compared with current users)
similar to that of former users (4-10 (1-39 to 12-13)).
THROMBOEMBOLIC EVENTS
Hospital admissions for the thromboembolic events
of deep vein thrombosis and pulmonary embolus were
increased in tamoxifen users, but this reached signifi¬
cance only for comparison of current users with not
current users (table V).
The 15 current users who had a thromboembolic
event ranged in age from 42 to 78 years (median 67) and
had been receiving tamoxifen for between one and 134
months (median 62). Four of the women had been
premenopausal at the time of starting tamoxifen treat¬
ment and had taken tamoxifen for 11, 38, 62, and
97 months.
Checking hospital discharge data for the six months
before the thromboembolic event revealed that eight of
the 25 cases had had inpatient surgery during this time.
The time between surgery and the thromboembolic
event was between three and seven weeks. Six of the
eight patients were current users of tamoxifen, and two
were in the control group. A ninth patient, a former
user, had metastatic colon cancer. The results of
reanalysis with these nine cases excluded showed no
increased risk for women randomised to tamoxifen
treatment and a smaller effect, with loss of statistical
significance, in the comparison of current users with
not current users.
Discussion
The primary comparison of the effects of allocated
tamoxifen treatment (table III, fig 1) has greatest
reliability because the equivalence of the groups on
unmeasured baseline factors should be ensured by
randomisation, but the effect of tamoxifen may be
diluted by failure to take account of subsequent
changes in its use. The analyses using time dependent
covariates take account of this factor but, being
observational in nature, are less reliable. We do not
know that the women being compared in these analyses
have equal distributions of risk factors and we acknow-
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Key messages
• Increasing use of tamoxifen as adjuvant treatment for breast cancer and its
use as a prophylactic in clinical trials highlight the need to determine the
consequences of long term treatment
• In this study the database for the Scottish adjuvant tamoxifen trial was
matched with records of inpatients in Scottish hospitals
• Tamoxifen treatment resulted in significant reduction in incidence of
hospital admission for myocardial infarction
• There was some evidence that tamoxifen increased risk of pulmonary
embolism
• The benefits of tamoxifen treatment for breast cancer outweigh any
adverse effects, but healthy women in clinical trials should be monitored for
thromboembolic events
ledge that the absence of information on smoking
and blood pressure is a limitation, but we have no
reason to suppose that these are associated with the
decision to change treatment. The main reason for
the change of status ofwomen remaining in the analysis
was locoregional relapse of disease which occurred
more often in women in the control arm.2 Treatment
other than tamoxifen could possibly increase the risk of
cardiovascular morbidity, and the observational com¬
parisons may therefore underestimate the benefit for
myocardial infarction but could overemphasise the risk
of deep vein thrombosis and pulmonary embolism.
CARDIOVASCULAR AND CEREBROVASCULAR MORBIDITY
Our results indicate a protective effect of tamoxifen
against hospital admission for acute myocardial infarc¬
tion. This protection was greatest in current users and
so may be lost when tamoxifen treatment is stopped.
This is consistent with our previous report of fatal
episodes. Our findings are also in keeping with reports
that concentrations of plasma cholesterol and its
low density lipoprotein fraction are lower in current
tamoxifen users than in former and non-users.M These
factors are known to be related to coronary artery
disease in men.®
A study of cardiovascular morbidity in 2365 patients
in the Swedish trial of adjuvant tamoxifen reported a
significant reduction of all cardiac disease in patients
receiving tamoxifen,10 but there was no apparent
decrease in either the myocardial infarction or
ischaemic heart disease subgroup. As well as showing
a reduction in myocardial infarction, our data suggest
that ischaemic heart disease may have been reduced in
the tamoxifen users. We found little association of
tamoxifen use with cerebrovascular events (cerebral
haemorrhage and cerebral thrombosis). Analysis of all
cerebrovascular events in the Swedish data (similar to
our cerebrovascular disease category) also failed to
show an effect (Rutqvist, personal communication).
THROMBOEMBOLIC EVENTS
The Swedish workers failed to find a difference in
the incidence of "thromboembolic disease" between
patients receiving adjuvant tamoxifen and controls.
They included cerebral thrombosis in this category. In
our separate analysis of the effect of tamoxifen on the
specific thromboembolic events of deep vein throm¬
bosis and pulmonary embolism, the patients taking
tamoxifen seemed to be at greater risk, but this was
significant only in the analysis by current use (table V).
Our finding clarifies the effect of tamoxifen
described in a retrospective review of venous and
arterial thromboembolic complications in seven con¬
secutive trials of adjuvant treatment for breast cancer
conducted by the Eastern Cooperative Oncology
Group." This indicated a substantially greater number
of events in premenopausal patients receiving chemo¬
therapy and tamoxifen than in those receiving chemo¬
therapy alone. It has been suggested that a decrease in
levels of antithrombin III in women treated with
tamoxifen may be one factor contributing to hyper¬
coagulability.12
Unlike in the above review, we censored for systemic
relapse in our analysis, reducing the likelihood that the
observed increase in thromboembolic events was
related to breast cancer. Nine thromboembolic events
occurred in patients who might be considered to have
been at increased risk due to recent surgery or similar
factors, but the time gap of 3-7 weeks between the two
events decreases the likelihood of a direct relation.
We could not identify all those who had had additional
surgery without experiencing a thromboembolic
event.
The numbers of subjects in our study are small, and
the results concerning deep vein thrombosis and
pulmonary embolism (our thromboembolic disease)
should be interpreted with caution. However, they
indicate that the incidence of thromboembolic events
within tamoxifen prevention trials should be carefully
monitored and that women entering these trials must
be informed of this potential risk.
CONCLUSION
It is important to appreciate that our results do not
cast doubt on the evidence that adjuvant tamoxifen is
beneficial to women with breast cancer. In addition,
our results and those which we have previously
reported concerning fatal myocardial infarction1
demonstrate an additional benefit for users of
tamoxifen which is greater than any possible harmful
thromboembolic effects.
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Appendix 3
Microsoft Access SQL queries
Ascertainment of Events
SELECT DISTINCTROWtamvalid.Surname, tamvalid.Initial, tamvaiid.DOB,
tamva!id.Event_date, cause_1, cause_2, cause_3, cause_4, cause_5,
cause_6
FROM tamvalid
WHERE (((tamvalid.Cause_1) like '-414?') AND ((tamvalid.Score)>=17)) OR
(((tamvalid.Score)>=17) AND ((tamvalid.Cause_2) like -414?')) OR
(((tamvalid.Score)>=17) AND ((tamvalid.Cause_3) like '-414?')) OR
(((tamvalid.Score)>=17) AND ((tamvalid.Cause_4) like '-414?')) OR
(((tamvalid.Score)>=17) AND ((tamvalid.Cause_5) like '-414?')) OR
(((tamvalid.Score)>=17) AND ((tamvalid.Cause_6) like '-414?'));
SELECT DISTINCTROW Surname, DOB, Score, Misc, Event_date
FROM tamvalid
WHERE Score>17 AND Misc LIKE '*6' AND event_date LIKE '*150*'
OR Score>17 AND Misc LIKE '*9' AND event_date LIKE '*150*';
Appendix 4






Date Created: 07-Oct-98 9:00:27 AM Def. Updatable: True














































































































































































































































































































































































































































































































































































































































































































































































































Microsoft Access update queries
DETERMINATION OF EVENT OR CENSORING
update TAM_(event) set EVENT = 0
where D_(event) is null
or D_(event) is not null and DCENSOR <= D_(event);
update TAM-(event) set EVENT = 1
where D_(event) is not null and D CENDOR > D_(event);
update TAMBASE set D_CENSOR = DMR
where DMR is not null;
update TAMBASE set DCENSOR = DD
where DMR is null
and DD is not null;
update TAMBASE set D CENSOR = D_FUP
where DD is null
and DMR is null;
update TAMBASE set D_CENSOR = datevalue('31/03/96')
where D_CENSOR > datevalue ('31/03/96');
DETERMINATION OF CENSORING DATE
update TAMBASE set D_CENSOR = DMR
where DMR is not null;
update TAMBASE set DCENSOR = DD
where DMR is null
and DD is not null;
update TAMBASE set D_CENSOR = D_FUP
where DD is null
and DMR is null;
update TAMBASE set D CENSOR = datevalue('31/03/96')
where D_CENSOR> datevalue ('31/03/96');
DETERMINATION OF TIME FROM RANDOMISATION TO TAMOXIFEN
START/STOP
update TAMBASE set START = TSTART-DRAND;
update TAMBASE set START = 9999
where START is null;
update TAMBASE set START = 0
where START < 0;
update TAMBASE set STOP - TSTOP-DRAND;
update TAMBASE set STOP
where STOP is null;
= 9999
Appendix 6
Case-control data for ischaemic heart disease prepared for
conditional logistic regression analysis
ihd cc 29/10/99
diagnosis age strata matching oestrogen outcome_ihd
2 5 10 1 1
2 5 10 2 1
6 11 2 1
6 11 2 1
6 11 2 0
6 11 2 0
6 11 1 1
6 11 1 0
6 11 2 0
6 11 1 0
6 11 1 0
6 11 1 1
6 11 2 1
6 11 1 0
6 11 2 0
6 11 2 0
6 11 2 0
6 11 2 0
2 6 12 2 1
2 6 12 2 1
2 6 12 1 0
2 6 12 1 1
2 6 12 2 0
2 6 12 2 0
2 6 12 2 0
2 6 12 2 0
2 6 12 2 0
2 6 12 1 0
2 6 12 1 1
2 6 12 2 0
2 6 12 1 0
2 6 12 2 0
2 6 12 2 0
2 6 12 2 0
2 6 12 1 1
2 6 12 1 0
1 7 13 2 1
1 7 13 2 0
1 7 13 2 0
1 7 13 1 0
1 7 13 2 0
1 7 13 2 0
1 7 13 2 0
1 7 13 2 1
1 7 13 2 0
1 7 13 2 1
1 7 13 2 0
1 7 13 1 1
1 7 13 2 0
1 7 13 2 0
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Appendix 7
Sample of case-control data for thromboembolism prepared for
conditional logistic regression analysis
t cc 31/10/99
diagnosis age strata matching oestrogen outcome t
10 19 2 0
10 19 2 0
8 15 2 0
10 19 2 0
8 15 2 0
7 13 2 0
7 13 2 0
11 21 2 0
11 21 2 0
11 22 2 0
9 17 2 1
9 17 2 1
9 18 2 1
10 19 2T~
8 16 2 1
10 19 2 1
5 10 2 1
7 13 2 1
11 21 2 1
10 19 2 1
11 21 2 1
4 8 1 1
2! 4 8 1 1
10 19 2 1
10 19 2 1
8 15 2 1
3 5 2 1
2 4 2 1
7 13 2 1
7 14 2 1
8 15 2 1
7 13 2 1
5 10 1 1
11 22 2 1
10 19 2 1
6 11 1 1
11 22 2 1
10 19 2 0
10 19 2 0
11 21 2 0
10 19 2 0
4 7 1 1
5 9 1 1
9 17 2 1
10 20 2 1
7 13 2 1
7 14 2 1
10 19 2 1
5 9 1 0
6 11 2 0
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